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This dissertation is an epidemiologic query designed to address important 
questions related to screening and diagnosis of prediabetes and diabetes. We used data 
from the Atherosclerosis Risk in Communities (ARIC) Study, an ongoing community-
based cohort initiated in 1987, to assess four main aims. 
First, we examined trajectories of kidney function by diabetes status. Persons with 
diagnosed diabetes declined almost twice as rapidly as persons without diabetes (-2.5 
ml/min/1.73 m2 per year [95%CI, -2.6, -2.4]; -1.4 ml/min/1.73 m2 per year [95%CI, -1.5, 
-1.4], respectively). Those with undiagnosed diabetes, likely early in the disease course, 
experienced relatively little short-term average decline, but declined in the long-term. 
This brief period of stagnation suggests potential hyperfiltration. 
Second, we compared the prognostic performance of five definitions of 
prediabetes in use by international organizations. Prediabetes prevalence ranged widely 
depending on the definition (9% to 38%), but all definitions identified persons at high-
risk for clinical outcomes. Fasting glucose 100-126 mg/dL was more sensitive for clinical 
complications, while HbA1c 5.7-6.4% and 6.0-6.4% were more specific and provided 
modest statistically significant improvements in risk discrimination. 
Third, we conducted a diagnostic testing study, comparing 1,5-anhydroglucitol 
(1,5-AG), a less burdensome test, to 2-hour glucose for identification of hyperglycemia. 
Their concordance was low and, while specific for high glucose levels, 1,5-AG missed 
many people with elevated 2-hour glucose.  
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Finally, we compared the prospective associations of 1,5-AG and 2-hour glucose 
with risk of future clinical outcomes. Low levels of 1,5-AG were associated with risk of 
future outcomes, but not as strongly as 2-hour glucose. 
Given the proven approaches to prevent progression to diabetes and reduce 
incidence of its complications, our data reinforced the need for prediabetes and diabetes 
screening and diagnosis, with consistent identification of individuals to inform public 
health planning. We proposed further understanding hyperfiltration and exploring new 
ways to optimize prediabetes definitions. While 1,5-AG does not appear to substitute for 
2-hour glucose and may have limited screening utility, additional research is needed to 
assess it as a measure of glycemic control in persons with diagnosed diabetes. Our 
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 Diabetes and prediabetes are major global public health challenges. Early 
identification provides opportunities to prevent diabetes and its associated complications. 
Thus, this dissertation focused on issues related to screening for prediabetes and diabetes. 
Specifically, we provide evidence that reinforces the need for diagnosis by quantifying 
trajectories in kidney function over time by diabetes status, and data to inform tailored 
screening and diagnosis strategies by addressing controversies in prediabetes screening, 
and evaluating whether an emerging biomarker of hyperglycemia, 1,5-anhydroglucitol, 
can be used for diabetes screening.  
Diabetes and prediabetes: a pressing public health problem 
Diabetes is a rising global problem, as the prevalence in the last several decades 
have been stable or increasing in every country1. In the United States, 11% of people are 
living with diabetes (25.5 million), and ~2.8 million of those cases are undiagnosed2. In 
general terms, diabetes is a disease characterized by chronic hyperglycemia that results 
from insufficient insulin secretion and/or action. The two most common forms of 
diabetes, type 1 and 2, have different disease etiologies. Type 2, accounts for 
approximately 95% of the diabetes in the U.S. and is the focus of this dissertation3. Type 
2 diabetes is often characterized by insulin resistance, whereas type 1 diabetes is 
associated with insufficient or lack of insulin secretion. In the absence of diabetes, insulin 
is secreted by the beta cells in the pancreas when blood glucose is high to promote the 
uptake of glucose into cells. Cellular resistance to the effects of insulin occurs when the 
action of insulin is insufficient, meaning insulin is still being secreted by the pancreas but 
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the uptake of glucose into cells is diminished, and higher concentrations of glucose 
remain in the blood4. 
Common risk factors for diabetes include age, race/ethnicity, family history of 
diabetes, obesity, hypertension, low HDL cholesterol, high triglycerides, physical 
inactivity, dietary factors, and, in women, a previous diagnosis of gestational diabetes5. 
Diabetes is strongly associated with increased micro- and macrovascular complications 
including retinopathy, nephropathy, and neuropathy, coronary heart disease, ischemic 
stroke, and peripheral arterial disease6. Indeed, persons with diabetes are at an 
approximately 2-4 times higher risk of cardiovascular disease than those without 
diabetes7. The public health burden of diabetes is substantial. In the U.S., diabetes is now 
the leading cause of blindness and end stage renal disease8,9. However, despite the well-
established relationship of diabetes as a risk factor for chronic kidney disease and end 
stage renal disease, the contribution of diabetes to kidney function decline over time in 
the general population is largely uncharacterized.  
The management of diabetes and its associated complications result in excess 
healthcare burden and medical costs. In the U.S. in 2014 alone, persons with diabetes 
were hospitalized at a rate of 327.2 (95% CI, 311.3, 343.1) per 1,000 and admitted to the 
emergency department at a rate of 648.9 (95% CI, 600.0, 696.9) per 1,0003. In 2012, total 
estimated cost (direct and indirect) of diagnosed diabetes in the U.S. was $245 billion3. 
Persons who are at high risk for diabetes are often termed as having 
“prediabetes”, a state characterized by hyperglycemia but where blood glucose 
concentrations do not yet meet the diagnostic threshold for diabetes. The prevalence of 
prediabetes varies substantially by the definition used, and in the U.S. prevalence 
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estimates range from 12-29% of the total adult population10. Among people with 
prediabetes, approximately 5 to 10% progress to diabetes annually11. Like diabetes, 
prediabetes is associated with adverse microvascular and macrovascular outcomes12,13. 
Importance of screening for prediabetes and diabetes 
It is important to consider whether screening in asymptomatic individuals for a 
particular disease is appropriate. Screening is indicated for those diseases that are 
burdensome and treatable and where available screening tests are acceptable (low patient 
burden) and able to effectively separate those with and without the disease. With these 
principles taken together, Table 1 describes objective characteristics for successful 
screening outlined by Riegelman (2005)14 that have been adapted to demonstrate the need 
and ability to screen for prediabetes and diabetes. In the context of hyperglycemia, 
screening is particularly important because prediabetes and diabetes are associated with 
increased microvascular and macrovascular complications and all-cause mortality; 
further, treatment and improvement in glycemic control can reduce microvascular 
complications15–19, and perhaps macrovascular complications20,21; approaches exist to 
prevent progression from prediabetes to diabetes22–24; the tests used for diagnosis can 
identify those with the disease25; and screening can be conducted with a minimally 
invasive blood draw. 
Importantly, the typical first line intervention for both prediabetes and diabetes is 
lifestyle management, which includes nutrition management, regular physical activity, 
and weight loss and maintenance26. Nutritional recommendations often suggest a healthy 
low-calorie diet, physical activity recommendations typically emphasize at least 150 
minutes of moderate to vigorous activity per week, and weight loss and maintenance is 
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aimed at 7% of body weight26. These general recommendations are tailored to individual 
needs. In the general U.S. population, meeting these goals without intervention is rare. 
One study conducted in NHANES demonstrated that only 3.1% of adults without 
diagnosed diabetes met dietary, physical activity, and weight loss/maintenance goals for 
reduction of type 2 diabetes risk27. Screening can help identify those at risk and presents 
an opportunity for intervention among the individuals who may benefit. 
The 2015 U.S. Preventative Services Task Force Final Recommendation 
Statement for Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus state 
that screening should be conducted every 3 years in asymptomatic adults aged 40-70 
years who are overweight or obese28. The recommendation also notes that clinicians 
should consider screening at earlier ages for persons with one or more additional risk 
factors for diabetes. The American Diabetes Association, however, recommends 
screening in all asymptomatic adults 45 years or older or adults of any age who are 
overweight or obese and who have at least one diabetes risk factor5. The Canadian Task 
Force on Preventative Health Care convened in 2012 recommends yet another approach. 
They suggest that adults with low or moderate risk of future diabetes determined by a risk 
score should not be screened. Using the same risk score, they suggest adults at high risk 
should have their Hemglobin A1c (HbA1c) measured every three to five years, and those 
at very high risk should have their HbA1c measured every year29. The National Institute 
for Health and Clinical Excellence also relies on a risk score to identify high-risk 
individuals who should be screened for diabetes using a blood test30. Despite differences 
in specific screening recommendations, there is broad agreement that screening for 
diabetes and prediabetes is important. 
 5 
Guidelines organizations have relied largely on observational data to inform 
screening recommendations. Evidence from trials and intervention studies is scarce due 
to the complexity, ethical issues, and the substantial sample size, resources, and follow-
up time needed to evaluate effects on clinical endpoints. Nonetheless, there have been 
two randomized control trials that assessed whether screening for diabetes in 
asymptomatic individuals reduces mortality; these found either no or a small benefit31,32. 
These trials were limited by improvements in treatment in the control group over time, 
along with the low prevalence of screen-detected diabetes among their participants, and 
lower than expected event rates. These studies illustrate the major challenges in 
conducting randomized control trials of screening questions. Therefore, rigorous 
observational studies and epidemiological evidence is critical. 
Approaches to screening and diagnosis of prediabetes and diabetes 
Diabetes screening approaches have evolved over time33. Identifying persons with 
diabetes dates back as far 1500 BC, although the first known “screening tests”—
involving the tasting of urine—were recorded in the first and second centuries AD34. 
Testing urine, although the methods to do so have evolved, continued as the primary 
means of diagnosis for hundreds of years34. In the late eighteenth century, work done by 
Matthew Dobson, an English physician, characterized diabetes as a system disorder and 
found sugar in both urine and blood7,34. This advancement laid the foundation for blood 
tests to diagnosis diabetes. 
In 1913, Ivar Christian Bang, a chemistry professor at the University of Lund in 
Sweden, developed a method to quantify the amount of glucose in the blood35. This 
advancement, paired with the discovery in the same year by A.T.B. Jacobsen, who 
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determined that ingestion of carbohydrates results in fluctuations in blood glucose, set the 
stage for measuring blood glucose following a carbohydrate challenge35. The 
development of the glucose tolerance test is attributed to Jerome Conn in 194036. 
In 1965, the World Health Organization published a report from an expert 
committee which recommended using laboratory criteria for the diagnosis of diabetes and 
included the glucose tolerance test and fasting glucose37. This was followed by the 1979 
report from the National Diabetes Data Group which formalized diabetes classification 
and recommended the use of fasting glucose (≥140 mg/dL) or 2-hour glucose following a 
75-g oral glucose tolerance test for diagnosis (≥200 mg/dL)38. It also established impaired 
glucose tolerance as a 2-hour glucose ≥140 mg/dL and <200 mg/dL when fasting glucose 
<140 mg/dL; and normal glucose levels as fasting glucose <115 mg/dL and 2-hour 
glucose <140 mg/dL. A lot of these developments were made possible by the work of Dr. 
Harry Keen—often considered a “father” of diabetes epidemiology—who was a member 
of the committee. Keen, along with Dr. Kelly West, championed screening for diabetes 
based on the prevalence of complications in asymptomatic persons with diabetes39,40. 
Given their findings and results of other early studies, the cut points for all continuous 
biomarkers used in guidelines were largely based off their relationship with 
microvascular outcomes, especially the prevalence of retinopathy, given its specificity to 
diabetes25. 
The clinical cut-points outlined by the National Diabetes Data Group remained in 
use until 1997 when the American Diabetes Association lowered the cut-point for 
diabetes diagnosis for fasting glucose from 140 mg/dL to 126 mg/dL (impaired fasting 
glucose: 110-126 mg/dL) based on an expert committee report41, followed by World 
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Health Organization in 199942. In 2003, American Diabetes Association again changed 
cut-points, this time for impaired fasting glucose from 110 mg/dL to 100 mg/dL43. 
In 2009, for the first time, an International Expert Committee recommended 
HbA1c for diagnosis44. At this time, HbA1c had been used for decades as the standard 
measure of chronic hyperglycemia to assess glycemic control among persons with 
diabetes. The 2009 report was published over 40 years after the glycation of HbA1c 
among persons with diabetes was discovered by Samuel Rahbar, an Iranian physician, 
and over 15 years after the Diabetes Control and Complications Trial (DCCT) 
demonstrated associations between HbA1c and diabetes complications6,45. This delay in 
uptake following the DCCT was partly due to the need to standardize the HbA1c assay, a 
problem addressed by the National Glycohemoglobin Standardization Program (NGSP). 
In 2010, American Diabetes Association guidelines formally recommended the use of the 
HbA1c test for diagnosis46. 
Today, prediabetes (impaired glucose tolerance, impaired fasting glucose, and 
impaired glycated hemoglobin) and diabetes continue to be diagnosed by fasting glucose, 
2-hour glucose, and/or HbA1c. A description of each biomarker and the construct it 
represents is listed in Table 2. Currently, international organizations generally agree on 
the tests and cutoffs that should be used to identify persons with diabetes. However, 
international guideline groups have not reached consensus on the thresholds for 
prediabetes (Table 3). While there are three different definitions of diabetes, any of 
which can be used for diagnosis, there are five different definitions of prediabetes 
currently in use, with inconsistent recommendations for their use by guidelines 
organizations. Further, since prediabetes or ‘borderline diabetes’ was first introduced in 
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the 1960s by Dr. Harry Keen its necessity has been debated. Some experts claim that 
prediabetes is an unnecessary label that can lead to “over-medicalization” and which 
serves to enhance the bottom line of pharmaceutical companies47,48. However, others 
recognize that since glucose levels—even below the threshold for a diagnosis of 
diabetes—are associated with increased risk of major complications and the disease 
process is continuous, identifying and categorizing persons early in the disease process is 
important to prevent diabetes. The optimal definition of prediabetes, approaches to the 
patients with prediabetes, and insurance coverage for lifestyle interventions and other 
treatments in persons with prediabetes remain controversial. 
 Current guidelines and recommendations take into consideration the limitations of 
each biomarker used for diagnosis of diabetes and identification of persons with 
prediabetes (Table 4). Two-hour glucose, in particular, has fallen out of favor—
especially in the U.S.—as a first line screening or diagnostic test given its high burden on 
the patient and healthcare system. Nonetheless, given its long history and place in 
diagnosis of diabetes, the two-hour post-challenge glucose test is still considered as an 
important “gold standard” for diabetes diagnosis. 
1,5-anhydroglucitol: A promising alternative to 2-hour glucose? 
1,5-anhydroglucitol (1,5-AG) is a biomarker that has received recent interest as a 
novel biomarker of hyperglycemia. The biology of 1,5-AG is distinct from either glucose 
or HbA1c. It is a six-carbon monosaccharide that differs from glucose by one fewer 
hydroxyl group49. In the absence of hyperglycemia, the amount of circulating 1,5-AG is 
thought to remain at steady-state50. 1,5-AG is largely obtained from dietary sources, 
although it is believed that there may be a small amount of 1,5-AG synthesized in the 
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liver and possible that there is a some degree of degradation50. Some 1,5-AG is excreted 
in urine even when blood glucose levels are normal, but it is approximately similar to the 
amount ingested and synthesized50. These inputs and outputs of 1,5-AG result in a 
relatively neutral exchange and constant pool in the body in the absence of 
hyperglycemia. Among healthy individuals, the reference intervals reported by the U.S. 
assay manufacturer, GlycoMark™ (Glycomark Inc, Winston-Salem, NC), are 10.7 to 
32.0μg/mL in males, and 6.8 to 29.3μg/mL in females51.  
In periods of hyperglycemia exceeding the renal threshold for glucose (blood 
glucose concentrations >~160-180mg/dL), given their molecular similarity, glucose and 
1,5-AG compete for reabsorption in the proximal tubule of the kidney, accelerating urine 
excretion and lowering the amount of circulating 1,5-AG in plasma. Thus, low 
concentrations of 1,5-AG in plasma reflect recent high blood glucose levels. After a 
period of hyperglycemia where the pool of 1,5-AG is decreased, 1,5-AG is thought to 
recover at rate of 0.3 μg/mL per day52. 
 There is some evidence to suggest there may be a number of factors that influence 
the absolute amount of 1,5-AG, which may be particularly relevant in the absence of 
hyperglycemia. Dietary sources vary greatly in their 1,5-AG content50,53. For example, 
soybeans have particularly high amounts of 1,5-AG, followed by rice, noodles, bread, 
and beef50. Beyond 1,5-AG content in foods, a recent study demonstrated that diet may 
directly influence 1,5-AG serum concentrations54. Because of the interplay of 1,5-AG and 
the kidneys, 1,5-AG may not be reliable in persons with chronic kidney disease or 
persons taking medications from the sodium-glucose co-transporter 2 (SGLT2) drug 
class55–57. Additionally persons with liver disease have been shown to have low 1,5-AG 
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values regardless of glucose level58. Other factors that may impact interpretation of 1,5-
AG include pregnancy or consumption of certain Chinese herbal supplements49,51,57. 
1,5-AG was first detected and characterized in plants in 1888, followed by 
humans in 197249. In the early 1980s, differences in 1,5-AG concentrations among those 
with and without diabetes were observed51. Today, assays have been developed that allow 
measurement of 1,5-AG concentration in serum or plasma. An assay developed in Japan 
and in use since 1991, is marketed as GlycoMark™ in the United States and is one of the 
leading 1,5-AG assays. GlycoMark™ measures 1,5-AG using a two-step enzymatic 
method and was approved by the Food and Drug Administration for use in 200349,57. 
There are several other 1,5-AG assays including the Determiner-L 1,5-AG (Kyowa 
Medex; Tokyo, Japan) which has been shown to be similar to GlycoMark™, with a mean 
difference between the two assays of 0.4μg/mL in a community-based population59. A 
third method, the Cusabio Human 1,5-AG ELISA Kit, has been sparsely used in the 
literature. 
1,5-AG is a non-fasting test and studies have suggested 1,5-AG may have utility 
in the setting of diagnosed diabetes to identify short-term glycemic changes, inform 
therapeutic decisions to minimize glycemic variability, and provide complementary 
information to HbA1c. The potential utility of 1,5-AG to provide information on short-
term monitoring of blood glucose largely stems from a trial of the GlycoMark™ assay 
which demonstrated that 1,5-AG changed quickly (~2 weeks) in response to medications 
that lowered blood glucose60, suggesting 1,5-AG could be used to monitor short-term 
changes in glucose control. Dungan et al demonstrated the ability of 1,5-AG to provide 
information for therapeutic decisions among persons with diabetes by utilizing 
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continuous glucose monitors and comparing changes in average glucose to HbA1c and 
1,5-AG. They showed that for patients with similar HbA1c, those experiencing more 
glycemic excursions had lower 1,5-AG61. This suggests that 1,5-AG could identify 
patients experiencing postprandial glucose that may benefit from a different treatment 
regimen. Although, it is worth noting, that there is no evidence to-date to suggest that 
changes in treatment based on 1,5-AG improve clinical outcomes. Studies that have 
assessed the relationship of 1,5-AG and outcomes have shown that in the setting of 
diabetes, 1,5-AG predicts adverse outcomes beyond HbA1c62,63. This aligns with the 
literature that postprandial glucose is an independent risk factor for macrovascular 
complications. 
 There have been very few studies of 1,5-AG in persons without a diagnosis of 
diabetes, although there is a small literature that suggests that 1,5-AG might have utility 
for diabetes screening64–66. Because testing for 1,5-AG is simple and minimally invasive 
(single serum or plasma blood sample) and fasting is not required, 1,5-AG is of 
substantial interest as a potential alternative to the more burdensome oral glucose 
tolerance test. Given its attractive test properties and low coefficient of variation (ranging 
from 1.3-5.7%) – it is worth understanding whether 1,5-AG has utility for diabetes 
screening51,67. 
Study Aims 
This dissertation was intended to tackle major questions related to screening for 
hyperglycemia by investigating the following specific aims:  
Aim 1. To characterize trajectories of kidney function over time by diabetes status. 
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Aim 2. To compare the prevalence and prospective associations of different definitions of 
prediabetes with incident diabetes, chronic kidney disease, cardiovascular disease, 
peripheral arterial disease, and all-cause mortality.  
Aim 3. To conduct a diagnostic testing study to evaluate the performance of 1,5-AG 
compared to 2-hour glucose to detect undiagnosed diabetes. 
Aim 4. To compare the prospective associations of 1,5-AG and 2-hour glucose with 
incident diabetes, cardiovascular disease, and all-cause mortality among persons 
without diabetes. 
Dissertation Data Source 
The analyses in this dissertation were conducted using data from the 
Atherosclerosis Risk in Communities (ARIC) Study. The ARIC Study is a community-
based cohort, initiated in 1987-1989 with 15,792 participants68. The study recruited 
participants from four communities in the United States (Washington County, Maryland; 
Forsyth County, North Carolina; Jackson, Mississippi; and suburban Minneapolis, 
Minnesota), collecting anthropometrics, blood samples, and self-report data at study 
visits. To date, there have been six study visits (1987-89, 1990-92, 1993-95, 1996-98, 
2011-13, 2016-17), and a seventh is planned (2018-19). 
For this dissertation, in collaboration with colleagues at the Baylor College of 
Medicine, 1,5-AG was measured in stored plasma samples collected from 11,656 
participants during the fourth visit (1996-98). These new measurements presented a 
unique opportunity for comparison to the 2-hour glucose; since the fourth visit was the 
only time the oral glucose tolerance test protocol was administered during the ARIC 
study. 
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In order to utilize the new Visit 4 measurements, aligning the values with 1,5-AG 
measurements at other ARIC study visits (Visits 2 and 5), which were conducted in 
serum samples at the University of Minnesota, was necessary. To correct for lab and 
methodological differences, we designed and conducted a calibration study at the Baylor 
College of Medicine using stored samples from the fifth study visit (2011-2013). Lab 
differences were addressed by comparing measurements of 1,5-AG in University of 
Minnesota serum samples from visit 5 to new measurements of 1,5-AG conducted at the 
Baylor College of Medicine laboratory in different serum aliquots from the same 
participants (n=50). Methodological differences were then addressed by comparing 
plasma samples from Baylor College of Medicine (n=200) to serum samples from 
University of Minnesota. This process aligned the new Visit 4 1,5-AG measurements 
with previous measures at the second and fifth study visits and is further detailed in the 
Methodological Supplement. ARIC is a rich source of data that provides the information, 
sample size, and general population necessary to answer the clinical questions outlined 
for this dissertation. 
Dissertation Structure 
This dissertation has four chapters, one per aim, a conclusion, and methodological 
supplement. Each chapter is formatted as a publishable manuscript. Chapter 1 quantifies 
the contribution of diabetes to kidney function decline over 25 years. Chapter 2 compares 
the 5 different definitions of prediabetes and their associations with future adverse 
outcomes and was published in Lancet Diabetes and Endocrinology69. Chapter 3 assesses 
the concordance of 1,5-AG and 2-hour glucose to identify undiagnosed diabetes in a 
community-based population. Chapter 4 examines the associations of 1,5-AG and 2-hour 
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glucose among those without diagnosed diabetes with risk of future adverse outcomes. 
The Methodological Supplement details the statistical calibration of the data necessary 
before using it in analyses. Finally, the Conclusion summarizes the findings and outlines 
next steps for this research.  
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Table 1. Characteristics for successful screening by Reigelman (2005)14 adapted to 
demonstrate the ability to successfully screen for diabetes and prediabetes 
 
 
Table 2. Biomarkers of hyperglycemia used for diagnosis of prediabetes and diabetes and 










Increased microvascular and 
macrovascular complications 
and all-cause mortality 
Increased microvascular and 





Glycemic control can reduce 
microvascular 
complications,15–19 and perhaps 
macrovascular 
complications20,21 
Early intervention through 
lifestyle or pharmacological 
intervention can reduce 






2-hour glucose, fasting 
glucose, and HbA1c separate 
those with and without chronic 
hyperglycemia25 
2-hour glucose, fasting glucose, 
and HbA1c separate those with 




Fasting or non-fasting blood 
draw depending on biomarker 
Fasting or non-fasting blood 
draw depending on biomarker 
Biomarker Biological definition Glycemic construct 
2-hour glucose following 
75-g glucose tolerance test 
Circulating blood glucose 
following a glucose challenge 
Post-prandial glycemic excursions 
Fasting glucose 
Circulating blood glucose level 
after a fasting period 
Glucose homeostasis 
Hemoglobin A1c 
The proportion of hemoglobin that 
has been glycated 
Average glycemia over the previous 
2-3 months 
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Table 3. Current definitions in use for diagnosis of prediabetes and diabetes 
 
 




2-hour glucose following 
75-g glucose tolerance test 
American Diabetes Association 
≥200 mg/dL ≥140 mg/dL & <200 mg/dL 
World Health Organization 
Fasting glucose 
American Diabetes Association 
≥126 mg/dL 
≥100 mg/dL & <126 mg/dL 
World Health Organization ≥110 mg/dL & <126 mg/dL 
HbA1c 
American Diabetes Association 
≥6.5% 
≥5.7% & <6.5% 
World Health Organization -- 
International Expert Committee ≥6.0% & <6.5% 
Limitation 
Biomarker 
2-hour glucose Fasting glucose HbA1c 
Requires fasting ✓ ✓  
Higher patient burden ✓   
Affected by recent activity, acute illness, or stress ✓ ✓  
Higher intra-individual variability ✓ ✓  
Pre-analytic issues ✓ ✓  
Affected by alterations in red cell turnover   ✓ 
More common assay interferences   ✓ 
Whole blood required   ✓ 
Cost   ✓ 
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Chapter 1. Diabetes and trajectories of estimated 
glomerular filtration rate: a prospective analysis 
of the Atherosclerosis Risk in Communities study 
 
Co-authors: Casey M Rebholz, Yingying Sang, Alexandra K Lee, Josef Coresh, Elizabeth 
Selvin, and Morgan Grams 
 
Abstract 
Objective. People with diabetes are at high risk for adverse kidney outcomes, including 
end-stage renal disease. To better characterize kidney disease development in persons 
with and without diabetes, we quantified trajectories of decline in estimated glomerular 
filtration rate (eGFR) in a community-based cohort with up to four measures of creatinine 
from 1987 to 2013. 
Research Design and Methods. Among 15,517 participants in the Atherosclerosis Risk in 
Communities (ARIC) Study, we classified participants as having no diabetes, 
undiagnosed diabetes, and diagnosed diabetes at baseline (1987-89). We used linear 
mixed models with random intercepts and slopes to quantify decline in eGFR by diabetes 
status. 
Results. Overall, the adjusted mean decline in eGFR among participants without diabetes 
at baseline was -1.4 ml/min/1.73 m2 per year (95% CI, -1.5, -1.4); and with diagnosed 
diabetes, was -2.5 ml/min/1.73 m2 per year (95% CI, -2.6, -2.4). Compared to participants 
without diabetes, participants with undiagnosed diabetes had higher baseline eGFR 
(adjusted difference, 2.3 ml/min/1.73 m2 [95% CI 1.1, 3.4]) and slower eGFR decline 
over the first three years (difference, 0.4 ml/min/1.73 m2 per year [95% CI, 0.1, 0.8]), but 
they had faster relative decline over the full study period (difference, -0.4 ml/min/1.73 m2 
per year [95% CI, -0.5, -0.3]). Among participants with diagnosed diabetes, steeper eGFR 
 18 
decline was observed among African-American participants as well as those with APOL1 
risk genotype, systolic blood pressure ≥140 mmHg, those on insulin, and those with 
HbA1c ≥9%. 
Conclusions. In summary, diagnosed diabetes was a strong risk factor for eGFR decline 
over a 26-year period, as was undiagnosed diabetes after an initial period of relatively 
little average eGFR decline. Steeper declines were seen in those with diagnosed diabetes 
and modifiable risk factors including higher systolic blood pressure and HbA1c, 
suggesting factors that should continue to be targeted for prevention of chronic kidney 
disease.  
Introduction 
Diabetes mellitus is increasingly prevalent worldwide1,2 and is associated with 
high mortality and morbidity, including adverse kidney events. Diabetes is among the 
strongest common risk factors for end-stage renal disease, and in industrialized countries 
diabetes contributes to approximately 50% of cases3. Less is known about the pattern of 
kidney function decline associated with diabetes that precedes end-stage renal disease. 
Identifying patterns of estimated glomerular filtration rate (eGFR) decline could 
inform monitoring practices for people at high risk of chronic kidney disease progression. 
A better understanding of when and in whom eGFR decline occurs would be useful for 
the design of clinical trials, since eGFR decline greater than 30% is now often used as a 
surrogate endpoint for chronic kidney disease progression4. Trajectories among persons 
with diabetes are of particular interest because of the possibility for early intervention and 
the prevention of chronic kidney disease development. However, eGFR trajectories 
among persons with new diabetes may be complex, due to the hypothesized period of 
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“hyperfiltration” whereby GFR increases, followed by progressive, rapid decline5. 
Using data from the Atherosclerosis Risk in Communities (ARIC) Study, an 
ongoing prospective community-based cohort of over 15,000 participants initiated in 
1987 with serial measurements of creatinine over 26 years, our aim was to characterize 
patterns of eGFR decline associated with diabetes, to identify demographic, genetic, and 
modifiable risk factors within the population with diabetes mellitus that were associated 
with steeper eGFR decline, and to assess for evidence of early hyperfiltration. 
Methods 
Study Population 
The ARIC study is comprised of 15,792 participants from four U.S. communities 
(Forsyth County, North Carolina; Jackson, Mississippi; suburban Minneapolis, 
Minnesota; and Washington County, Maryland)6. Six study visits have been completed to 
date. We included data from the four visits with creatinine measurements (Visit 1 1987-
89 (serum), Visit 2 1990-90 (serum), Visit 4 1996-98 (plasma), and Visit 5 2011-13 
(serum)). Institutional review boards at each site approved the study and all participants 
provided informed consent. 
Of the 15,792 participants who attended the first visit, we excluded those who had 
eGFR ≤15 ml/min/1.73 m2 or end-stage renal disease at baseline (Visit 1, n=25), those 
not black or white race or black from the Minnesota or Maryland sites (n=103), and who 
were missing eGFR measurements (n=147), resulting in 15,517 participants in our study 
population. 
Diabetes Assessment 
Diabetes status was assessed at Visit 1 (baseline) and categorized as no diabetes, 
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undiagnosed diabetes, and diagnosed diabetes. Undiagnosed diabetes was defined as a 
fasting glucose ≥126 mg/dL or non-fasting glucose ≥200 mg/dL without medication or 
physician diagnosis. Diagnosed diabetes was defined as a self-report of physician 
diagnosis or use of glucose-lowering medication. 
Kidney Function Estimation 
Creatinine measurements were calibrated across study visits to minimize 
methodological differences and converted to eGFR using the Chronic Kidney Disease 
Epidemiology Collaboration (CKD-EPI) equation7,8. End stage renal disease was defined 
as identification of incident disease due to renal replacement therapy (dialysis, transplant) 
from the United States Renal Data System (USRDS) during follow-up9. For our analysis, 
participants were assigned an eGFR of 15 ml/min/1.73 m2 at the onset of end-stage renal 
disease and then censored, meaning subsequent visit-based eGFR values were not 
included. 
Covariate Assessment 
Age, sex, race, history of coronary heart disease, smoking status, annual family 
income, education status, and use of hypertension and diabetes medications were self-
reported10. Systolic blood pressure was measured three times using a random zero 
sphygmomanometer with the participant in the resting state. The second and third 
measurements were then averaged to obtain one value11. Height and weight were 
measured with standard protocols and the measurements were used to calculate body 
mass index (weight (kg)/height (m)2)10. 
APOL1 risk status, Hemoglobin A1c (HbA1c), and 1,5-anhydroglucitol were 
examined among those with diagnosed diabetes. APOL1 risk status, which has also been 
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demonstrated to be associated with chronic kidney disease progression12,13, was assessed 
in African Americans who provided consent for DNA testing at Visit 1 per methods 
described previously13. We imputed APOL1 risk status as low-risk for white participants, 
and characterized black participants as APOL1-low risk or APOL1-high risk based on the 
number of risk alleles. HbA1c, a marker of glycemic control and diabetes severity among 
those with diabetes, was measured in Visit 2 whole blood samples using the Tosoh A1c 
2.2 and Tosoh G7 (Tosoh Bioscience)14, methods certified by the National 
Glycohemoglobin Standardization Program and aligned to the Diabetes Control and 
Complications Trial. 1,5-anhydroglucitol (GlycoMark assay), a novel biomarker that 
reflects hyperglycemic excursions and may be associated with kidney disease 
progression15, was measured in serum samples using the Roche Modular P800 Chemistry 
Analyzer (Roche Diagnostics Corporation). For additional detail on study design and 
timing of measurements see Figure B-1. 
Statistical analysis 
We categorized people into groups of no diabetes, undiagnosed diabetes, and 
diagnosed diabetes at baseline (Visit 1), and compared baseline clinical characteristics 
using ANOVA for continuous variables and Pearson’s chi-squared tests for categorical 
variables. We generated a scatterplot of eGFR and age across visits by diabetes status at 
baseline, using locally weighted scatterplot smoothing to find a curve of best fit for each 
diabetes group. To estimate individual eGFR slopes over time, we used linear mixed 
effects models with random intercepts and random slopes. These models were fit on 
diabetes status at baseline as a nominal variable to adjust the baseline level of eGFR and 
included an interaction term between diabetes status at baseline and time to estimate 
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annual decline in eGFR by diabetes categories. Linear mixed models were run unadjusted 
and adjusted, with the latter model including the following diabetes and kidney-disease 
related risk factors: age, sex, race-center, body mass index, systolic blood pressure, 
hypertension medication use, HDL, prevalent coronary heart disease, annual family 
income, education status, and smoking status, as well as each variable interacted with 
time. Continuous covariates were centered at the analytic population mean. We tested 
model assumptions and considered different covariance structures, comparing nested 
models using Akaike’s Information Criteria. We identified the unstructured covariance 
model as the most optimal and conservative approach. From the mixed models, we 
described the overall mean annual decline by diabetes status at baseline, and used the 
random effects to estimate best linear unbiased predictions to describe the distributions of 
yearly slopes in eGFR by diabetes status at baseline and displayed them using kernel 
density plots.  
Because of substantial variation in annual eGFR slope among people with 
diagnosed diabetes, we sought to identify risk factors that were associated with faster 
decline. Among those with diagnosed diabetes, we compared unadjusted and adjusted 
mean annual decline in eGFR by race-APOL1 risk status (white, black- APOL1 low risk, 
black- APOL1 high risk), systolic blood pressure (<140 mmHg, ≥140 mmHg), smoking 
status (never, former, current), prevalent coronary heart disease (no prevalent coronary 
heart disease, prevalent coronary heart disease), diabetes medication use (no medication 
use, oral medication use only [sulfonylureas], and any insulin use), HbA1c (<7%, ≥7 & 
<9%, ≥9%), and 1,5-anhydroglucitol (≥10 μg/mL, <10 μg/mL). Because some of these 
variables were only available at Visit 2, we required that participants included in this 
 23 
subgroup analysis attend both Visit 1 and Visit 2 and not be missing information on 
APOL1 or the variables assessed at Visit 2 to ensure a consistent sample size. In addition 
to diabetes and kidney-disease related risk factors in the adjusted model, we also included 
diabetes medication use and HbA1c to account for diabetes severity in these analyses. 
Next, to enable assessment of potential hyperfiltration, we used a linear spline 
model to allow the slope to change for each of the diabetes categories between the first 3 
years of follow-up (Visit 1 to Visit 2) and the subsequent time period (Visit 2 to Visit 5). 
We reported the unadjusted and adjusted distributions of annual eGFR slopes by diabetes 
status (assessed at baseline) from Visit 1 to Visit 2 and Visit 2 to Visit 5. 
To test the robustness of our results, we conducted a sensitivity analysis where we 
did not assign eGFR values of 15 ml/min/1.73 m2 in those who developed end stage renal 
disease. All analyses were conducted in Stata 13 (StataCorp, College Station, TX). 
Results 
Study Population Characteristics 
There were 15,517 participants included in the analysis: 13,698 (88%) without 
diabetes, 634 (4%) with undiagnosed diabetes, and 1,185 (8%) with diagnosed diabetes at 
baseline. There were 47,695 total eGFR measurements, three or more measurements per 
person among 76% of participants (78% among no diabetes, 67% among undiagnosed 
diabetes, 58% among diagnosed diabetes), and 375 cases of end-stage renal disease 
during follow-up (188 among no diabetes, 38 among undiagnosed diabetes, 149 among 
diagnosed diabetes). 
 At baseline, participants with undiagnosed and diagnosed diabetes were older, 
more likely to be black, more likely to have hypertension and coronary heart disease, and 
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had higher mean body mass index and lower mean HDL, compared to those without 
diabetes (Table 1). Income and education levels were also lower among those with 
undiagnosed and diagnosed diabetes compared to those without diabetes. 
Decline in eGFR by Diabetes Status 
Overall, there was a nearly linear association between eGFR and age over time, 
regardless of diabetes status (Figure 1). The crude mean annual decline in eGFR was 
slowest among those without diabetes at baseline (decline of -1.6 ml/min/1.73 m2 per 
year [95% CI, -1.6, -1.5]), faster among those with undiagnosed diabetes at baseline 
compared to those without diabetes (decline of -2.1 ml/min/1.73 m2 per year [95% CI, -
2.2, -2.0]; difference of -0.6 ml/min/1.73 m2 per year [95% CI, -0.7, -0.4]), and nearly 
twice as rapid among those with diagnosed diabetes compared to those without diabetes 
(decline of -2.9 ml/min/1.73 m2 per year [95% CI, -3.0, -2.8]; difference of -1.3 
ml/min/1.73 m2 per year [95% CI, -1.4, -1.2]). Adjustment for diabetes and kidney 
disease-related risk factors attenuated the results slightly, but those with undiagnosed and 
diagnosed diabetes still had statistically significantly steeper declines than those without 
diabetes (decline among those without diabetes: -1.4 ml/min/1.73 m2 per year [95% CI -
1.5, -1.4]; decline among those with undiagnosed diabetes: -1.8 ml/min/1.73 m2 per year 
[95% CI -2.0, -1.7], difference vs. no diabetes of -0.4 ml/min/1.73 m2 per year [95% CI, -
0.5, -0.3, p<0.001]; decline among those with diagnosed diabetes: -2.5 ml/min/1.73 m2 
per year [95% CI -2.6, -2.4], difference vs. no diabetes of -1.1 ml/min/1.73 m2 per year 
[95% CI, -1.2, -1.0, p<0.001]). 
 The decline in eGFR per year varied greatly across individuals, particularly 
among those with diabetes at baseline (Figure 2). Crude yearly individual predicted 
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slopes ranged from (10th to 90th percentile) -2.3 to -1.0 ml/min/1.73 m2 per year among 
those without diabetes (median: -1.6 ml/min/1.73 m2 per year); this range was from -3.1 
to -1.4 ml/min/1.73 m2 per year among those with undiagnosed diabetes (median: -2.1 
ml/min/1.73 m2 per year); and from -4.1 to -2.0 ml/min/1.73 m2 per year among those 
with diagnosed diabetes (median: -2.9 ml/min/1.73 m2 per year). While adjustment for 
risk factors related to diabetes and kidney disease reduced some of the variation between 
diabetes categories, the differences in eGFR decline were still statistically significant.  
Factors Associated with eGFR Decline Among Diagnosed Diabetes 
Among participants with diagnosed diabetes at baseline, those who were black, 
who had systolic blood pressure ≥140 mmHg, who used diabetes medications, had a 
HbA1c ≥7%, or had 1,5-anhydroglucitol <10 μg/mL were at risk for steeper annual 
declines than their counterparts (Table 2). Smoking status and prevalent coronary heart 
disease were not associated with significantly steeper eGFR decline in unadjusted 
analyses. Adjustment for diabetes- and kidney disease-related risk factors and diabetes 
medication use and HbA1c (used as proxies for diabetes severity), attenuated the 
differences in decline for all subgroups with the exception of smoking status, leaving 
black race along with APOL1 susceptible genotype, systolic blood pressure ≥140 mmHg, 
current smoking, insulin use, and HbA1c ≥9% as the risk factors indicative of steeper 
decline. 
eGFR Trajectories by Time Period 
When the effect of diabetes on eGFR decline was assessed in two different time 
periods, we saw potential evidence of hyperfiltration. From Visit 1 to Visit 2, the 
distribution of adjusted decline in eGFR among those with undiagnosed diabetes at 
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baseline was less negative than those without diabetes, suggesting that they did not 
experience as much decline over the 3-year interval (Figure 3). Similarly, the adjusted 
mean annual decline in eGFR was largest among those with diagnosed diabetes, followed 
by those without diabetes, and then by those with undiagnosed diabetes at baseline (-2.5 
ml/min/1.73 m2 per year [95% CI, -2.8, -2.1]; -1.7 ml/min/1.73 m2 [95% CI, -1.9, -1.4]; 
and -1.3 ml/min/1.73 m2 per year [95% CI, -1.7, -0.8], respectively). This resulted in a 
difference in slope over the first three years comparing undiagnosed to no diabetes at 
baseline of 0.4 ml/min/1.73 m2 per year (95% CI, 0.1, 0.8). The unadjusted distribution of 
slopes and mean decline and followed a similar pattern. Additionally, those with 
undiagnosed diabetes showed suggestion of a higher eGFR at baseline than those without 
diabetes at baseline in the unadjusted model (0.7 ml/min/1.73 m2 [95% CI -0.6, 2.0]), 
which was statistically significantly higher after adjustment (2.3 ml/min/1.73 m2 [95% CI 
1.1, 3.4]). 
Over the remainder of follow-up, from Visit 2 to Visit 5, we observed that the 
distributions of unadjusted and adjusted slopes among those with undiagnosed diabetes at 
baseline were more negative than those without diabetes at baseline (Figure B-2). 
Sensitivity analyses without imputation of eGFR for those who developed end 
stage renal disease attenuated the values of the mean annual declines in eGFR, but the 
significant differences between diabetes categories remained (Table B-1). 
Discussion 
 In this prospective, community-based cohort followed for over 26 years, we 
observed that diabetes is an important risk factor for kidney function decline. Persons 
with undiagnosed diabetes at baseline were also at higher risk of eGFR decline; 
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interestingly, this followed a period of relatively little average eGFR decline, which may 
reflect early hyperfiltration. Large individual variation in eGFR trajectories was 
observed, particularly among persons with diabetes, with race, systolic blood pressure, 
and glycemia explaining some of the risk differences. Given the well-established 
evidence that glycemic control prevents or slows microvascular damage, our findings 
reinforce the need for early diagnosis of diabetes and glycemic control following 
diagnosis16–18. Our results also suggest racial disparities persist over and above measured 
genetic and traditional risk factors.  
Few other community-based studies have evaluated differences in kidney function 
decline by diabetes status over a long period through mid- and late-life. One study of 
10,184 Canadians aged 66 years or older with creatinine measured during outpatient 
visits showed results largely consistent our findings but with much shorter follow-up 
(median of 2 years)19.  
Other studies of eGFR change in a general population have found smaller declines 
than our results20,21. A study conducted in Japanese participants aged 40 to 79 years 
found a decline of only -0.4 ml/min/1.73 m2 per year over the course of two assessments 
10 years apart (compared to our estimate among those without diabetes: -1.6 ml/min/1.73 
m2 per year). This is particularly interesting, as Japan is known to have a higher 
prevalence of chronic kidney disease and end-stage renal disease than the U.S.20. 
However, this study evaluated participants over a shorter time frame and required 
attendance at both assessments, which may decreased the likelihood of capturing severe 
cases and resulted in underestimation of decline. 
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The Baltimore Longitudinal Study of Aging also assessed kidney function over 
time in a general population of 446 men, ranging in age from 22 to 97 years at baseline, 
each with up to 14 measurements of creatinine clearance assessed between 1958 and 
198121. They also found a smaller decline than we did (-0.8 ml/min per year), although 
this study also had notable differences. Their main analysis excluded participants with 
hypertension and history of renal disease or urinary tract infection, and those treated with 
diuretics and/or anti-hypertensive medications. Without applying those exclusions, their 
overall estimate was -1.1 ml/min per year, which better reflects a community-based 
population and our results. The study also took place prior to ARIC, and risk factor and 
treatment patterns may have differed due to secular trends. In addition, they used 
creatinine clearance instead of eGFR as a measure of kidney function, and while this may 
not affect computation of change, creatinine clearance estimates are known to be higher 
than GFR22.  
In our evaluation of risk factors that might explain the variation in decline seen 
among those with diagnosed diabetes, we observed that black race, systolic blood 
pressure ≥140 mmHg, insulin use, and HbA1c ≥9% were particularly important. 
Although the APOL1 high-risk genotype is a known risk factor for eGFR decline, 
African-Americans with low-risk APOL1 status continued to be at higher risk than whites 
even after adjustment for traditional risk factors, diabetes medication use, and HbA1c. 
This suggests there could be differences over time by risk factors, diabetes severity, 
access to health care, quality of health care, or health care utilization not accounted for in 
our analysis. 
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Our results are relevant to the design and conduct of clinical trials. Hard clinical 
outcomes like end-stage renal disease are relatively rare and a 30-40% decline in eGFR is 
now accepted as a surrogate endpoint for chronic kidney disease progression4. We 
provide data on patient subgroups that may experience accelerated trajectories of kidney 
function decline, which has implications for estimating sample size and ensuring 
adequate power in future clinical trials. Our results also suggest that endpoints of eGFR 
decline might not be appropriate for patients with new onset diabetes, where declines 
may actually be slower than among persons without diabetes. 
Slower eGFR decline among those with undiagnosed diabetes, who are likely 
early in the course of diabetes is consistent with the hypothesis of hyperfiltration. Similar 
to other studies, we found that persons with undiagnosed diabetes had higher GFR at the 
outset, but this was a transient phenomenon as they ultimately experienced larger 
declines in kidney function than those without diabetes over the course of follow-up23–25. 
Whether hyperfiltration is a universal aspect of early disease and, if not, whether it 
portends worse long-term outcomes is uncertain. Existing studies investigating 
hyperfiltration as a precursor to adverse kidney outcomes are inconsistent24,26,27 and often 
confounded by diabetes severity factors like duration27. We extended this literature by 
separating undiagnosed and diagnosed diabetes to help address that confounding. 
Our analysis has certain limitations. Detection of possible hyperfiltration was 
limited to two measurements of eGFR per person over a three-year time interval, and up 
to three measurements in the subsequent 23 years. Undiagnosed diabetes at Visit 1 was 
defined solely by glucose, which may have led to some misclassification. A single 
measurement of fasting glucose is prone to measurement error, given that only 76% of 
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those with diabetes by a single fasting glucose are confirmed by a second measurement. 
This suggests we could have overestimated the prevalence of undiagnosed diabetes, 
although this bias would be conservative28. There were also changes in clinical 
definitions of diabetes during the study period. At the time of Visit 1 (1987-1989), a 
higher threshold of glucose was recommended for the diagnosis of diabetes (140 mg/dL). 
We employed a more conservative definition (≥126 mg/dL) for consistency with current 
clinical guidelines29. Additionally, while we were able to use undiagnosed diabetes to 
likely capture those early in the course of disease, we did not have information on 
diabetes duration at baseline among those with undiagnosed or diagnosed diabetes. 
Finally, albuminuria, itself a strong predictor of eGFR decline, was not assessed in ARIC 
until Visit 4. 
Study strengths include the racially diverse community-based cohort of middle-
aged adults in the U.S. in the late 1980s followed through the early 2010s. Changes in 
kidney function were captured prior to the approval of new diabetes medications with 
kidney-related effects, such as sodium-glucose cotransporter (SGLT)-2 inhibitors, which 
might confound results. We also had complete follow-up for end stage renal disease from 
the linkage of ARIC to the USRDS surveillance system, allowing us to account for those 
who develop end-stage renal disease, even if they did not return to a study visit. 
In conclusion, we found that diabetes was associated with much steeper kidney 
function decline in a community-based population followed over 26 years. We quantified 
the annual expected decline in eGFR among those without diabetes, with undiagnosed 
diabetes, and with diagnosed diabetes, which may be useful to inform future monitoring 
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and clinical trials. Our results reinforce the importance of glycemic and risk factor control 
in the prevention of chronic kidney disease and end stage renal disease. 
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Age (years) 54.5 (5.7) 56.0 (5.7) 56.4 (5.7) <0.001 
Female, % 55.2 48.4 57.6 <0.001 
Race-center, %     
Forsyth County, NC – White 23.5 16.7 16.0 <0.001 
Forsyth County, NC – Black 2.9 4.4 4.8 
Jackson, MS – Black 21.1 31.1 41.7 
Minneapolis, MN – White 26.8 23.2 12.7 
Washington County, MD – White 25.7 24.6 24.7 
eGFR (mL/min/1.73 m2) 102.6 (14.7) 103.3 (17.5) 102.3 (20.9) 0.42 
eGFR <60 mL/min/1.73 m2, % 0.9 1.4 4.1 <0.001 
Systolic blood pressure (mmHg) 120.1 (18.3) 130.4 (19.6) 129.1 (21.3) <0.001 
Hypertension, % 31.4 59.8 60.1 <0.001 
Body mass index (kg/m2) 27.2 (5.1) 31.2 (5.7) 31.0 (6.0) <0.001 
HDL (mg/dL) 52.5 (17.2) 43.6 (13.5) 45.2 (15.4) <0.001 
Prevalent coronary heart disease, % 4.2 6.6 12.6 <0.001 
Smoking status, %     
Never smoker 41.2 42.7 44.9 0.018 
Former smoker 32.3 34.9 31.1 
Current smoker 26.5 22.4 24.0 
Annual family income less than $25,000, % 35.2 49.2 61.3 <0.001 
Educational status, %     
Less than high school 8.4 12.8 19.7 <0.001 
High school 46.1 49.1 50.5 
Vocational school 8.6 8.2 6.8 
College 26.5 21.8 16.9 
Graduate/professional school 10.4 8.2 6.1 
Data are means (SD) unless otherwise noted 
* Baseline variables with missingness (variable, n): systolic blood pressure, 7; hypertension, 75; body mass index, 13; HDL, 109; prevalent coronary 
heart disease, 319; smoking status, 14; annual family income, 898; and educational status, 25 
† p-value for global test: ANOVA for continuous variables and Pearson’s chi-squared tests for categorical variables 
Abbreviations: eGFR estimated glomerular filtration rate; HDL high-density lipoprotein  
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Figure 1. Scatterplot of eGFR and age according to visit with lowess smoothers by diabetes status at baseline 
   
Abbreviations: eGFR estimated glomerular filtration rate 
 
Legend 
Visit 1  Visit 2  Visit 4  Visit 5; No diabetes  Undiagnosed diabetes  Diagnosed diabetes  
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Figure 2. Distribution of annual unadjusted and adjusted eGFR slopes from best linear unbiased predictions, by diabetes status 
Unadjusted        Adjusted 
 
 Percentile and corresponding change in eGFR per year (mL/min/1.73m2) 
 Unadjusted Adjusted* 
 10th 25th 50th 75th 90th 10th 25th 50th 75th 90th 
No diabetes -2.3 -1.9 -1.6 -1.3 -1.0 -1.9 -1.6 -1.4 -1.2 -1.0 
Undiagnosed diabetes -3.1 -2.5 -2.1 -1.7 -1.4 -2.4 -2.0 -1.8 -1.5 -1.3 
Diagnosed diabetes -4.1 -3.4 -2.9 -2.4 -2.0 -3.5 -2.7 -2.5 -2.2 -1.8 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their means: age (ref=54.67 years), sex 
(ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, Minneapolis-White, Washington County-White), systolic blood 
pressure (ref=121.22), hypertension medication use (ref=no; yes), body mass index (ref=27.68), HDL (ref=51.60), prevalent coronary heart disease (ref=no; 
yes), smoking status (ref=never; former, current), annual family income (ref: <$25,000; ≥$25,000), and educational status (ref: high school; less than high 
school, vocational school, college, graduate/professional school) 
Abbreviations: eGFR estimated glomerular filtration rate 
Legend: No diabetes  Undiagnosed diabetes  Diagnosed diabetes 
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Table 2. Unadjusted and adjusted differences in mean annual change in eGFR among those with diagnosed diabetes who attended Visits 1 
& 2, by subgroups of interest, n=838 
Subgroup n 
Unadjusted difference (95%CI) 
from reference, ml/min/1.73m2 
p-value for 
difference 
Adjusted* difference (95%CI) 
from reference, ml/min/1.73m2 
p-value for 
difference 
Race and APOL1† (Visit 1)      
White 495 0 (REF)  0 (REF)  
Black – APOL1 Low Risk 290 -1.3 (-1.7, -0.9) <0.001 -0.7 (-1.2, -0.3) 0.001 
Black – APOL1 High Risk 53 -1.7 (-2.5, -1.0) <0.001 -1.3 (-2.1, -0.6) 0.001 
Systolic blood pressure‡ (Visit 1)      
< 140 mmHg 643 0 (REF)  0 (REF)  
≥ 140 mmHg 195 -1.3 (-1.7, -0.8) <0.001 -1.0 (-1.4, -0.5) <0.001 
Smoking status§ (Visit 1)      
Never Smoker 400 0 (REF)  0 (REF)  
Former Smoker 258 0.1 (-0.4, 0.5) 0.808 -0.2 (-0.7, 0.2) 0.271 
Current Smoker 180 -0.3 (-0.8, 0.2) 0.224 -0.6 (-1.1, -0.1) 0.018 
Prevalent coronary heart disease|| (Visit 1)      
No prevalent coronary heart disease 743 0 (REF)  0 (REF)  
Prevalent coronary heart disease 95 -0.6 (-1.3, 0.0) 0.068 -0.6 (-1.2, 0.1) 0.080 
Diabetes medication use¶ (Visit 1)      
No medication use 279 0 (REF)  0 (REF)  
Oral medication use only 319 -0.7 (-1.1, -0.3) 0.002 -0.3 (-0.7, 0.2) 0.270 
Any insulin use 240 -1.8 (-2.2, -1.3) <0.001 -1.1 (-1.6, -0.6) <0.001 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their means: age (ref=56.09 years), sex 
(ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, Minneapolis-White, Washington County-White), systolic blood 
pressure (ref=128.04), hypertension medication use (ref=no; yes), body mass index (ref=30.87), HDL (ref=45.08), prevalent coronary heart disease (ref=no; 
yes), smoking status (ref=never; former, current), annual family income (ref: <$25,000; ≥$25,000), and educational status (ref: high school; less than high 
school, vocational school, college, graduate/professional school), diabetes medication use (ref=no medication use; oral medication use only, any insulin use), 
and HbA1c (ref=8.49) 
Adjusted for all covariates with the exception of: † race-center; ‡ systolic blood pressure; § smoking status; || prevalent coronary heart disease; ¶ diabetes 
medication use; # HbA1c 
** Adjusted difference from REF when 1,5-anhydroglucitol is adjusted for all covariates except HbA1c: -0.4 ml/min/1.73m2 (95% CI, -0.8, 0.0), p=0.060 
Abbreviations: eGFR estimated glomerular filtration rate; HbA1c hemoglobin A1c 
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Table 2., continued 
Subgroup n 
Unadjusted difference (95%CI) 
from reference, ml/min/1.73m2 
p-value for 
difference 
Adjusted* difference (95%CI) 
from reference, ml/min/1.73m2 
p-value for 
difference 
HbA1c# (Visit 2)      
< 7% 250 0 (REF)  0 (REF)  
≥ 7 & < 9% 270 -0.6 (-1.0, -0.1) 0.011 -0.1 (-0.6, 0.4) 0.623 
≥ 9% 318 -1.5 (-1.9, -1.0) <0.001 -0.7 (-1.2, -0.2) 0.004 
1,5-anhydroglucitol** (Visit 2)      
≥ 10 μg/mL 238 0 (REF)  0 (REF)  
< 10 μg/mL 600 -0.9 (-1.3, -0.5) <0.001 0.1 (-0.4, 0.6) 0.717 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their means: age (ref=56.09 years), sex 
(ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, Minneapolis-White, Washington County-White), systolic blood 
pressure (ref=128.04), hypertension medication use (ref=no; yes), body mass index (ref=30.87), HDL (ref=45.08), prevalent coronary heart disease (ref=no; 
yes), smoking status (ref=never; former, current), annual family income (ref: <$25,000; ≥$25,000), and educational status (ref: high school; less than high 
school, vocational school, college, graduate/professional school), diabetes medication use (ref=no medication use; oral medication use only, any insulin use), 
and HbA1c (ref=8.49) 
Adjusted for all covariates with the exception of: † race-center; ‡ systolic blood pressure; § smoking status; || prevalent coronary heart disease; ¶ diabetes 
medication use; # HbA1c 
** Adjusted difference from REF when 1,5-anhydroglucitol is adjusted for all covariates except HbA1c: -0.4 ml/min/1.73m2 (95% CI, -0.8, 0.0), p=0.060 
Abbreviations: eGFR estimated glomerular filtration rate; HbA1c hemoglobin A1c 
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Figure 3. Distribution of annual unadjusted and adjusted eGFR slopes from Visit 1 to Visit 2 from best linear unbiased predictions, by 
diabetes status 
Unadjusted        Adjusted 
  
 Percentile and corresponding change in eGFR per year (mL/min/1.73m2) 
 Unadjusted Adjusted* 
 10th 25th 50th 75th 90th 10th 25th 50th 75th 90th 
No diabetes -2.6 -2.4 -2.3 -2.1 -2.0 -2.3 -1.9 -1.6 -1.4 -1.2 
Undiagnosed diabetes -2.3 -2.1 -1.9 -1.7 -1.6 -2.0 -1.5 -1.2 -0.9 -0.7 
Diagnosed diabetes -3.8 -3.4 -3.3 -3.0 -2.8 -3.5 -2.7 -2.4 -2.0 -1.7 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their means: age (ref=54.67 years), sex 
(ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, Minneapolis-White, Washington County-White), systolic blood 
pressure (ref=121.22), hypertension medication use (ref=no; yes), body mass index (ref=27.68), HDL (ref=51.60), prevalent coronary heart disease (ref=no; 
yes), smoking status (ref=never; former, current), annual family income (ref: <$25,000; ≥$25,000), and educational status (ref: high school; less than high 
school, vocational school, college, graduate/professional school); Abbreviations: eGFR estimated glomerular filtration rate 
Legend: No diabetes  Undiagnosed diabetes  Diagnosed diabetes 
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Abstract 
Background. No consensus on definitions of prediabetes exists among international 
organisations. Analysis of associations with different definitions and clinical 
complications can inform the comparative value of different prediabetes definitions. We 
compared the risk of future outcomes across different prediabetes definitions based on 
fasting glucose concentration, HbA1c, and 2 h glucose concentration during over two 
decades of follow-up in the community-based Atherosclerosis Risk in Communities 
(ARIC) study. We aimed to analyse the associations of definitions with outcomes to 
provide a comparison of different definitions. 
Methods. We did a prospective cohort study of participants in the ARIC study who did 
not have diagnosed diabetes and who attended visit 2 (1990–92; n=10844) and who 
attended visit 4 (1996–98; n=7194). ARIC participants were enrolled from four 
communities across the USA. Fasting glucose concentration and HbA1c were measured 
at visit 2 and fasting glucose concentration and 2 h glucose concentration were measured 
at visit 4. We compared prediabetes definitions based on fasting glucose concentration 
(American Diabetes Association [ADA] fasting glucose concentration cutoff 5.6–6.9 
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mmol/L and WHO fasting glucose concentration cutoff 6.1–6.9 mmol/L), HbA1c (ADA 
HbA1c cutoff 5.7–6.4% [39–46 mmol/mol] and International Expert Committee [IEC] 
HbA1c cutoff 6.0–6.4% [42–46 mmol/mol]), and 2 h glucose concentration (ADA and 
WHO 2 h glucose concentration cutoff 7.8–11.0 mmol/L). 
Findings. Prediabetes defined using the ADA fasting glucose concentration cutoff 
(prevalence 4112 [38%] of 10 844 people; 95% CI 37.0–38.8) was the most sensitive for 
major clinical outcomes, whereas using the ADA HbA1c cutoff (2027 [19%] of 10884 
people; 18.0–19.4) and IEC HbA1c cutoff (970 [9%] of 10844 people; 8.4–9.5), and the 
WHO fasting glucose concentration cutoff (1213 [11%] of 10844 people; 10.6–11.8) 
were more specific. After demographic adjustment, HbA1c -based definitions of 
prediabetes had higher hazard ratios and better risk discrimination for chronic kidney 
disease, cardiovascular disease, peripheral arterial disease, and all-cause mortality than 
did fasting glucose concentration-based definitions (all p<0.05). The C-statistic for 
incident chronic kidney disease was 0.636 for ADA fasting glucose concentration clinical 
categories and 0.640 for ADA HbA1c clinical categories (difference –0.005, 95% CI –
0.008 to –0.001). The C-statistics were 0.662 for ADA fasting glucose clinical 
concentration categories and 0.672 for ADA HbA1c clinical categories for atherosclerotic 
cardiovascular disease, 0.701 for ADA fasting glucose concentration clinical categories 
and 0.722 for ADA HbA1c clinical categories for peripheral arterial disease, and 0.683 
for ADA fasting glucose concentration clinical categories and 0.688 for ADA HbA1c 
clinical categories for all-cause mortality. Prediabetes defined using the ADA HbA1c 
cutoff showed a significant overall improvement in the net reclassification index for 
cardiovascular outcomes and death compared with prediabetes defined with glucose-
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based definitions. ADA fasting glucose concentration clinical categories, WHO fasting 
glucose concentration clinical categories, and ADA and WHO 2 h glucose concentrations 
clinical categories were not significantly different in terms of risk discrimination for 
chronic kidney disease, cardiovascular outcomes, or mortality outcomes. 
Interpretation. Our results suggest that prediabetes definitions using HbA1c were more 
specific and provided modest improvements in risk discrimination for clinical 
complications. The definition of prediabetes using the ADA fasting glucose concentration 
cutoff was more sensitive overall.  
Funding US National Institutes of Health. 
Introduction 
Prediabetes is a pressing clinical and public health problem that affects 
approximately 12–30% of US adults aged 18 years and older, depending on the definition 
used.1 International organisations largely agree on the clinical cutoff points for diagnosis 
of diabetes and, in 2010, HbA1c ≥6.5% (≥48 mmol/mol) was adopted for diagnosis of 
diabetes by many international groups, in part based on the association of HbA1c with 
retinopathy.2–5 By contrast, the category of prediabetes does not have a uniform 
definition. The American Diabetes Association (ADA) recommends using the following 
criteria to identify people with prediabetes: fasting glucose con centration between 5.6 
and 6.9 mmol/L (100–125 mg/dL; impaired fasting glucose), HbA1c of 5.7–6.4% (39–46 
mmol/mol), or 2 h glucose concentration after a 75 g oral glucose tolerance test of 7.8–
11.0 mmol/L (140–199 mg/dL; impaired glucose tolerance).6 WHO also recommends 2 h 
glucose of 7.8–11.0 mmol/L to identify impaired glucose tolerance, but recommends a 
fasting glucose concentration of 6.1–6.9 mmol/L (110–125 mg/dL) to identify impaired 
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fasting glucose.2 In 2009, the International Expert Committee (IEC) recommended 
HbA1c of 6.0–6.4% (42–46 mmol/mol) for the identification of an intermediate risk 
group, which has been adopted by some organisations.5 Identification of individuals with 
pre- diabetes provides an opportunity for intervention through lifestyle modification and 
pharmacological interventions to prevent progression to diabetes.6,7 Consensus on 
definitions of prediabetes could help guide resource allocation and aid public health 
efforts to identify people at risk of developing diabetes and its complications.  
 Although the selection of biomarker cutoff points for screening or diagnosis 
requires a broad range of considerations, associations with clinical outcomes are an 
important factor.8 Therefore, the aim of this study was to compare the prognostic 
performance of the abovementioned definitions of prediabetes in their associations with 
major clinical complications such as incident diabetes, chronic kidney disease, 
atherosclerotic cardiovascular disease, peripheral arterial disease, and all-cause mortality. 
We compared the risk of future outcomes across different definitions of prediabetes by 
fasting glucose concentration, HbA1c, and 2 h glucose concentration during over two 
decades of follow-up in the community-based Atherosclerosis Risk in Communities 
(ARIC) study.  
Methods 
Study design and participants  
This prospective cohort study was based on the ARIC study, which originally 
enrolled 15792 adults aged 45–64 years from the communities of Jackson, MS; Forsyth 
County, NC; suburban Minneapolis, MN; and Washington County, MD, USA. We 
excluded participants with prevalent diabetes, chronic kidney disease, atherosclerotic 
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cardiovascular disease, or peripheral arterial disease, those who were missing variables of 
interest, or those who fasted for less than 10 h (see appendix for full details). Detailed 
methods of the study have been previously published.9 Briefly, the first examination, 
including medical, social, and demographic assessment, took place from 1987 to 1989, 
with three follow-up visits approximately every 3 years, and a fifth visit between 2011 
and 2013. Institutional review board approval was acquired at all study sites and written 
consent was obtained from all participants. 
Procedures 
We did two main comparisons. First, with visit 2 (1990–92) as baseline, when 
both fasting glucose concentration and HbA1c were measured. And, second, with visit 4 
(1996–98) as baseline, when both fasting glucose concentration and 2 h glucose 
concentration were measured. Our final sample size included 10 844 participants who 
attended visit 2 and 7194 participants who attended visit 4 (appendix). Fasting glucose 
was measured using a hexokinase method in serum at visit 2 and in plasma at visit 4. We 
formally compared and recalibrated fasting glucose concentrations to ensure equivalence 
of the measurements over time.10 HbA1c was measured in stored whole-blood samples 
from visit 2 by high-performance liquid chromatography using the Tosoh A1c 2.2 Plus 
and Tosoh G7 methods (Tosoh Bioscience, San Francisco, CA, USA), aligned to those 
used in the Diabetes Control and Complications Trial.11 2 h plasma glucose concentration 
was measured following a 75 g oral glucose tolerance test administered using a 
hexokinase method at visit 4.12 We defined prediabetes using three definitions recognised 
by the ADA: fasting glucose concentration cutoff 5.6–6.9 mmol/L, HbA1c cutoff 5.7–
6.4% (39–46 mmol/mol), and 2 h glucose cutoff 7.8–11.0 mmol/L, along with definitions 
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recommended by WHO (fasting glucose concentration cutoff 6.1–6.9 mmol/L), and IEC 
(HbA1c cutoff 6.0–6.4% [42–46 mmol/mol]). 
Participants were prospectively followed up and incidents of diabetes, chronic 
kidney disease, atherosclerotic cardiovascular disease (coronary heart disease and 
ischaemic stroke), peripheral arterial disease, and all-cause mortality were recorded until 
end of follow-up in 2013 (loss to follow-up was also recorded). Incident diabetes was 
defined by self-report of a physician diagnosis of diabetes or use of glucose-lowering 
medication reported during a study visit or annual telephone call.13,14 Chronic kidney 
disease was defined as an estimated glomerular filtration rate (eGFR) of <60 mL/min per 
1.73 m² measured at a study visit and a reduction in eGFR of at least 25% from the 
baseline visit to the follow-up visit, or chronic kidney disease-related hospital admission 
or death by continuous active surveillance, or an end-stage renal disease event identified 
by the US Renal Data System registry.15 Incident atherosclerotic cardiovascular disease 
events were adjudicated and included any coronary heart disease hospital admission or 
death, or ischaemic stroke hospital admission or death, and were obtained by continuous 
active surveillance. Peripheral arterial disease events were identified from hospital 
admission records (International Classification of Diseases 9 discharge codes) for 
peripheral arterial disease (440.2, 440.3, 440.4) or leg revascularisation (38.18, 39.25, 
39.29, 39.50). All-cause mortality was ascertained from hospital and National Death 
Index records. BMI, waist-to-hip ratio, blood pressure, lipid concentrations, and eGFR 
(calculated from serum creatinine using the Chronic Kidney Disease Epidemiology 
Collaboration Equation)16 were measured following standard protocols.17–19 Age, sex, 
race centre (white, Minneapolis; black, Jackson; white, Washington County; black, 
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Forsyth County; white, Forsyth County; as defined in the ARIC study design), education 
level, smoking status, alcohol use, parental history of diabetes, and use of lipid-lowering 
medications were reported at study visits. Hypertension was defined as an elevated 
systolic (≥140 mm Hg) or diastolic (≥90 mm Hg) blood pressure from the mean of two 
measurements taken at a study visit or the use of blood-pressure-lowering medications. 
Statistical analysis 
We compared baseline characteristics of the study participants at the relevant visit 
across clinical categories (normoglycaemia, prediabetes, and undiagnosed diabetes) for 
the different definitions of prediabetes. We calculated sensitivity, specificity, positive 
predictive value, negative predictive value, positive likelihood ratio, and negative 
likelihood ratio of each prediabetes definition using 10 year Kaplan-Meier estimates 
comparing people with prediabetes to those with normoglycaemia against people with 
and without the events of interest. Cox proportional hazards models were used to estimate 
adjusted hazard ratios of incident events associated with the different clinical categories, 
with normoglycaemia as the reference group. Demographic-adjusted models included 
age, sex, and race centre. Fully adjusted models included all variables in demographic-
adjusted models plus education level, BMI, waist-to-hip ratio, total cholesterol con- 
centration, HDL cholesterol concentration, triglyceride concentrations, eGFR, 
hypertension, smoking status, alcohol use, lipid-lowering medication use, and family 
history of diabetes. We used Harrell’s C-statistic to compare discrimination of models 
with the different clinical categories with respect to future outcomes and obtained 95% 
CIs with a jackknife approach.20 We calculated the continuous net reclassification index 
(cNRI) for 10 year risk of each outcome for the different clinical categories, using 
 45 
prediabetes defined using ADA fasting glucose concentration cutoffs as the reference. 
We did sensitivity analyses stratifying by race and sex and after excluding people with 
undiagnosed diabetes.21 
As an ancillary analysis, we replicated our study using data from the Third 
National Health and Nutrition Examination Survey (NHANES III), a nationally 
representative sample of the US population, to assess the generalisability of our results 
(appendix). Only prospective information on fatal cardiovascular disease and all-cause 
mortality was available in NHANES. All analyses were done using Stata/SE (version 13).  
Role of the funding source 
The funder of this study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. All authors had access to the data and the 
corresponding author had final responsibility to submit for publication. 
Results 
In comparison with people with prediabetes defined using ADA fasting glucose 
concentration cutoffs at visit 2, use of ADA HbA1c cutoffs to define prediabetes was 
more likely to identify people who were women, black, current smokers, had 
hypertension, and who had less high-school education; it was less likely to identify 
current drinkers (Table 1). In comparison with people defined using ADA fasting 
glucose concentration cutoffs at visit 4, use of ADA and WHO 2 h glucose concentration 
to define prediabetes was more likely to identify women, and less likely to identify black 
and obese people, but baseline risk factors were otherwise similar (Table 2). 
Characteristics of participants identified as having prediabetes using WHO fasting 
glucose concentration cutoffs and using IEC HbA1c cutoffs are shown in the appendix. 
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The prevalence of prediabetes varied between different definitions of prediabetes (Table 
3). Cross-tabulation of the different definitions are shown in the appendix. Among 10844 
participants included in the analyses for visit 2, 3152 incident cases of diabetes, 2608 
incident cases of chronic kidney disease, 1556 incident atherosclerotic cardiovascular 
events, 266 incident cases of peripheral arterial disease, and 3177 deaths were reported in 
approximately 22 years of follow-up. Among 7194 participants included in the analyses 
for visit 4, 1859 incident cases of diabetes, 1444 incident cases of chronic kidney disease, 
760 incident atherosclerotic cardiovascular events, 115 incident cases of peripheral 
arterial disease, and 1568 deaths were reported in approximately 16 years of follow-up 
(appendix). Comparison of the sensitivity and specificity for each definition of 
prediabetes for 10 year risk of each outcome showed that definitions using ADA and IEC 
HbA1c cutoffs, and WHO fasting glucose concentration cutoffs had higher specificity 
than ADA fasting glucose concentration cutoffs for all outcomes, whereas ADA fasting 
glucose concentration cutoffs, and ADA and WHO 2 h glucose concentration cutoffs, 
were more sensitive than WHO fasting glucose concentration cutoffs (Table 4). ADA 
and IEC HbA1c cutoffs, and WHO fasting glucose concentration cutoffs had higher 
positive predictive values and negative likelihood ratios for incident diabetes and higher 
positive likelihood ratios for all outcomes compared with ADA fasting glucose 
concentration cutoffs. Negative predictive values were numerically similar across 
outcomes. 
In Cox proportional hazard models for age, sex, and, race centre, prediabetes by 
all five definitions was significantly associated with risk of future clinical outcomes 
(Table 5). In participants identified as having prediabetes using HbA1c -based 
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definitions, incidence rates were higher, hazard ratios were larger, and C-statistics for 
chronic kidney disease, atherosclerotic cardiovascular disease, peripheral arterial disease, 
and all-cause mortality were higher, than in participants identified using ADA and WHO 
fasting glucose concentration cutoffs (Table 5; appendix). Adjusting for additional risk 
factors did not alter our findings (appendix). The differences in the C-statistics between 
HbA1c-based definitions and glucose-based definitions, although statistically significant, 
were small (improvement in the C-statistic was generally less than 0.02). Prediabetes 
defined using ADA HbA1c cutoffs also showed significant overall improvement in the 
cNRI for atherosclerotic cardiovascular disease, peripheral arterial disease, and all-cause 
mortality compared to prediabetes defined using ADA and WHO fasting glucose 
concentration cutoffs (appendix). The cNRI results show that the improvement was 
modest and primarily driven by the correct reclassification of non-events, consistent with 
the higher specificity of the HbA1c-based definitions than the ADA fasting glucose 
concentration-based definition. For incident diabetes, after demographic adjustment, IEC 
HbA1c cutoffs had the largest hazard ratio, but the ADA fasting glucose concentration 
cutoffs had a significantly higher C-statistic and better classified people at risk for future 
incident diabetes based on overall cNRI improvement (Table 5; appendix). However, 
after adjustment for additional risk factors (fully adjusted model), no significant 
difference in the C-statistics for ADA fasting glucose clinical categories compared with 
the other definitions remained (appendix). The hazard ratios and C-statistics for all 
outcomes were similar when all ADA and WHO glucose prediabetes definitions were 
compared, with the exception of incident diabetes. Although the hazard ratio for WHO 
fasting glucose-defined prediabetes was higher, the C-statistic for ADA fasting glucose-
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defined prediabetes was modestly, although significantly, improved for classification of 
people at risk of developing diabetes (Table 5; appendix). However, these differences did 
not persist after adjustment for additional risk factors (fully adjusted model).  
Exclusion of people with undiagnosed diabetes did not alter our findings 
(appendix). We did not observe consistent differences in results across outcomes in 
analyses by race, with the exception of incident diabetes which was significantly different 
between black and white people (appendix). Across all definitions, black people were less 
likely to report a subsequent diagnosis of diabetes or glucose-lowering-medication use 
during follow-up than were white people in the demographic adjusted model (all p 
interaction <0.05; appendix). After adjustment for additional risk factors (fully adjusted 
model) the difference between black people and white people was reduced, although the 
interaction for some definitions (WHO fasting glucose concentration, IEC HbA1c, ADA 
HbA1c, and ADA and WHO 2 h glucose concentration) remained statistically significant 
(appendix). In analyses stratified by sex, a stronger association existed between 
prediabetes and undiagnosed diabetes with peripheral arterial disease in women than in 
men for both HbA1c-based and fasting glucose-based definitions (appendix). By contrast, 
ADA and WHO 2 h glucose was not significantly associated with incident peripheral 
arterial disease in men or women. Mortality associations, regardless of definition, were 
also stronger in women than in men. Our ancillary analysis in NHANES III (appendix) 
showed similar patterns in prevalence, sensitivity, and specificity for the different 
definitions of prediabetes. For all-cause mortality, patterns in hazard ratios and Harrell’s 
C-statistic were also similar. For fatal cardiovascular disease, hazard ratios for 
prediabetes identified using IEC HbA1c cutoffs were the largest, followed by ADA 
 49 
fasting glucose concentration cutoffs, ADA HbA1c cutoffs, ADA and WHO 2 h glucose 
concentration cutoffs, and WHO fasting glucose concentration cutoffs (appendix). 
Discussion 
In this cohort study, we showed that prevalence of prediabetes and performance 
of various definitions of prediabetes were significantly different when analysed in the 
context of long-term complications. Use of ADA fasting glucose concentration cutoffs or 
ADA and WHO 2 h glucose concentration cutoffs to define prediabetes resulted in higher 
prevalence estimates than did use of WHO fasting glucose concentration cutoffs, ADA 
HbA1c cutoffs, or IEC HbA1c cutoffs. With the ADA fasting glucose concentration 
definition, over a third of the study population was estimated to have prediabetes. ADA 
HbA1c cutoffs, IEC HbA1c cutoffs, and WHO fasting glucose concentration cutoffs were 
the most specific definitions for identification of people at risk for long-term clinical 
outcomes, resulting in higher positive likelihood ratios than the other definitions, whereas 
ADA fasting glucose concentration cutoffs and ADA and WHO 2 h glucose 
concentration cutoffs were more sensitive than ADA and IEC HbA1c cutoffs, and WHO 
fasting glucose concentration cutoffs. These differences in sensitivity and specificity are 
important for choosing a definition of prediabetes for use in a screening programme. 
Differences in risk discrimination across prediabetes definitions were modest, but clinical 
categories for prediabetes based on HbA1c (ADA or IEC) definitions performed slightly 
better than those based on fasting glucose concentrations for microvascular and 
macrovascular outcomes. Net reclassification improvement also supported prediabetes 
defined by ADA HbA1c cutoffs as a better classifier for people at risk of future 
cardiovascular and mortality outcomes. In minimally adjusted models, fasting glucose-
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defined prediabetes was slightly better for prediction of future diabetes than HbA1c-
defined prediabetes. This result is not surprising because most cases of diabetes would 
have been identified by a healthcare provider during follow-up on the basis of elevations 
in glucose concentrations since HbA1c was not recommended for use in diagnosis until 
2009. Clinical categories defined using ADA fasting glucose concentration, WHO fasting 
glucose concentration, and ADA and WHO 2 h glucose concentration were generally 
similar for risk discrimination of clinical outcomes. Across all definitions of prediabetes, 
whether defined using fasting glucose concentration, HbA1c, or 2 h glucose 
concentration, black people were less likely to report a diagnosis of diabetes or diabetes 
medication use during follow-up. This suggests that for the same level of 
hyperglycaemia, black people might be more likely to have delays in diagnosis, reflecting 
disparities in socioeconomic status or access to care. There was little evidence for race 
interaction for the other clinical outcomes. Our findings complement existing evidence 
and extend previous findings in ARIC. One ARIC study22 found that fasting glucose 
concentration of 5.6–6.9 mmol/L and 2 h glucose of 7.8–11.0 mmol/L had similar 
associations with incident cardiovascular disease and all-cause mortality during a median 
follow-up time of 6.3 years. Our results confirm these findings, but with approximately 
10 more years of follow-up and more incident events. Our findings are also consistent 
with results from the Emerging Risk Factors Collaboration (ERFC),23 a 73-study, 
participant-level meta-analysis of 294998 individuals. The ERFC study found that, 
compared with fasting glucose, random glucose, or postload glucose, HbA1c provided a 
small, but significant, improvement in the C-statistic for discrimination of cardiovascular 
disease risk. By contrast, in the 2001 DECODE study24 of 22514 participants from ten 
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different European centres followed up for 8.8 years, 2 h glucose was more strongly 
associated with atherosclerotic cardiovascular death and all-cause mortality than was 
fasting glucose concentration. We do note that measurements in different blood 
specimens (plasma, whole blood) were collected in DECODE across the ten European 
centres. Methodological and study population differences notwithstanding, the reasons 
why our results do not agree with the DECODE findings are unclear. Meta-analyses25,26 
have also shown conflicting results for whether impaired fasting glucose or impaired 
glucose tolerance is more strongly associated with cardiovascular disease outcomes. 
Several limitations of our study should be considered in the interpretation of our 
findings. First, we did not have concurrent measurements of fasting glucose, HbA1c, and 
2 h glucose, and all classifications were based on single measurements whereas in clinical 
practice, these measurements might be repeated. In practice, clinical decisions are based 
on a compendium of laboratory, clinical, and epidemiological information. Nonetheless, 
for prediabetes, there are currently no formal recommendations or consensus regarding 
repeating tests for confirmation. Second, as part of the ARIC study protocol, abnormal 
laboratory values including raised fasting glucose concentration (>11.1 mmol/L) or 2 h 
glucose (>16.7 mmol/L) were reported back to the participants, although less than 1.5% 
of participants had elevated values that prompted a report. HbA1c results at visit 2 were 
not reported to participants as they were measured retrospectively (>10 years after sample 
collection). The reporting of the glucose measures to participants might have increased 
the probability of a diagnosis of diabetes.27 Third, we used a definition of incident 
diabetes based on self-report. Fourth, our findings might not be generalisable beyond 
black and white Americans. Fifth, despite the large sample size and number of events, the 
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possibility exists that the study might have been underpowered to detect moderate 
differences between definitions, particularly given the overlap of definitions. Finally, 
although our results in ARIC were consistent with findings for all-cause and 
cardiovascular mortality in NHANES III, further replication, especially for other major 
complications in diverse populations, is needed. The strengths of this study include our 
ability to compare the prognostic value of multiple definitions of prediabetes, rigorous 
assessment of hyperglycaemia and related risk factors with standardised protocols and 
trained personnel, active surveillance for major clinical complications, and over two 
decades of follow-up in a large, community-based population. A number of 
considerations need to be weighed when deciding between definitions of prediabetes for 
screening programmes, and the optimal choice will depend on objectives. Long-term risk 
associations, along with considerations such as cost, availability, and the specific 
strengths and weaknesses of each biomarker, are all relevant. It is difficult to establish 
whether a strategy that would identify large numbers of people, including many people at 
low risk of future outcomes, might be more beneficial than strategies that are highly 
specific, but might miss some high-risk individuals who should receive preventive 
interventions. Prediabetes defined by ADA and IEC HbA1c cutoffs, and WHO fasting 
glucose concentration cutoffs identified fewer people, but these definitions were more 
specific for the identification of people at risk for long-term outcomes. HbA1c-based 
definitions had higher relative risk associations and showed small, but statistically 
significant, improvements in risk discrimination for a broad range of clinical 
complications. Whereas prediabetes defined by ADA fasting glucose concentration 
cutoffs was more sensitive, it was not as strongly associated with long-term risk of 
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clinical complications. For long-term prediction of clinical outcomes, prediabetes 
definitions based on 2 h glucose concentration did not better predict the risk of chronic 
kidney disease or cardiovascular outcomes than fasting glucose concentration. The 
comparative usefulness of different definitions of prediabetes will vary depending on the 
goals of the screening programme; however, data on long-term prognostic performance 
can, and should, help to inform use of and recommendations for different definitions of 
prediabetes. 
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Table 1. Baseline characteristics of ARIC participants (Visit 2, 1990-92) without a history of cardiovascular disease or diagnosed diabetes 
by different definitions of prediabetes* 






 ADA fasting glucose clinical categories ADA HbA1c clinical categories 
Visit 2 (1990-92) 
N = 10,844 
<5.6 mmol/L 
n = 6,215 
5.6-6.9 mmol/L 
n = 4,112 
≥7.0 mmol/L 
n = 517 
<39 mmol/mol 
n = 8,355 
39-46 mmol/mol 
n = 2,027 
≥48 mmol/mol 
n = 462 
Age (years) 56.8 (5.6) 57.6 (5.7) 57.7 (5.6) 56.8 (5.6) 58.2 (5.6) 58.1 (5.6) 
Female, % 63.2 47.8 54.4 57.4 54.2 61.5 
Black, % 17.3 25.1 37.3 15.0 40.4 49.8 
Less than high school education, % 16.3 21.3 28.1 15.6 28.9 32.3 
Body Mass Index (kg/m2) 26.4 (4.8) 28.9 (5.2) 31.6 (6.1) 27.0 (4.8) 29.3 (5.8) 32.3 (6.3) 
Obese (≥30 kg/m2), % 18.8 34.5 54.4 21.7 38.4 59.5 
Waist-to-hip ratio 0.90 (0.1) 0.94 (0.1) 0.97 (0.1) 0.91 (0.1) 0.94 (0.1) 0.97 (0.1) 
Fasting glucose (mmol/L) 5.11 (0.3) 5.98 (0.4) 8.62 (2.5) 5.39 (0.5) 5.89 (0.7) 8.29 (2.9) 
HbA1c (mmol/mol) 34.9 (4.2) 37.6 (4.8) 52.7 (17) 34.3 (3.1) 41.9 (1.9) 57.6 (15.6) 
Hypercholesterolemia, % 74.0 81.7 87.6 75.8 82.8 87.9 
Hypertension, % 24.5 37.8 54.6 26.9 42.4 53.9 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
97.3 (13) 96.9 (14) 99.7 (15) 
96.8 (13) 98.2 (15) 101 (16) 
Current smoker, % 21.6 21.6 19.7 19.8 27.9 23.6 
Current drinker, % 60.8 59.2 54.2 63.3 50.0 41.8 
Family history of diabetes, % 20.3 24.6 33.7 21.3 25.2 34.0 
* Mean (SD) unless otherwise indicated 
 Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; WHO, World Health Organization 
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Table 2. Baseline characteristics of ARIC participants (Visit 4, 1996-98) without a history of cardiovascular disease or diagnosed diabetes 
by different definitions of prediabetes* 






 ADA fasting glucose clinical categories ADA/WHO 2-hour glucose clinical categories 
Visit 4 (1996-98) 
N = 7,194 
<5.6 mmol/L 
n = 4,720 
5.6-6.9 mmol/L 
n = 2,142 
≥7.0 mmol/L 
n = 332 
<7.8 mmol/L 
n = 4,442 
7.8-11.0 mmol/L 
n = 2,009 
≥11.0 mmol/L 
n = 743 
Age (years) 62.7 (5.5) 62.9 (5.5) 63.1 (5.4) 62.1 (5.4) 63.6 (5.6) 64.3 (5.5) 
Female, % 63.2 47.8 51.8 55.4 62.5 62.1 
Black, % 14.5 21.2 25.6 17.1 15.4 20.5 
Less than high school education, % 13.6 18.2 23.2 13.6 17.0 21.7 
Body Mass Index (kg/m2) 27.4 (5.0) 30.1 (5.3) 32.1 (6.0) 27.7 (5.1) 29.2 (5.3) 30.5 (5.6) 
Obese (≥30 kg/m2), % 24.0 45.1 60.2 26.2 38.5 48.7 
Waist-to-hip ratio 0.93 (0.1) 0.97 (0.1) 0.98 (0.1) 0.93 (0.1) 0.95 (0.1) 0.97 (0.1) 
Fasting glucose (mmol/L) 5.09 (0.3) 6.00 (0.3) 8.72 (2.5) 5.26 (0.5) 5.54 (0.6) 7.06 (2.3) 
2-hour glucose (mmol/L) 6.76 (2.0) 8.23 (2.5) 14.8 (4.3) 5.84 (1.1) 9.10 (0.9) 13.7 (3.0) 
Hypercholesterolemia, % 73.6 82.5 87.7 73.4 81.0 86.7 
Hypertension, % 36.1 47.8 60.5 34.3 47.9 59.5 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
88.2 (12) 88.3 (13) 89.6 (12) 88.1 (12) 88.5 (13) 88.7 (13) 
Current smoker, % 14.0 14.4 11.8 15.6 11.7 10.8 
Current drinker, % 55.2 55.3 49.1 57.8 51.7 46.7 
Family history of diabetes, % 19.8 26.3 33.1 19.2 26.2 30.8 
* Mean (SD) unless otherwise indicated 
 Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; WHO, World Health Organization 
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Table 3. Prevalence (95% confidence interval) of prediabetes by definition 
 
 Prevalence (95%CI) 
Visit 2 (1990-92) 
ADA fasting glucose, 5.6-6.9 mmol/L 37.9 (37.0, 38.8) 
WHO fasting glucose, 6.1-6.9 mmol/L 11.2 (10.6, 11.8) 
ADA HbA1c, 39-46 mmol/mol 18.7 (18.0, 19.4) 
IEC HbA1c, 42-46 mmol/mol 8.95 (8.42, 9.50) 
  
Visit 4 (1996-98)  
ADA fasting glucose, 5.6-6.9 mmol/L 29.8 (28.7, 30.8) 
WHO fasting glucose, 6.1-6.9 mmol/L 8.63 (8.00, 9.30) 
ADA/WHO 2-hour glucose, 7.8-11.0 mmol/L 27.9 (26.9, 29.0) 
Abbreviations: ADA, American Diabetes Association; CI, confidence 
interval; IEC, International Expert Committee; WHO, World Health 
Organization  
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Table 4. 10-year sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative 
likelihood ratio and corresponding 95% confidence intervals of incident clinical outcomes according to different definitions of prediabetes 
(vs. normoglycemia) at baseline 
 Visit 2 (1990-92) Visit 4 (1996-98) 





















Incident diabetes       
Sensitivity 0.73 (0.70, 0.76) 0.41 (0.37, 0.44) 0.52 (0.49, 0.55) 0.34 (0.31, 0.37) 0.61 (0.58, 0.64) 0.28 (0.26, 0.31) 0.55 (0.51, 0.58) 
Specificity 0.63 (0.62, 0.64) 0.91 (0.90, 0.91) 0.83 (0.83, 0.84) 0.93 (0.92, 0.93) 0.74 (0.73, 0.75) 0.94 (0.94, 0.95) 0.72 (0.71, 0.73) 
PPV 0.15 (0.14, 0.16) 0.28 (0.26, 0.31) 0.22 (0.21, 0.24) 0.31 (0.28, 0.34) 0.28 (0.26, 0.30) 0.44 (0.40, 0.48) 0.21 (0.20, 0.23) 
NPV 0.96 (0.96, 0.97) 0.95 (0.94, 0.95) 0.95 (0.95, 0.96) 0.94 (0.93, 0.94) 0.92 (0.91, 0.93) 0.89 (0.88, 0.90) 0.92 (0.91, 0.93) 
+LR 1.98 (1.89, 2.08) 4.41 (3.97, 4.89) 3.14 (2.90, 3.39) 4.81 (4.28, 5.41) 2.34 (2.19, 2.50) 4.84 (4.19, 5.58) 1.96 (1.82, 2.12) 
-LR 0.43 (0.38, 0.48) 0.66 (0.64, 0.69) 0.58 (0.54, 0.62) 0.71 (0.68, 0.74) 0.52 (0.48, 0.57) 0.76 (0.73, 0.79) 0.63 (0.58, 0.68) 
Chronic kidney disease       
Sensitivity 0.48 (0.43, 0.53) 0.18 (0.14, 0.23) 0.31 (0.27, 0.37) 0.15 (0.11, 0.19) 0.37 (0.31, 0.44) 0.15 (0.11, 0.20) 0.32 (0.26, 0.39) 
Specificity 0.61 (0.60, 0.61) 0.89 (0.88, 0.89) 0.81 (0.80, 0.82) 0.91 (0.90, 0.91) 0.69 (0.68, 0.70) 0.91 (0.91, 0.92) 0.69 (0.68, 0.70) 
PPV 0.04 (0.04, 0.05) 0.05 (0.04, 0.07) 0.05 (0.05, 0.07) 0.05 (0.04, 0.07) 0.04 (0.03, 0.05) 0.06 (0.04, 0.08) 0.03 (0.03, 0.04) 
NPV 0.97 (0.97, 0.97) 0.97 (0.96, 0.97) 0.97 (0.97, 0.97) 0.97 (0.96, 0.97) 0.97 (0.96, 0.97) 0.97 (0.96, 0.97) 0.97 (0.96, 0.97) 
+LR 1.21 (1.08, 1.35) 1.58 (1.27, 1.98) 1.64 (1.40, 1.92) 1.60 (1.24, 2.08) 1.20 (1.01, 1.42) 1.72 (1.26, 2.35) 1.03 (0.85, 1.26) 
-LR 0.86 (0.78, 0.95) 0.92 (0.88, 0.97) 0.85 (0.79, 0.91) 0.94 (0.90, 0.98) 0.91 (0.83, 1.01) 0.93 (0.88, 0.98) 0.99 (0.90, 1.08) 
Atherosclerotic cardiovascular disease       
Sensitivity 0.47 (0.43, 0.52) 0.16 (0.13, 0.19) 0.34 (0.30, 0.39) 0.18 (0.15, 0.21) 0.39 (0.34, 0.44) 0.12 (0.09, 0.16) 0.32 (0.28, 0.37) 
Specificity 0.61 (0.60, 0.62) 0.89 (0.88, 0.89) 0.81 (0.81, 0.82) 0.91 (0.91, 0.92) 0.69 (0.68, 0.70) 0.91 (0.90, 0.92) 0.69 (0.68, 0.70) 
PPV 0.06 (0.06, 0.07) 0.07 (0.06, 0.09) 0.09 (0.08, 0.11) 0.10 (0.08, 0.12) 0.07 (0.06, 0.08) 0.07 (0.06, 0.10) 0.06 (0.05, 0.07) 
NPV 0.95 (0.95, 0.96) 0.95 (0.94, 0.95) 0.96 (0.95, 0.96) 0.95 (0.95, 0.96) 0.95 (0.94, 0.95) 0.94 (0.94, 0.95) 0.95 (0.94, 0.95) 
+LR 1.20 (1.10, 1.32) 1.36 (1.11, 1.66) 1.84 (1.63, 2.08) 2.03 (1.68, 2.45) 1.25 (1.10, 1.43) 1.36 (1.03, 1.79) 1.04 (0.89, 1.21) 
-LR 0.87 (0.80, 0.94) 0.95 (0.92, 0.99) 0.81 (0.76, 0.86) 0.90 (0.87, 0.94) 0.89 (0.82, 0.96) 0.97 (0.93, 1.00) 0.98 (0.91, 1.06) 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin A1c; PPV, positive predictive value; NPV, 




Table 4., continued 
 Visit 2 (1990-92) Visit 4 (1996-98) 





















Peripheral arterial disease 
Sensitivity 0.54 (0.41, 0.66) 0.19 (0.11, 0.31) 0.30 (0.20, 0.43) 0.14 (0.06, 0.24) 0.42 (0.29, 0.57) 0.08 (0.02, 0.19) 0.37 (0.24, 0.51) 
Specificity 0.60 (0.59, 0.61) 0.88 (0.88, 0.89) 0.81 (0.80, 0.81) 0.91 (0.90, 0.91) 0.69 (0.68, 0.70) 0.91 (0.90, 0.92) 0.69 (0.68, 0.70) 
PPV 0.01 (0.01, 0.01) 0.01 (0.01, 0.02) 0.01 (0.01, 0.02) 0.01 (0.00, 0.02) 0.01 (0.01, 0.02) 0.01 (0.00, 0.02) 0.01 (0.01, 0.01) 
NPV 1.00 (0.99, 1.00) 0.99 (0.99, 1.00) 0.99 (0.99, 1.00) 0.99 (0.99, 1.00) 0.99 (0.99, 1.00) 0.99 (0.99, 0.99) 0.99 (0.99, 1.00) 
+LR 1.35 (1.08, 1.69) 1.66 (1.02, 2.71) 1.56 (1.08, 2.25) 1.46 (0.80, 2.69) 1.36 (0.99, 1.87) 0.85 (0.33, 2.18) 1.17 (0.82, 1.68) 
-LR 0.77 (0.59, 0.99) 0.91 (0.81, 1.03) 0.87 (0.74, 1.01) 0.95 (0.87, 1.05) 0.84 (0.66, 1.06) 1.02 (0.94, 1.10) 0.92 (0.75, 1.13) 
All-cause mortality       
Sensitivity 0.46 (0.42, 0.49) 0.15 (0.12, 0.17) 0.31 (0.27, 0.35) 0.16 (0.13, 0.18) 0.35 (0.31, 0.39) 0.13 (0.10, 0.15) 0.33 (0.29, 0.37) 
Specificity 0.61 (0.60, 0.62) 0.89 (0.88, 0.89) 0.81 (0.81, 0.82) 0.91 (0.91, 0.92) 0.69 (0.68, 0.70) 0.91 (0.91, 0.92) 0.69 (0.68, 0.70) 
PPV 0.08 (0.07, 0.08) 0.08 (0.07, 0.10) 0.11 (0.09, 0.12) 0.11 (0.09, 0.13) 0.10 (0.08, 0.11) 0.12 (0.10, 0.15) 0.09 (0.08, 0.11) 
NPV 0.94 (0.93, 0.95) 0.94 (0.93, 0.94) 0.94 (0.94, 0.95) 0.94 (0.93, 0.94) 0.92 (0.91, 0.92) 0.92 (0.91, 0.92) 0.92 (0.91, 0.93) 
+LR 1.15 (1.06, 1.26) 1.26 (1.04, 1.53) 1.65 (1.46, 1.86) 1.74 (1.45, 2.10) 1.12 (0.99, 1.25) 1.43 (1.14, 1.80) 1.07 (0.95 1.21) 
-LR 0.90 (0.84, 0.97) 0.97 (0.94, 1.00) 0.85 (0.81, 0.90) 0.93 (0.90, 0.96) 0.95 (0.89, 1.01) 0.96 (0.93, 0.99) 0.97 (0.91, 1.03) 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin A1c; PPV, positive predictive value; NPV, 
negative predictive value; WHO, World Health Organization; +LR, positive likelihood ratio, -LR, negative likelihood ratio 
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Table 5. Demographic adjusted hazard ratio and Harrell’s C-statistic (95% confidence intervals) for incident outcomes by different 
















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.91 (2.69, 3.15)* 1.17 (1.08, 1.27)* 1.24 (1.12, 1.38)* 1.34 (1.03, 1.74)* 1.12 (1.04, 1.21)* 
≥7.0 mmol/L‡ 19.7 (17.6, 22.2)* 1.75 (1.49, 2.05)* 2.10 (1.74, 2.53)* 3.40 (2.30, 5.01)* 1.55 (1.35, 1.79)* 




<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 3.81 (3.48, 4.16)* 1.28 (1.14, 1.43)* 1.22 (1.05, 1.41)* 1.35 (0.95, 1.92) 1.25 (1.13, 1.38)* 
≥7.0 mmol/L‡ 14.5 (13.0, 16.2)* 1.69 (1.45, 1.97)* 1.95 (1.63, 2.34)* 3.09 (2.14, 4.47)* 1.52 (1.32, 1.75)* 
C-statistic (95% CI) 0.693 (0.683, 0.703) 0.636 (0.625, 0.647) 0.660 (0.646, 0.673) 0.700 (0.668, 0.732) 0.683 (0.674, 0.693) 
ADA HbA1c 
definition 
<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 3.42 (3.15, 3.72)* 1.42 (1.29, 1.57)* 1.70 (1.51, 1.92)* 1.84 (1.37, 2.47)* 1.49 (1.37, 1.62)* 
≥48 mmol/mol‡ 20.8 (18.4, 23.4)* 2.04 (1.73, 2.40)* 2.40 (1.98, 2.90)* 5.38 (3.75, 7.73)* 1.81 (1.57, 2.10)* 
C-statistic (95% CI) 0.693 (0.683, 0.703) 0.640 (0.629, 0.651) 0.672 (0.659, 0.685) 0.722 (0.690, 0.754) 0.688 (0.679, 0.697) 
IEC HbA1c 
definition 
<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 4.14 (3.74, 4.58)* 1.50 (1.32, 1.70)* 1.91 (1.65, 2.21)* 1.95 (1.34, 2.82)* 1.56 (1.40, 1.73)* 
≥48 mmol/mol‡ 17.9 (15.9, 20.2)* 1.96 (1.67, 2.30)* 2.27 (1.88, 2.74)* 4.99 (3.49, 7.11)* 1.73 (1.50, 1.99)* 
C-statistic (95% CI) 0.669 (0.659, 0.680) 0.639 (0.628, 0.650) 0.668 (0.655, 0.682) 0.718 (0.686, 0.750) 0.687 (0.678, 0.696) 
Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; IEC, International Expert Committee; HbA1c, hemoglobin A1c; HR, hazard 
ratio; WHO, World Health Organization 
Outcome Definitions: Incident diabetes: self-report of a physician diagnosis of diabetes or use of glucose-lowering medication during a study visit or annual 
telephone call; Chronic kidney disease: subsequent estimated glomerular filtration rate (eGFR) measurement < 60 mL/min/1.73 m2 measured at a study visit 
and an eGFR decline from baseline visit of at least 25% at the follow-up visit, or chronic kidney disease related hospitalization or death, or an end stage renal 
disease event identified by the United States Renal Data System registry; Atherosclerotic cardiovascular disease: any coronary heart disease hospitalization 
and death and ischemic stroke hospitalization and death (adjudicated events); Peripheral arterial disease: events identified from hospitalization records 
(International Classification of Disease, Ninth Revision (ICD-9) discharge codes) for peripheral arterial disease (440.2, 440.3, 440.4) or leg revascularization 
(38.18, 39.25, 39.29, 39.50); All-cause mortality: ascertained from hospital and National Death Index records 
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<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 3.43 (3.10, 3.80)* 1.08 (0.96, 1.21) 1.25 (1.07, 1.45)* 1.09 (0.73, 1.63) 1.15 (1.03, 1.28)* 
≥7.0 mmol/L‡ 25.3 (21.9, 29.2)* 1.45 (1.16, 1.82)* 1.79 (1.36, 2.37)* 1.99 (1.02, 3.88)* 1.68 (1.37, 2.05)* 




<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 4.48 (3.97, 5.05)* 1.23 (1.04, 1.47)* 1.10 (0.87, 1.40) 0.63 (0.29, 1.35) 1.29 (1.10, 1.51)* 
≥7.0 mmol/L‡ 18.5 (16.2, 21.2)* 1.45 (1.16, 1.81)* 1.67 (1.27, 2.20)* 1.85 (0.96, 3.56) 1.65 (1.35, 2.01)* 
C-statistic (95% CI) 0.694 (0.681, 0.708) 0.625 (0.610, 0.640) 0.658 (0.638, 0.677) 0.710 (0.662, 0.757) 0.687 (0.673, 0.700) 




<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 2.56 (2.30, 2.86)* 1.16 (1.03, 1.31)* 1.08 (0.92, 1.27) 0.83 (0.54, 1.29) 1.17 (1.05, 1.31)* 
≥11.0 mmol/L‡ 10.6 (9.41, 11.9)* 1.39 (1.18, 1.63)* 1.44 (1.17, 1.78)* 0.93 (0.50, 1.72) 1.33 (1.15, 1.55)* 
C-statistic (95% CI) 0.728 (0.716, 0.741) 0.626 (0.611, 0.641) 0.659 (0.639, 0.678) 0.705 (0.658, 0.752) 0.685 (0.672, 0.698) 
Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; IEC, International Expert Committee; HbA1c, hemoglobin A1c; HR, hazard 
ratio; WHO, World Health Organization 
Outcome Definitions: Incident diabetes: self-report of a physician diagnosis of diabetes or use of glucose-lowering medication during a study visit or annual 
telephone call; Chronic kidney disease: subsequent estimated glomerular filtration rate (eGFR) measurement < 60 mL/min/1.73 m2 measured at a study visit 
and an eGFR decline from baseline visit of at least 25% at the follow-up visit, or chronic kidney disease related hospitalization or death, or an end stage renal 
disease event identified by the United States Renal Data System registry; Atherosclerotic cardiovascular disease: any coronary heart disease hospitalization 
and death and ischemic stroke hospitalization and death (adjudicated events); Peripheral arterial disease: events identified from hospitalization records 
(International Classification of Disease, Ninth Revision (ICD-9) discharge codes) for peripheral arterial disease (440.2, 440.3, 440.4) or leg revascularization 
(38.18, 39.25, 39.29, 39.50); All-cause mortality: ascertained from hospital and National Death Index records
 61 
Chapter 3. Diagnostic performance of 1,5-
anhydroglucitol compared to 2-hour glucose in the 
Atherosclerosis Risk in Communities Study 
 
Co-authors: Alexandra K Lee, Christie M Ballantyne, Ron C Hoogeveen, James S 
Pankow, Morgan Grams, Anna Köttgen, and Elizabeth Selvin 
 
Abstract 
Background: Glucose measured two hours after a carbohydrate challenge (2-hour 
glucose) has long been a gold standard for diabetes diagnosis, but it has fallen out of 
favor primarily due to the high patient burden and the availability of alternative 
diagnostic markers. Plasma concentrations of 1,5-anhydroglucitol (1,5-AG) decrease in 
response to hyperglycemia, and thus low 1,5-AG may be a less burdensome biomarker of 
hyperglycemic excursions. However, few studies have directly compared 2-hour glucose 
and 1,5-AG in a community-based setting. 
Methods: We conducted a cross-sectional analysis of 7,813 Atherosclerosis Risk in 
Community (ARIC) Study participants without diagnosed diabetes who attended the 
1996-98 visit, when both 2-hour glucose and 1,5-AG were measured. We examined 
diagnostic performance of low 1,5-AG (<10 µg/mL, <12 µg/mL, or <16 µg/mL) to detect 
elevated 2-hour glucose as the gold standard (≥200 mg/dL). 
Results: The proportion of the population with elevated 2-hour glucose, or 1,5-AG <10 
µg/mL was 10.5%, and 5.6%, respectively. 3.5% of participants had 1,5-AG <10 µg/mL 
without glucose elevations (false positives). Comparing the diagnostic performance of 
1,5-AG<10 µg/mL to 2-hour glucose ≥200 mg/dL resulted in a sensitivity of 19.4% (95% 
CI, 16.8, 22.3) and specificity of 96.1% (95% CI, 95.6, 96.5). Higher cut-points of 1,5-
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AG resulted in higher sensitivity but lower specificity for detecting elevations in 2-hour 
glucose. The area under the ROC curve comparing 1,5-AG <10 µg/mL to elevated 2-hour 
glucose was 0.66. False positive results were associated with decreased kidney function 
and kidney damage. 
Conclusions: Although less burdensome from the patient perspective, 1,5-AG is unlikely 
to be useful for diabetes screening in the general U.S. population, although the high 
specificity of 1,5-AG may help to identify very high-risk individuals. The large 
proportion of false positives suggests further research is needed to understand the 
determinants of 1,5-AG beyond glycemic excursions.  
Introduction 
In 2015, approximately 1.5 million people in the United States were diagnosed 
with diabetes1,2.The measurement of 2-hour glucose following a 75-g oral glucose 
tolerance test has been a long-standing “gold standard” for diagnosis of diabetes and was 
first recommended by the National Diabetes Data Group in 19793–7. However, given the 
high patient burden along with its high within-person variability8, 2-hour glucose has 
fallen out of favor in clinical practice as a primary diagnostic tool, mostly supplanted by 
fasting glucose and hemoglobin A1c (HbA1c), which measure slightly different aspects 
of glucose control9.  
While evidence is preliminary and conflicting, some prior studies have suggested 
that 1,5-anhydroglucitol (1,5-AG) may have utility as a screening test for diabetes with 
similar performance to 2-hour fasting glucose10–12. 1,5-AG is a monosaccharide (the 1-
deoxy form of glucose), primarily acquired through diet13. In states of euglycemia, 
concentrations of 1,5-AG remain at steady state in the blood. In states of overt 
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hyperglycemia, where glucose exceeds the renal threshold (typically >160-180 mg/dL), 
1,5-AG competes with glucose for reabsorption in the renal proximal tubule and is 
excreted in the urine, resulting in lowered concentrations in the blood14. Therefore, low 
blood concentrations of 1,5-AG reflect recent glycemic excursions above the renal 
threshold. Unlike 2-hour glucose, 1,5-AG does not require fasting, a carbohydrate 
challenge, or multiple blood draws.  
The objective of this study was to quantify the concordance of 1,5-AG with 2-
hour glucose and evaluate its utility as a test to screen or diagnose diabetes. The 
concurrent measurements of 2-hour glucose and 1,5-AG in the Atherosclerosis Risk in 
Communities (ARIC) Study, a large community-based cohort study in the United States, 
presents a unique opportunity to formally compare these biomarkers, as well as with 




The ARIC Study recruited 15,792 participants beginning in 1987 from four 
communities (Washington County, Maryland; Minneapolis, Minnesota; Jackson, 
Mississippi; and Forsyth County, North Carolina)15. To date, six study visits through 
2017 have been completed. Institutional review boards provided necessary study 
approvals and all participants gave informed consent. We conducted a cross-sectional 
analysis using data collected from ARIC participants who attended the fourth study visit, 
which occurred from 1996 to 1998, when both 2-hour glucose and 1,5-AG were 
measured. Of the 11,656 participants in attendance, we excluded participants if they had a 
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history of diabetes at or before the fourth visit defined as a self-report of a physician 
diagnosis of diabetes or self-report of medications for diabetes (n=1,511), were missing 
2-hour glucose, fasting glucose, or 1,5-AG measurements (n=2,251), did not fast for 10 
or more hours (n=33), or were not black or white race or black from the Minnesota or 
Washington County sites (n=48; Figure D-1). Thus, our final study sample included 
7,813 participants. 
Measurement of Biomarkers of Hyperglycemia 
A questionnaire was administered to participants to determine their eligibility for 
the oral glucose tolerance test during the fourth study visit. Participants were excluded 
from taking the glucose challenge if they had been treated for diabetes at the third ARIC 
visit or were taking diabetes medications, had prior surgery to remove part of the stomach 
or intestines, were on kidney dialysis, did not fast 10 hours or more, or were not willing 
to participate16. Two-hour glucose was measured in plasma following a 75-g oral glucose 
tolerance test and measurements were considered invalid if participants did not consume 
the glucola solution within 10 minutes, finish all of the solution (residual amount ≥145 
ml), if information on blood draw timing was not available, or if blood was not drawn 
within 110-130 minutes of consumption of the solution.  
Fasting plasma glucose was measured prior to the administration of the glucose 
tolerance test. Samples were analyzed at the Baylor College of Medicine using an 
enzymatic method on the Roche Hitachi 911 machine.  
1,5-AG (GlycoMark) was measured in 2015-2016 in stored plasma samples from 
the fourth study visit at Baylor College of Medicine using the Beckman AU480 
Chemistry Analyzer. The inter-assay coefficient of variation was 4.54%.  
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HbA1c was not available at the fourth ARIC visit. However, HbA1c was 
measured in stored whole blood samples from the second study visit (6 years earlier) 
using high-performance liquid chromatography methods certified by the National 
Glycohemoglobin Standardization Program and aligned to the Diabetes Control and 
Complications Trial assay17. In a secondary analysis, we compared HbA1c to 1,5-AG and 
fasting glucose values measured from samples taken at the same time point (second study 
visit, 1990-1992). 1,5-AG measurements from the second study visit were measured in 
2012-2013 at University of Minnesota using a Roche Modular P800 system. Fasting 
glucose values at the second study visit were measured in serum at University of 
Minnesota using the Coulter DACOS machine. 
Detection of Hyperglycemia 
We evaluated the diagnostic performance of 1,5-AG relative to clinical cut-points 
for hyperglycemia based on current diabetes clinical practice guidelines2. We examined 
categories of hyperglycemia (considered gold standards) defined by an elevated 2-hour 
glucose (≥200 mg/dL), a fasting glucose (≥126 mg/dL), or both elevated 2-hour glucose 
and fasting glucose2,18. In secondary analyses, we used 1,5-AG and HbA1c measurements 
from visit 2 (6 years prior) to compare 1,5-AG to elevated HbA1c (≥6.5%) and 
hyperglycemia based on HbA1c ≥6.5% and fasting glucose ≥126 mg/dL18. Outcome 
definitions are shown in Table D-1. 
Covariate Assessment 
Age, sex (male or female), race (black or white), parental history of diabetes (yes 
or no), and education level (less than high school, high school graduate or vocational 
school, college education or higher) were self-reported at the first study visit. Dietary 
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intake, including dairy and bread and/or rice consumption, was assessed at the third study 
visit. Participants self-reported the number of servings they consumed on average for 
various foods19. All other covariates were assessed at the fourth study visit. 
Anthropometric measurements including height, weight, and waist-to-hip ratio were 
measured using standard protocols and body mass index was calculated as kilograms of 
weight divided by height in meters squared. Lipids (total cholesterol, HDL cholesterol, 
triglycerides) were obtained using standard methods. Systolic and diastolic blood 
pressures were assessed with systematic protocols and the first two measurements of each 
were averaged. Smoking status (current, former, never) and drinking status (current, 
former, never) were self-reported16. Creatinine was measured in plasma and used to 
estimate glomerular filtrate rate (eGFR) with the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation20. Albumin and creatinine were measured in urine 
samples21 and albumin-to-creatinine ratio (ACR) was calculated. Liver enzymes (Alanine 
aminotransferase [ALT] and aspartate aminotransferase [AST]) were also assessed.  
Race-center was defined as 5-level variable combining race and study center, 
given race may be confounded with study center because of the ARIC Study design 
(Washington County, Maryland-White; Minneapolis, Minneapolis-White; Forsyth 
County, North Carolina-White; Forsyth County, North Carolina-Black; Jackson, 
Mississippi-Black). Servings of dairy products were combined into a dairy intake variable 
and categorized into tertiles of consumption. Similarly servings of bread and/or rice 
products were combined into a bread and rice intake variable and divided into tertiles. 
Hypertension was defined as mean systolic blood pressure ≥140 mmHg, mean diastolic 
blood pressure ≥90 mmHg, or self-report of blood pressure lowering medication use. 
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Chronic kidney disease was defined by Kidney Disease Improving Global Outcomes 
(KDIGO) guidelines stage G3b, G4, or G5 (eGFR <45ml/min/1.73m2)22. Elevated levels 
of liver enzymes were defined using lab provided cutoffs (ALT >38.1 U/L or AST >44.4 
U/L). 
Statistical Analysis 
In our main analyses, we categorized low 1,5-AG using the manufacturer-
suggested threshold (1,5-AG <10 µg/mL). However, because there is currently no 
universally agreed-upon cut-point for this novel biomarker, we also defined low 1,5-AG 
using the percentile equivalents of a 2-hour glucose of 200 mg/dL (90 percentile; 1,5-AG 
<12 µg/mL) or a fasting glucose of 126 mg/dL (95 percentile; 1,5-AG <10 µg/mL), and 
calculated Youden’s index from non-parametric ROC curves (1,5-AG <16 µg/mL), 
rounding each identified value to the nearest integer.  
We compared clinical characteristics of the participants according to different 
definitions of hyperglycemia and low 1,5-AG (<10 µg/mL) using t-tests for means and 
Pearson’s Chi squared tests for proportions. We evaluated the prevalence of elevated 2-
hour glucose, elevated fasting glucose, and both elevated 2-hour glucose and fasting 
glucose and assessed their concordance with the prevalence of low 1,5-AG (<10 µg/mL) 
using a Venn Diagram. This analysis resulted in the identification of true negative results, 
those without hyperglycemia (2-hour <200 mg/dL and fasting glucose <126 mg/dL) and 
1,5-AG ≥10 µg/mL; false positive results, those without hyperglycemia (2-hour <200 
mg/dL and fasting glucose <126 mg/dL) and 1,5-AG <10 µg/mL; false negative results, 
those with hyperglycemia (2-hour ≥200 mg/dL and/or fasting glucose ≥126 mg/dL) and 
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1,5-AG ≥10 µg/mL; and true positive results, those with hyperglycemia (2-hour ≥200 
mg/dL and/or fasting glucose ≥126 mg/dL) and 1,5-AG <10 µg/mL. 
To investigate the ability of 1,5-AG to detect states of hyperglycemia in this 
population of individuals without diagnosed diabetes, we calculated sensitivity, 
specificity, positive and negative likelihood ratios, and positive and negative predictive 
values. We generated scatterplots and calculated Pearson’s and Spearman’s correlations 
of 1,5-AG with 2-hour glucose and fasting glucose. We constructed non-parametric ROC 
curves by multiplying 1,5-AG values by -1 since 1,5-AG is inversely associated with 
hyperglycemia.  
We then further investigated the true negative, false positive, false negative, true 
positive groups using multinomial logistic regression to assess predictors of those 
categories, with true negative as the reference, adjusting for age, sex, and race-center. 
The predictors we examined were age, sex, race-center, body mass index, total 
cholesterol, triglycerides, HDL, hypertension, eGFR, ACR (log transformed), dairy 
intake (tertiles), and bread and/or rice intake (tertiles). We also examined scatterplots and 
Spearman’s and Pearson’s correlations of 1,5-AG and the dietary intake variables. 
Sensitivity and Secondary Analyses 
Because concerns have been raised regarding the reliability of 1,5-AG in the 
setting of chronic kidney disease23,24 and liver disease,25 we conducted sensitivity 
analyses excluding these individuals. We excluded participants with G3b, G4, or G5 
chronic kidney disease (n=75) and in a separate analysis excluded participants with 
elevated liver enzymes (ALT>38.1 U/L or AST>44.4 U/L; n=225; Figure D-1). We 
evaluated the diagnostic performance of 1,5-AG relative to categories of hyperglycemia 
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and reported sensitivity, specificity, positive and negative likelihood ratios, and positive 
and negative predictive values and ROC curves in each subgroup. 
In a secondary analysis, we compared 1,5-AG measured at Visit 2 to 
hyperglycemia defined by elevated HbA1c, elevated fasting glucose, and the combination 
of elevated HbA1c and fasting glucose (as the gold standards) from the second study visit 
(n=11,582; Figure D-1; HbA1c was only available at the second ARIC visit). 
  Statistical analyses were conducted in Stata 15.1 (StataCorp, College Station, 
TX). The Venn diagram was created using RStudio (RStudio, Inc., Boston, MA) Eulerr 
Package26.  
Results 
The 7,813 study participants ranged in age from 52-75 years; 57% were female, 
and 16% black. 1,5-AG, 2-hour glucose, and fasting glucose had means (SD) of 20.6 
(6.85) µg/mL, 137 (52.2) mg/dL, and 102 (17.5) mg/dL, respectively. In all, 818 (10.5%) 
participants had 2-hour glucose ≥200 mg/dL, 398 (5.1%) participants had fasting glucose 
≥126 mg/dL, and 435 (5.6%) participants had 1,5-AG <10 µg/mL. 
1,5-AG <10 µg/mL was associated with traditional diabetes risk factors; those 
with low concentrations were more likely to be black and have parental history of 
diabetes, have higher fasting glucose and 2-hour glucose concentrations, higher 
triglycerides, and reduced kidney function and more likely to have kidney damage than 
their counterparts with 1,5-AG ≥10 µg/mL (Table 1). However, there were no significant 
differences in body mass index (p=0.27) or hypertension (p=0.26) comparing individuals 
with 1,5-AG <10 µg/mL vs. ≥10 µg/mL. 2-hour glucose ≥200 mg/dL and fasting glucose 
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≥126 mg/dL were associated with traditional diabetes risk factors, including body mass 
index and hypertension (Table 1). 
The overall prevalence of elevated 2-hour glucose, or elevated fasting glucose, or 
low 1,5-AG (<10 µg/mL) was 15.0%, with the remaining 85.0% of participants classified 
as true negatives (Figure 1). 2.1% (n=164) of participants had hyperglycemia (defined by 
2-hour glucose or fasting glucose) and 1,5-AG <10 µg/mL (true positives). It was rare for 
participants to have elevated fasting glucose and 1,5-AG <10 µg/mL but not elevated 2-
hour glucose (0.1%, n=5). 3.5% of participants (n=271) had isolated 1,5-AG <10 µg/mL, 
meaning over half of participants with 1,5-AG <10 µg/mL (271/435) did not have 
hyperglycemia (false positives). 9.4% of participants (n=738) had hyperglycemia 
(defined by 2-hour glucose or fasting glucose), but did not have 1,5-AG <10 µg/mL 
(false negatives). 
 The 1.5% (n=120) of participants identified by all three biomarkers (2-hour, 
fasting, and 1,5-AG) had a mean (SD) 2-hour glucose of 322 (84.0) mg/dL and a fasting 
glucose of 184 (57.8) mg/dL. Whereas, the 2.5% of participants (n=194) identified by 
elevated 2-hour glucose and fasting glucose, but not 1,5-AG, had mean (SD) 2-hour 
glucose 261 (39.5) mg/dL and fasting glucose 145 (17.5) mg/dL. 
When assessing the performance of 1,5-AG to identify hyperglycemia, we found 
that regardless of the cut-point used, 1,5-AG tended to be highly specific but insensitive 
for the identification of hyperglycemia (Table 2). Overall, 1,5-AG had high negative 
predictive values for identifying hyperglycemia. 
Scatterplots assessing the continuous associations of 1,5-AG with fasting and 2-
hour glucose demonstrated moderate correlations, but only at low concentrations of 1,5-
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AG (e.g., below 10 µg/mL); at higher concentrations of 1,5-AG, the variables were 
essentially uncorrelated (Figure D-2). 
The area under the ROC curve comparing 1,5-AG continuously to 2-hour glucose 
≥200 mg/dL was 0.66 (95% CI 0.64, 0.68). Conducting the same analysis but comparing 
1,5-AG to fasting glucose ≥126 mg/dL, and both 2-hour glucose ≥200 mg/dL and fasting 
glucose ≥126 mg/dL the resulting areas under the ROCs were 0.72 (95% CI 0.69, 0.75), 
and 0.78 (95% CI 0.75, 0.81), respectively (Figure 2). By way of comparison, the ROC 
curve for fasting glucose compared to 2-hour glucose ≥200 mg/dL was 0.84 (95% CI 
0.82, 0.86) and for 2-hour glucose compared to fasting glucose ≥126 mg/dL was 0.94 
(95% CI 0.92, 0.95). 
Compared to true negatives (no hyperglycemia and 1,5-AG ≥10 µg/mL), false 
positives (1,5-AG <10 µg/mL with normal 2-hour glucose and fasting glucose) were 
older, more likely to be black, had lower eGFR, and had higher ACR (Table 3). False 
negatives were older, had higher body mass index, triglycerides, and ACR, had lower 
HDL, and were more likely to have hypertension compared to true negatives (Table 3). 
Interestingly, there were no dietary correlates of false positive 1-5 AG, although a high-
bread and rice diet showed suggestion of association with higher 1-5AG and high-intake 
of dairy products showed suggestion of association with lower 1,5-AG (Figure D-3). 
 Regardless or whether we excluded the small number of participants with G3b, 
G4, or G5 chronic kidney disease (n=75) or elevated liver enzymes (n=225) performance 
of 1,5-AG to identify hyperglycemia remained largely unchanged (Table D-2 and Table 
D-3).  
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Among the 11,582 eligible participants without diagnosed diabetes who attended 
Visit 2 (6 years earlier), 4.1% had HbA1c ≥6.5% and 6.5% had 1,5-AG <10 µg/mL. 1,5-
AG had high specificity but low sensitivity for the identification of hyperglycemia 
defined by HbA1c in Visit 2 measurements (Table D-4). The areas under the ROC 
curves for 1,5-AG compared to HbA1c ≥6.5%, elevated fasting glucose, or both elevated 
HbA1c and elevated fasting glucose were 0.74 (95% CI, 0.71, 0.77), 0.67 (95% CI, 0.64, 
0.69), and 0.80 (95% CI, 0.77, 0.83), respectively.  
Discussion 
In this community-based population of persons with no history of diabetes, 1,5-
AG was not highly concordant with 2-hour glucose. 1,5-AG demonstrated high 
specificity but low sensitivity to identify hyperglycemia in a community-based setting. 
Generally, the test characteristics of 1,5-AG suggest it has limited utility for diabetes 
screening in the general U.S. population. 
Interestingly, despite that 1,5-AG demonstrated high specificity as a marker of 
hyperglycemia, the risk factor relationships for low 1,5-AG were not as strong compared 
to other definitions of hyperglycemia in this population. However, the specificity of 1,5-
AG also suggests that it is capturing a small number of potentially high-risk individuals 
experiencing glycemic excursions. This was demonstrated by the fact that the mean 2-
hour glucose and fasting glucose among participants identified by all three biomarker cut-
points was higher than those identified by the two glucose measures alone. 
Prior studies of the performance of 1,5-AG to identify hyperglycemia have been 
conflicting as to the utility of 1,5-AG for screening10–12,27. The reasons for the differences 
in results of prior studies in persons without diagnosed diabetes may relate to the 
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characteristics of the study populations, differences in the method of measurement of 1,5-
AG, and/or chance variation given the small sample sizes of prior studies.  
There may be important non-glycemic factors that influence 1,5-AG outside of 
the setting of overt diabetes, which could help explain its lack of concordance with 
traditional glucose tests. 
Population characteristics in particular may contribute to the heterogeneity in the 
determinants of 1,5-AG among those without diagnosed diabetes. Dietary factors, for 
instance, differ across populations and may be important. Our recent work, along with the 
contributions of others, suggests that diet may directly affect 1,5-AG concentrations, 
particularly outside the setting of overt diabetes28,29. Different foods have varying 
amounts of 1,5-AG30,31. Soybeans have particularly high 1,5-AG content, followed by 
modest amounts in foods like bread and rice, and very small amounts in dairy products30. 
It is possible that the varying quantities of these foods across populations could influence 
1,5-AG and its performance as a measure of hyperglycemia, particularly in 
predominately non-diabetic populations. While we did not observe dietary factors as 
driving forces of the false positive group, the correlations were in the expected directions 
and our capacity to assess these relationships was limited. Additional controlled studies 
are needed to understand the influence of diet on 1,5-AG, particularly outside of the 
setting of diagnosed diabetes. 
Previous genetic analyses have suggested that there may be differences in 1,5-AG 
due to variants that influence glucose metabolism32. Prevalence of kidney and liver 
disease may also be relevant. Other investigators have suggested the reliability of 1,5-AG 
may be uncertain in setting of kidney disease given its renal handling and one study 
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observed concentrations may also be altered in the setting of liver disease25,27,33. False 
positives in our data were more likely to have reduced kidney function and increased 
kidney damage. Nonetheless, our results were similar after excluding the small numbers 
of individuals with chronic kidney disease, impaired kidney function, or elevated liver 
enzymes. All of these factors taken together suggest that there is heterogeneity in the 
means to obtain low 1,5-AG outside of glycemic excursions, like diet, genetics, reduced 
kidney function, increased kidney damage, and liver disease, which could help explain its 
lack of concordance with traditional glucose tests. 
 Our analysis has some limitations to consider in the context of these results. This 
study was conducted in a population with a low prevalence of hyperglycemia. We also 
only had single measures of 2-hour glucose and fasting glucose to define states of 
hyperglycemia. Two-hour glucose and fasting glucose were both measured in 1996-98, 
while 1,5-AG was measured in stored samples in 2015-16. Technological differences or 
differences due to long-term storage could have decreased the concordance of the 
measures. In our assessment of factors related to those with false positive results, we did 
not have concurrently available dietary data. While we would expect dietary habits to be 
relatively stable over time, it is possible that there were changes over the three-year gap 
in measurements. Self-reported dietary data is notoriously problematic, which may have 
led to misclassification and underestimation of any true relationship with 1,5-AG. 
Additionally, while not our primary aim, HbA1c, a biomarker routinely used for 
diagnosis of diabetes, was not available at the contemporaneous study visit with 2-hour 
glucose. We performed a secondary analysis comparing 1,5-AG and HbA1c at the second 
study visit to help address this concern. 
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There were also several strengths to our approach. Our primary strength was the 
large, racially diverse community-based U.S. population of relevant age for diabetes 
screening. All measurements in ARIC were conducted by trained staff using standardized 
protocols. We were able to compare 1,5-AG to multiple measures of hyperglycemia (2-
hour glucose, fasting glucose and HbA1c). 
Comparing 1,5-AG and 2-hour glucose allowed us to assess the concordance 
between two markers that reflect postprandial hyperglycemia. Our results are consistent 
with our understanding of the biology of 1,5-AG as indicating substantial glycemic 
excursions (glucose concentrations exceeding the renal threshold). Fasting glucose 
concentrations of >160 mg/dL were rare in the present population (n=95, 1.2%). We also 
observed that there might be several reasons people have low 1,5-AG values outside of 
the setting of diabetes, which require further investigation. Our results suggest that people 
identified by 1,5-AG in addition to the traditional definitions (2-hour glucose, fasting 
glucose) are a very high-risk population. In conclusion, 1,5-AG is a specific biomarker 




Table 1. Participant characteristics according to elevated 2-hour glucose and/or elevated fasting glucose and low 1,5-AG (<10 μg/mL), the 
ARIC Study (1996-1998), n=7,813* 

















Age (years) 63.0 (5.6) 64.8 (5.6) <0.001 63.2 (5.6) 63.6 (5.5) 0.15 63.2 (5.6) 64.1 (5.9) <0.001 
Female, % 56.4 62.1 0.002 57.3 50.0 0.004 56.9 57.9 0.67 






Washington County, MD-White 27.0 32.8 27.4 31.4 27.8 23.9 
Minneapolis, MN-White 33.2 26.9 32.8 26.6 32.6 31.5 
Forsyth County, NC-White 23.7 23.8 23.9 20.6 23.8 23.0 
Forsyth County, NC-Black 1.9 2.1 1.9 2.5 1.9 1.8 
Jackson, MS-Black 14.2 14.4 14.0 18.8 13.9 19.8 
Body mass index (kg/m2) 28.2 (5.3) 30.2 (5.6) <0.001 28.3 (5.3) 31.8 (5.9) <0.001 28.4 (5.4) 28.7 (5.4) 0.27 
Obese, % 30.5 47.6 <0.001 31.0 56.8 <0.001 32.0 36.3 0.063 
Waist-to-hip ratio 0.9 (0.1) 1.0 (0.1) <0.001 0.9 (0.1) 1.0 (0.1) <0.001 0.9 (0.1) 1.0 (0.1) 0.068 
Fasting glucose (mg/dL) 
98.7 (9.6) 127.4 (37.6) <0.001 98.9 (9.3) 153.7 (39.8) <0.001 100.4 (12.5) 
123.4 
(49.1) <0.001 
2-hour glucose (mg/dL) 124.2 (33.3) 247.7 (53.5) <0.001 130.6 (41.2) 258.4 (79.3) <0.001 134.0 (45.9) 190.1 (101) <0.001 
1,5-AG (µg/mL) 20.5 (6.1) 16.5 (7.2) <0.001 20.4 (6.1) 14.5 (7.9) <0.001 20.8 (5.6) 6.9 (2.5) <0.001 
Total cholesterol (mg/dL) 
201.5 (36.0) 203.4 (38.2) 0.17 201.6 (35.7) 204.3 (44.8) 0.14 201.8 (36.2) 
200.2 
(37.0) 0.36 
HDL cholesterol (mg/dL) 51.2 (16.5) 45.4 (14.8) <0.001 51.1 (16.5) 41.3 (13.0) <0.001 50.7 (16.4) 49.0 (17.4) 0.033 
Triglycerides (mg/dL) 136.1 (76.4) 182.3 (107) <0.001 138.0 (77.1) 195.9 (126) <0.001 140.1 (79.9) 154.1 (102) <0.001 
Data are means (SD) unless otherwise noted 
* Variables with missingness (variable, n): body mass index, 11; obese, 11; waist-to-hip ratio, 8; hypertension, 29; education level, 11; smoking 
status, 10; drinking status, 9; ACR stage, 55 
† p-value for global test: t-test for continuous variables and Pearson’s chi-squared tests for categorical variables 
Abbreviations: HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine-ratio 
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Table 1., continued 

















Hypertension, % 41.4 62.3 <0.001 42.6 62.5 <0.001 43.4 46.2 0.26 
Less than high school, % 15.4 20.6 <0.001 15.7 21.7 0.001 15.9 17.1 0.52 
Current smoker, % 13.9 11.4 0.042 13.7 11.8 0.28 13.8 11.3 0.14 
Current drinker, % 54.6 47.2 <0.001 54.0 49.5 0.079 53.8 53.3 0.85 
Parental history of diabetes, % 21.2 30.4 <0.001 21.6 33.4 <0.001 21.8 28.0 0.002 
eGFR <60 (mL/min/1.73m2), % 5.5 6.5 0.25 5.5 6.3 0.52 5.4 8.5 0.006 





<0.001 >30 & ≤300 4.2 7.6 4.3 10.7 4.3 10.0 
>300 0.6 2.0 0.6 2.3 0.7 0.9 
Data are means (SD) unless otherwise noted 
* Variables with missingness (variable, n): body mass index, 11; obese, 11; waist-to-hip ratio, 8; hypertension, 29; education level, 11; smoking 
status, 10; drinking status, 9; ACR stage, 55 
† p-value for global test: t-test for continuous variables and Pearson’s chi-squared tests for categorical variables 
Abbreviations: HDL, high-density lipoprotein; eGFR, estimated glomerular filtration rate; ACR, albumin-creatinine-ratio 
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Figure 1. Distribution of participants according to clinical cut-points of elevated 2-hour glucose and/or elevated fasting glucose, and low 
1,5-AG (<10 μg/mL), n=7,813 
  
 79 
Table 2. Diagnostic performance of 1,5-AG to identify elevated 2-hour glucose and/or fasting glucose, n=7,813 









1,5-anhydroglucitol compared to 2-hour glucose ≥200 mg/dL (n=818) 
<10 µg/mL  19.4% 96.1% 4.93 0.84 36.6% 91.1% 
(n = 435) (16.8, 22.3) (95.6, 96.5) (4.11, 5.90) (0.81, 0.87) (32.0, 41.3) (90.4, 91.7) 
<12 µg/mL 27.6% 92.6% 3.75 0.78 30.5% 91.6% 
(n = 741) (24.6, 30.8) (92.0, 93.2) (3.27, 4.31) (0.75, 0.82) (27.2, 34.0) (91.0, 92.3) 
<16 µg/mL  46.7% 77.9% 2.11 0.68 19.8% 92.6% 
(n=1,928) (43.2, 50.2) (76.9, 78.9) (1.94, 2.30) (0.64, 0.73) (18.1, 21.7) (91.9, 93.2) 
1,5-anhydroglucitol compared to fasting glucose ≥126 mg/dL (n=398) 
<10 µg/mL  31.4% 95.8% 7.51 0.72 28.7% 96.3% 
(n = 435) (26.9, 36.2) (95.3, 96.3) (6.27, 9.01) (0.67, 0.77) (24.5, 33.2) (95.8, 96.7) 
<12 µg/mL 38.9% 92.1% 4.93 0.66 20.9% 96.6% 
(n = 741) (34.1, 43.9) (91.5, 92.7) (4.26, 5.70) (0.61, 0.72) (18.0, 24.0) (96.1, 97.0) 
<16 µg/mL  57.8% 77.1% 2.52 0.55 11.9% 97.1% 
(n=1,928) (52.8, 62.7) (76.1, 78.1) (2.30, 2.77) (0.49, 0.62) (10.5, 13.5) (96.7, 97.6) 
1,5-anhydroglucitol compared to 2-hour glucose ≥200 mg/dL and fasting glucose ≥126 mg/dL (n=314) 
<10 µg/mL  38.2% 95.8% 9.10 0.65 27.6% 97.4% 
(n = 435) (32.8, 43.8) (95.3 96.2) (7.62, 10.9) (0.59, 0.70) (23.4, 32.0) (97.0, 97.7) 
<12 µg/mL 47.8% 92.1% 6.06 0.57 20.2% 97.7% 
(n = 741) (42.1, 53.5) (91.5, 92.7) (5.27, 6.97) (0.51, 0.63) (17.4, 23.3) (97.3, 98.0) 
<16 µg/mL  67.8% 77.1% 2.97 0.42 11.0% 98.3% 
(n=1,928) (62.4, 73.0) (76.2, 78.1) (2.72, 3.23) (0.36, 0.49) (9.68, 12.5) (97.9, 98.6) 
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Figure 2. Receiver operator characteristic (ROC) curve of 1,5-AG for detection of elevated 2-hour glucose and/or elevated fasting glucose  
 
Abbreviations: ROC, receiver operating characteristic  
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Table 3. Adjusted OR (95% CI) to assess predictors of discordance of true negative, false positive, false negative, and true positive results, 
n=7,813 
 Adjusted* OR (95% CI) 
 
True Negative 
2-hour <200 mg/dL, 
fasting glucose <126 




2-hour <200 mg/dL, 
fasting glucose <126 




2-hour ≥200 mg/dL 
and/or fasting glucose 
≥126 mg/dL, and 1,5-
AG ≥10 µg/mL 
n=712 
True Positive 
2-hour ≥200 mg/dL 
and/or fasting glucose 
≥126 mg/dL, and 1,5-
AG <10 µg/mL 
n=158 
Age (years) 1 (REF) 1.23 (1.10, 1.37) 1.33 (1.24, 1.42) 1.18 (1.03, 1.36) 
Female (male, ref) 1 (REF) 1.22 (0.95, 1.56) 1.28 (1.09, 1.50) 0.86 (0.63, 1.17) 
Race-center (Minneapolis, MN-white, ref)     
Jackson, MS-black 1 (REF) 1.70 (1.21, 2.41) 1.35 (1.05, 1.74) 1.35 (0.84, 2.15) 
Washington County, MD-white 1 (REF) 0.83 (0.59, 1.16) 1.52 (1.24, 1.86) 1.04 (0.70, 1.56) 
Forsyth County, NC-black 1 (REF) 1.02 (0.41, 2.57) 1.50 (0.88, 2.55) 1.01 (0.31, 3.30) 
Forsyth County, NC-white 1 (REF) 1.08 (0.77, 1.50) 1.26 (1.02, 1.57) 0.89 (0.57, 1.37) 
Body mass index (kg/m2) 1 (REF) 0.88 (0.77, 0.99) 1.40 (1.31, 1.50) 1.45 (1.28, 1.65) 
Total cholesterol (mg/dL) 1 (REF) 0.98 (0.97, 1.00) 1.01 (0.99, 1.02) 1.01 (0.99, 1.03) 
Triglycerides (mg/dL) 1 (REF) 0.99 (0.98, 1.00) 1.03 (1.02, 1.03) 1.03 (1.03, 1.04) 
HDL (mg/dL) 1 (REF) 1.02 (0.98, 1.06) 0.85 (0.83, 0.88) 0.76 (0.70, 0.81) 
Hypertension (no, ref) 1 (REF) 0.90 (0.69, 1.16) 2.33 (1.98, 2.74) 1.50 (1.09, 2.07) 
eGFR (mL/min/1.73 m2) 1 (REF) 0.96 (0.92, 1.00) 1.03 (1.00, 1.06) 1.04 (0.98, 1.10) 
Log ACR (ug/mg) 1 (REF) 2.01 (1.26, 3.20) 1.78 (1.30, 2.39) 4.41 (2.59, 7.49) 
Bold indicates p < 0.05 
* Adjusted for age, sex, race-center; continuous variables are scaled per 5 units 
* Variables with missingness (variable, n): body mass index, 11; hypertension, 29; log ACR, 55; dairy intake, 216; bread and/or rice intake, 208 




Table 3., continued 
 Adjusted* OR (95% CI) 
 
True Negative 
2-hour <200 mg/dL, 
fasting glucose <126 




2-hour <200 mg/dL, 
fasting glucose <126 




2-hour ≥200 mg/dL 
and/or fasting glucose 
≥126 mg/dL, and 1,5-
AG ≥10 µg/mL 
n=712 
True Positive 
2-hour ≥200 mg/dL 
and/or fasting glucose 
≥126 mg/dL, and 1,5-
AG <10 µg/mL 
n=158 
Dairy intake (lowest tertile, ref) 1 (REF)    
Middle tertile 1 (REF) 1.04 (0.76, 1.42) 1.03 (0.85, 1.25) 0.86 (0.58, 1.28) 
Highest tertile 1 (REF) 1.13 (0.83, 1.54) 1.15 (0.95, 1.39) 1.02 (0.69, 1.50) 
Bread and rice intake (lowest tertile, ref) 1 (REF)    
Middle tertile 1 (REF) 0.94 (0.70, 1.27) 1.07 (0.88, 1.29) 1.05 (0.71, 1.57) 
Highest tertile 1 (REF) 0.83 (0.61, 1.13) 1.03 (0.85, 1.25) 1.29 (0.87, 1.90) 
Bold indicates p < 0.05 
* Adjusted for age, sex, race-center; continuous variables are scaled per 5 units 
* Variables with missingness (variable, n): body mass index, 11; hypertension, 29; log ACR, 55; dairy intake, 216; bread and/or rice intake, 208 
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Abstract 
Objectives. 1,5-anhydroglucitol (1,5-AG) is a novel biomarker of glycemic control that 
has been proposed to monitor recent hyperglycemic excursions in persons with diabetes. 
The clinical utility of 1,5-AG outside of the setting of diagnosed diabetes is unclear, but it 
is possible that it may identify people at high risk for diabetes and its complications. The 
objective of this study was to compare the associations of 1,5-AG with 2-hour glucose for 
risk of major clinical complications. 
Research Design and Methods. We conducted a prospective analysis of 6,644 
Atherosclerosis Risk in Communities (ARIC) Study participants without diagnosed 
diabetes followed for nearly 20 years for incident diagnosed diabetes, chronic kidney 
disease, cardiovascular disease, and all-cause mortality. All participants were disease-free 
at baseline. We assessed associations of 1,5-AG and 2-hour glucose (modeled 
categorically and continuously with restricted cubic splines) with adverse outcomes using 
Cox models with evaluated improvement in risk discrimination using the c-statistic.  
Results. 1,5-AG <10 µg/mL was statistically significantly associated with incident 
diabetes (HR: 2.70, 95% CI 2.31, 3.15), and showed suggestion of association with 
incident chronic kidney disease, cardiovascular disease, and all-cause mortality compared 
to 1,5-AG ≥10 µg/mL. Continuous associations of 1,5-AG with outcomes displayed a 
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clear threshold effect, with risk associations generally observed only in the 1,5-AG <10 
µg/mL group. Comparing associations of 1,5-AG and 2-hour glucose with outcomes 
resulted in larger c-statistics for 2-hour glucose than 1,5-AG for all outcomes (difference 
in c-statistic [2-hour glucose-1,5-AG] for diagnosed diabetes: 0.17 [95%CI, 0.15, 0.19]; 
chronic kidney disease 0.02 [95%CI 0.00, 0.05]; cardiovascular disease 0.03 [95%CI, 
0.00, 0.06]; and all-cause mortality 0.04 [95%CI, 0.02, 0.06]). 1,5-AG did also not 
improve risk stratification when added to models with traditional glucose measures 
(fasting or 2-hour glucose). 
Conclusions. In this community-based population without diagnosed diabetes, low 1,5-
AG was modestly associated with major clinical outcomes and did not outperform 2-hour 
glucose. Further research is needed to determine the utility of 1,5-AG outside of the 
setting of diagnosed diabetes. 
Introduction 
Diabetes poses a substantial burden on patients, providers, and the health care 
system1. Persons with diabetes are at increased risk for microvascular and macrovascular 
disease and at high risk of death2. There is widespread screening for diabetes in the U.S., 
with the aim of identifying and intervening early in the disease process to prevent major 
complications. Routine measurement of biomarkers of hyperglycemia is used to screen 
and diagnose diabetes3 and identify those at increased risk for its associated outcomes. 
Glucose measured after the administration a 75-g oral glucose load (simulated 
carbohydrate-rich meal) is a well-established test used to diagnose diabetes. In the setting 
of insulin resistance and/or impaired insulin secretion, blood glucose concentrations will 
remain elevated (≥200 mg/dL) two hours following the oral glucose load. 1,5-
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Anhydroglucitol (1,5-AG) is a less common measure of hyperglycemia that reflects 
glycemic excursions, although through a different mechanism. 1,5-AG is a 
monosaccharide that remains stable in blood at normal levels of glycemia. However, 
when circulating plasma glucose exceeds the renal threshold for glucose reabsorption 
(~160-180 mg/dL), 1,5-AG and glucose compete for reabsorption in the renal proximal 
tubule, resulting in increased excretion of 1,5-AG in the urine and lower 1,5-AG 
concentrations in the blood. 1,5-AG is attractive as an alternative measure of 
hyperglycemia as it is a non-fasting test, does not involve administration of a 
carbohydrate challenge, and can be measured in a single blood sample. Some 
investigators have suggested the utility of 1,5-AG for diabetes screening4–6. 
Elevated 2-hour glucose and low 1,5-AG concentrations are both associated with 
future outcomes including microvascular and macrovascular events, and all-cause 
mortality7–11. However, prior studies have not compared associations of 2-hour glucose to 
1,5-AG in the same study population. We therefore evaluated and compared the 
associations of 1,5-AG and 2-hour glucose with risk for future diagnosed diabetes, 
chronic kidney disease, cardiovascular disease, and all-cause mortality in adults in the 
Atherosclerosis Risk in Communities (ARIC) Study, a U.S-based prospective cohort. 
Methods 
Study Population 
The ARIC Study was initiated in 1987, enrolling 15,792 participants from four 
communities (Washington County, Maryland; Minneapolis, Minnesota; Jackson, 
Mississippi; and Forsyth County, North Carolina) in the first study visit12. Since the 
baseline visit (Visit 1), there have been six subsequent completed or ongoing visits (Visit 
 86 
2: 1990-92, Visit 3:1993-95, Visit 4:1996-98, Visit 5: 2011-13, Visit 6: 2016-17, and 
Visit 7: 2018-19). Investigators obtained study approvals from institutional review boards 
and written informed consent from all participants. 
Our study population included the 11,656 participants who attended the fourth 
visit (1996-98) when both 1,5-AG and 2-hour glucose were measured. We then excluded 
participants ineligible for the oral glucose tolerance test or missing glycemic markers 
(n=3,587), those with prevalent diagnosed diabetes, chronic kidney disease, or 
cardiovascular disease (n=1,299), those who were not black or white or who were black 
from the Washington Country or Minneapolis sites (n=43), and those missing covariates 
of interest (n=81; see Figure E-1 for more details). We followed the resulting 6,644 
participants over ~20 years for incident disease, including diagnosed diabetes, chronic 
kidney disease, cardiovascular disease, and all-cause mortality. 
Exposure Measurements 
1,5-AG, 2-hour glucose, and fasting glucose were measured in plasma at the 
Baylor College of Medicine. 1,5-AG was measured using the GlycoMark assay in 2015-
2016 in stored samples obtained from ARIC participants at the fourth study visit (inter-
assay CV, 4.54%). Blood samples were collected in the fasting state and 2-hours 
following administration of 75-g glucose load among those without diagnosed diabetes or 
currently taking medications for diabetes at the study visit. The oral glucose tolerance test 
protocol also excluded participants who had prior stomach or intestinal surgery, those on 
dialysis, those who were fasting for less than 10 hours13 (see Figure E-1 for detail). 
Glucose was measured in plasma using the hexokinase method with the Roche Hitachi 
911 automated chemistry analyzer (or autoanalyzer). For categorical analyses of these 
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biomarkers, we used the following cut points: 1,5-AG ≥10 µg/mL, <10µg/mL; 2-hour 
glucose < 200 mg/dL, ≥200 mg/dL; and fasting glucose <126 mg/dL, ≥126 mg/dL. 
We previously evaluated the cross-sectional concordance of 1,5-AG, 2-hour 
glucose, and fasting glucose and found substantial discordance across these measures14. 
To assess the clinical implications of this discordance, we cross-tabulated categories of 
1,5-AG with clinical categories of 2-hour glucose and fasting glucose and compared 
those identified as “true negatives” (TN), “false positives” (FP), “false negatives” (FN), 
and “true positives” (TP). That is, we defined a TN as those without hyperglycemia (2-
hour <200 mg/dL and fasting glucose <126 mg/dL) and 1,5-AG ≥10 µg/mL. We defined 
a FP as those without hyperglycemia (2-hour <200 mg/dL and fasting glucose <126 
mg/dL) and 1,5-AG <10 µg/mL. We defined a FN as those with hyperglycemia (2-hour 
≥200 mg/dL and/or fasting glucose ≥126 mg/dL) and 1,5-AG ≥10 µg/mL. Finally, we 
defined a TP as those with hyperglycemia (2-hour ≥200 mg/dL and/or fasting glucose 
≥126 mg/dL) and 1,5-AG <10 µg/mL. 
Assessment of Outcomes 
We followed participants prospectively from baseline (Visit 4; 1996-98) for 
incident diabetes and major clinical outcomes (incident chronic kidney disease, 
cardiovascular disease, and all-cause mortality) for nearly 20 years (end of follow-up: 
December 31, 2013 for chronic kidney disease; December 31, 2015 for all other 
outcomes). We defined incident diabetes as self-report of physician diagnosis or glucose-
lowering medication use during a study visit or annual or semi-annual telephone call;15 
chronic kidney disease as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 
m2 (from CKD-EPI equation16 using creatinine) at Visit 5 (2011-13) and a decline from 
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Visit 4 of at least 25%, a chronic kidney disease-related hospitalization or death17, or end 
stage renal disease event identified by linkage to the United States Renal Data System; 
cardiovascular disease as an adjudicated hospitalization or death from coronary heart 
disease or ischemic stroke12; and all-cause mortality as identified from surveillance of all 
ARIC participants. 
Covariate Measurement 
Participants reported demographic characteristics (age, sex, race, parental history 
of diabetes, and education level) at cohort initiation (Visit 1). Because race may be 
confounded by study center12, we defined race-center as Washington County, Maryland-
White; Minneapolis, Minneapolis-White; Forsyth County, North Carolina-White; Forsyth 
County, North Carolina-Black; Jackson, Mississippi-Black. 
Other covariates were measured at baseline of the present study (Visit 4). Height, 
weight, waist-to-hip ratio, total cholesterol, HDL cholesterol, and triglycerides were 
measured using standard anthropometric and phlebotomy protocols18,19. Body mass index 
was calculated from weight and height (kg/m2). Mean systolic and diastolic blood 
pressure were calculated by averaging two measurements20. We defined hypertension as 
self-report of hypertensive medications, mean systolic blood pressure ≥140 mmHg, or 
mean diastolic blood pressure ≥90mmHg. Participants self-reported whether they were 
currently, formerly, or never smokers and/or drinkers18. eGFRcr was calculated from 
creatinine using the CKD-EPI equation16. We derived albumin-to-creatinine ratio from 
albumin and creatinine measurements in urine samples21. 
Statistical analysis 
We compared participants’ baseline characteristics by categories generated from 
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the cross-tabulation of 1,5-AG with clinical categories of 2-hour glucose and fasting 
glucose (TN, FP, FN, TP). We used Cox proportional hazards models to characterize 
associations with incident outcomes, using categories of each biomarker (1,5-AG ≥10 
µg/mL, <10µg/mL; 2-hour glucose < 200 mg/dL, ≥200 mg/dL; and fasting glucose <126 
mg/dL, ≥126 mg/dL) and using restricted cubic splines with four knots located at the 5th, 
35th, 65th, and 95th percentiles to more flexibly model each of the biomarkers. We 
graphed the continuous associations of 1,5-AG, 2-hour glucose, and fasting glucose with 
incident diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-cause 
mortality and compared the prognostic value of the associations by calculating 
differences in Harrell’s C-statistic. 
We also evaluated the associations of the categories generated from the cross-
tabulation of 1,5-AG with clinical categories of 2-hour glucose and fasting glucose (TN, 
FP, FN, TP) with risk of future diagnosed diabetes, chronic kidney disease, 
cardiovascular disease, and all-cause mortality, using TN as the reference. To assess 
whether 1,5-AG helped further risk stratify those in addition to 2-hour glucose and/or 
fasting glucose, we again used Harrell’s c-statistic to compare continuous spline models. 
We primarily present unadjusted results given the importance in understanding 
the comparative overall (crude) associations, which would be most relevant for informing 
diabetes screening. We also conducted two supplementary analyses evaluating the 
associations after adjustment for potential confounding variables. In these analyses, 
Model 1 included age, sex, race-center and Model 2 included all variables in Model 1 
plus body mass index, systolic blood pressure, hypertension medication use (no, yes), 
total cholesterol, HDL, triglycerides, education (less than high school, high 
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school/vocational school, college or higher), smoking status (current, former, never), 
drinking status (current, former, never), parental history of diabetes (no, yes), eGFRcr, 
and log transformed albumin-to-creatinine ratio). For all of our analyses, we used Stata 
15.1 (StataCorp, College Station, TX). 
Results 
At baseline, participants were a mean of 63 years old, 60% female, and 17% 
black. Mean (SD) 2-hour glucose, fasting glucose, and 1,5-AG were 136 (51.8) mg/dL, 
101 (17.7) mg/dL, and 20.0 (6.2) µg/mL. Overall, 86% of participants were classified as 
TN, while 3% were FP, 9% were FN, and 2% were TP (Table 1). Participants in the FP 
group were more likely to be female, black, and tended to have lower triglycerides 
(Table 1). Among the TP group, participants were less likely to be female and have 
hypertension, more likely to have a parental history of diabetes, and tended to have 
higher triglycerides and ACR (Table 1). Those with hyperglycemia (2-hour ≥200 mg/dL 
and/or fasting glucose ≥126 mg/dL) irrespective of 1,5-AG (FN, TP) were more likely to 
be obese, have hypertension, have parental history of diabetes, and tended to have higher 
body mass index and triglycerides and lower HDL compared to those without 
hyperglycemia (2-hour <200 mg/dL and fasting glucose <126 mg/dL [TN, FP]; Table 1).  
In total, there were 1,750 cases of incident diagnosed diabetes (median follow-up 
of 15.8 years), 1,334 chronic kidney disease events (median follow-up of 15.7 years), 808 
cardiovascular disease events (median follow-up of 17.7 years), and 1,788 deaths 
(median follow-up of 17.8 years). Categorical analyses suggested that compared to 1,5-
AG ≥10 µg/mL, 1,5-AG <10 µg/mL was associated with increased risk of incident 
diabetes, and may be associated with future chronic kidney disease, cardiovascular 
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disease, and all-cause mortality (Table 2). 2-hour glucose ≥200 mg/dL and fasting 
glucose ≥126 mg/dL were statistically significantly associated with increased risk of all 
outcomes compared to their reference categories (Table 2). Adjustment for additional 
covariates did not alter our inferences (Table E-1). 
When modeled with restricted cubic splines, values of 1,5-AG below the tenth 
percentile (12.3 µg/mL) were associated with incident diagnosed diabetes, chronic kidney 
disease, cardiovascular disease, and all-cause mortality in the primary unadjusted analysis 
(Figure 1, Panel A). The lowest levels of 1,5-AG were associated with the highest risk of 
future outcomes, although risk was not linear across the entire distribution. Higher values 
of 2-hour glucose (200 mg/dL) and fasting glucose (116 mg/dL) were strongly associated 
with incident diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-
cause mortality (Figure 1, Panels B and C). When comparing the models using Harrell’s 
c-statistic, 2-hour glucose and fasting glucose provided more prognostic value for future 
adverse events than 1,5-AG (Table 3). These comparisons remained irrespective of 
adjustment for most covariates (Table E-2). 
Our analysis of the cross-tabulations of 1,5-AG with fasting and 2-hour glucose 
revealed that in the absence of hyperglycemia (low fasting [<126 mg/dL] and 2-hour 
[<200 mg/dL] glucose), 1,5-AG <10 µg/mL (FP) was significantly associated with future 
diagnosed diabetes (HR: 1.37, 95% CI: 1.06, 1.78; Table 4). Hyperglycemia categories 
(2-hour ≥200 mg/dL and/or fasting glucose ≥126 mg/dL [FN, TP]) irrespective of 1,5-AG 
were associated with incident diagnosed diabetes, chronic kidney disease, cardiovascular 
disease, and all-cause mortality (Table 4). Results were similar after adjustment (Table 
E-3). Despite the fact that the TP group was at the highest risk, 1,5-AG did not provide 
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additional information for risk stratification when we assessed increases in Harrell’s c-
statistic when added to unadjusted continuous models of 2-hour glucose and/or fasting 
glucose (differences in c-statistic of model with 2-hour glucose, fasting glucose, and 2-
hour glucose and fasting glucose-those models + 1,5-AG were not statistically 
significantly different than 0 for all outcomes; data not shown).  
Discussion 
In our comparison of 1,5-AG and 2-hour glucose for risk of future adverse 
outcomes among persons without diagnosed diabetes, we observed that low values of 1,5-
AG were indicative of increased risk of incident diagnosed diabetes, chronic kidney 
disease, cardiovascular disease, and all-cause mortality. Consistent with prior studies9,10 
and the biology of 1,5-AG, the signal for adverse outcomes seemed to be largely driven 
by those persons with 1,5-AG concentrations <10 µg/mL, meaning risk associations for 
1,5-AG demonstrated a clear threshold effect, with virtually no risk associations observed 
at higher 1,5-AG values. Nonetheless, the prognostic value of 1,5-AG was less than that 
of 2-hour or fasting glucose for the same outcomes.  
We also tested whether 1,5-AG could add prognostic information above and 
beyond fasting or 2-hour glucose, but did not find evidence of its incremental 
contribution. In general, our results suggest the utility of 1,5-AG outside the setting of 
diabetes—for instance, as a screening test alone or in combination with glucose to 
identify individuals at high risk of future outcomes—is likely to be limited. 
We did find that persons with “isolated low 1,5-AG” (persons with 2-hour 
glucose <200 mg/dL and fasting glucose <126 mg/dL, but 1,5-AG <10 µg/mL; FP) were 
at high risk for future diabetes. This finding is provocative. Causes of low 1,5-AG outside 
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the setting of hyperglycemia are largely uncharacterized but potential non-glycemic 
determinants include diet,22–24 kidney function,25 liver disease,26 and genetic variants 
related to glucose metabolism27. Another explanation is that these individuals were 
misclassified by both 2-hour glucose and fasting glucose but identified as having 
disordered glucose metabolism by 1,5-AG. Controlled studies are needed to better 
understand determinants of low 1,5-AG outside of hyperglycemia. 
Our study was among the first to directly compare associations of 1,5-AG and 2-
hour glucose in a large, community-based U.S. population with rigorous ascertainment of 
major clinical outcomes. Additional strengths included the detailed phenotypic 
characterization of the population and long duration of follow-up. Some limitations of 
this study that should be considered in the interpretation of our results include that we 
only had a single measure of each biomarker. And although 1,5-AG was measured in 
samples from the same visit as 2-hour glucose, these assays were conducted in stored 
samples, many years later. Cases of incident diagnosed diabetes during the follow-up 
period in this study would have been identified largely on the basis of glucose (HbA1c 
was not recommended for diagnosis of diabetes until 201028), and elevated values of 
glucose (2-hour ≥300 mg/dL; fasting glucose ≥200 mg/dL) were reported back to 
participants. Therefore, it was likely that glucose measures would be more strongly 
associated with incident diabetes. 
In summary, we observed that associations of 1,5-AG with adverse outcomes 
were not as strong as 2-hour or fasting glucose among persons without diagnosed 
diabetes. It is unlikely that 1,5-AG is a feasible routine screening test for undiagnosed 
diabetes in the general population. However, we identified a group of individuals with 
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isolated low 1,5-AG who were at increased risk of future diabetes. The reasons for 
“isolated” low 1,5-AG are largely uncharacterized and it is not clear why individuals 
might have low values of 1,5-AG without concurrent hyperglycemia. Further 
understanding the determinants of low 1,5-AG outside of the setting of diabetes is 
important to continue to inform its utility in clinical practice. 
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Table 1. Baseline risk factors by hyperglycemia and 1,5-AG concordance categories among those without prevalent diabetes, chronic 
kidney disease, or cardiovascular disease, n=6,644 
 No hyperglycemia Hyperglycemia 
 True Negative (TN) False Positive (FP) False Negative (FN) True Positive (TP) 
 2-hour <200 mg/dL, fasting 
glucose <126 mg/dL, and 
1,5-AG ≥10 µg/mL 
2-hour <200 mg/dL, fasting 
glucose <126 mg/dL, and 
1,5-AG <10 µg/mL 
2-hour ≥200 mg/dL and/or 
fasting glucose ≥126 mg/dL, 
and 1,5-AG ≥10 µg/mL 
2-hour ≥200 mg/dL and/or 
fasting glucose ≥126 mg/dL, 
and 1,5-AG <10 µg/mL 
 N=5681 N=220 N=610 N=133 
Age (years) 62.6 (5.5) 63.4 (6.1) 64.4 (5.6) 63.3 (5.4) 
Female, % 59.2 66.4 63.9 51.9 
Black, % 16.0 22.7 18.2 21.1 
Body mass index (kg/m2) 28.2 (5.3) 27.5 (5.2) 30.3 (5.8) 30.8 (5.6) 
Obese, % 30.2 28.2 47.4 51.1 
Fasting glucose (mg/dL) 98.1 (8.8) 98.1 (9.4) 119.5 (21.1) 167.8 (61.9) 
2-hour glucose (mg/dL) 123.0 (33.0) 124.7 (31.1) 226.0 (38.5) 299.7 (87.3) 
1,5-AG (µg/mL) 20.9 (5.5) 7.5 (2.2) 19.0 (5.4) 6.0 (2.9) 
Total cholesterol (mg/dL) 202.5 (35.5) 199.2 (36.2) 203.4 (38.9) 205.9 (37.1) 
HDL cholesterol (mg/dL) 52.0 (16.6) 55.2 (18.2) 46.9 (15.4) 43.3 (14.1) 
Triglycerides (mg/dL) 134.9 (75.4) 123.4 (60.6) 171.7 (95.5) 198.7 (142.4) 
Hypertension, % 38.1 38.6 61.1 46.6 
Less than high school, % 14.3 15.5 20.8 18.0 
Current smoker, % 14.0 14.1 12.0 9.8 
Current drinker, % 55.6 59.1 48.2 50.4 
Parent history of diabetes, % 21.1 24.5 30.7 38.3 
eGFRcr (ml/min/1.732 m2) 88.2 (12.5) 87.6 (12.8) 88.0 (12.7) 91.4 (12.5) 
ACR (Median, IQR; ug/mg) 3.4 (1.8, 6.4) 3.9 (1.9, 7.1) 3.7 (1.6, 7.4) 5.1 (2.0, 10.6) 
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; eGFRcr, estimated glomerular filtration rate (creatinine); ACR, albumin-to-creatinine ratio 
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Table 2. Unadjusted hazard ratios and 95% CI of categories of 1,5-AG, 2-hour glucose, and fasting glucose for risk of incident diagnosed 
diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality, n=6,644 
 
Biomarker Categories 
 Diagnosed diabetes Chronic kidney disease 
n Events HR (95% CI) Events HR (95% CI) 
1,5-AG ≥10 µg/mL 6,291 1,575 1 (REF) 1,253 1 (REF) 
1,5-AG <10 µg/mL 353 175 2.70 (2.31, 3.15) 81 1.19 (0.95, 1.49) 
2-hour glucose <200 mg/dL 5,970 1,275 1 (REF) 1,163 1 (REF) 
2-hour glucose ≥200 mg/dL 674 475 6.68 (6.00, 7.43) 171 1.46 (1.25, 1.72) 
Fasting glucose <126 mg/dL 6,315 1,458 1 (REF) 1,250 1 (REF) 
Fasting glucose ≥126 mg/dL 329 292 13.8 (12.1, 15.7) 84 1.48 (1.19, 1.85) 
 
 Cardiovascular disease All-cause mortality 
n Events HR (95% CI) Events HR (95% CI) 
1,5-AG ≥10 µg/mL 6,291 756 1 (REF) 1,685 1 (REF) 
1,5-AG <10 µg/mL 353 52 1.27 (0.96, 1.68) 103 1.12 (0.92, 1.37) 
2-hour glucose <200 mg/dL 5,970 690 1 (REF) 1,544 1 (REF) 
2-hour glucose ≥200 mg/dL 674 118 1.64 (1.35, 1.99) 244 1.51 (1.32, 1.73) 
Fasting glucose <126 mg/dL 6,315 745 1 (REF) 1,660 1 (REF) 
Fasting glucose ≥126 mg/dL 329 63 1.79 (1.39, 2.32) 128 1.63 (1.36, 1.95) 
Bold indicates p<0.05 
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Figure 1. Distributions and unadjusted associations of 1,5-AG, 2-hour glucose, and fasting glucose with incident diagnosed diabetes, 
chronic kidney disease, cardiovascular disease, and all-cause mortality modeled with restricted cubic splines, n=6,644 
PANEL A. 1,5-AG 
Diagnosed diabetes     Chronic kidney disease 
 
Cardiovascular disease    All-cause mortality 
 
Models centered at 10th percentile: 12.3 µg/mL; note different scale of y-axis (HR 95%CI) for incident diagnosed diabetes 
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval 
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PANEL B. 2-hour glucose 
Diagnosed diabetes     Chronic kidney disease 
 
Cardiovascular disease    All-cause mortality 
 
Models centered at 90th percentile: 200 mg/dL; note different scale of y-axis (HR 95%CI) for incident diagnosed diabetes  




PANEL C. Fasting glucose 
Diagnosed diabetes     Chronic kidney disease 
 
Cardiovascular disease    All-cause mortality 
 
Models centered at 90th percentile: 116 mg/dL; note different scale of y-axis (HR 95%CI) for incident diagnosed diabetes 
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval 
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Table 3. Differences in Harrell’s C-statistics from unadjusted associations of 1,5-AG, 2-hour glucose, and fasting glucose with incident 
diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality modeled with restricted cubic splines, n=6,644 
 Differences in Harrell’s C-statistic (95% CI) 






2-hour glucose – 1,5-AG 0.17 (0.15, 0.19) 0.02 (0.00, 0.05) 0.03 (0.00, 0.06) 0.04 (0.02, 0.06) 
Fasting glucose – 1,5-AG 0.18 (0.17, 0.20) 0.02 (0.00, 0.04) 0.05 (0.02, 0.07) 0.04 (0.02, 0.06) 
Bold indicates p<0.05 
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; CI, confidence interval 
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Table 4. Unadjusted hazard ratios and 95% CI of categories of hyperglycemia and 1,5-AG concordance for risk of incident diagnosed 
diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality, n=6,644 
 
Categories of Hyperglycemia 
and 1,5-AG concordance 
 Diagnosed diabetes Chronic kidney disease 
n Events HR (95% CI) Events HR (95% CI) 
True Negative (TN) 5681 1166 1 (REF) 1112 1 (REF) 
False Positive (FP) 220 59 1.37 (1.06, 1.78) 39 0.89 (0.65, 1.22) 
False Negative (FN) 610 409 6.10 (5.45, 6.84) 141 1.29 (1.09, 1.54) 
True Positive (TP) 133 116 15.9 (13.1, 19.3) 42 1.89 (1.39, 2.58) 
  Cardiovascular disease All-cause mortality 
 n Events HR (95% CI) Events HR (95% CI) 
True Negative (TN) 5681 653 1 (REF) 1466 1 (REF) 
False Positive (FP) 220 27 1.09 (0.74, 1.60) 55 0.98 (0.75, 1.28) 
False Negative (FN) 610 103 1.59 (1.29, 1.96) 219 1.49 (1.29, 1.72) 
True Positive (TP) 133 25 1.77 (1.19, 2.64) 48 1.52 (1.14, 2.02) 
Bold indicates p<0.05 




This dissertation investigated epidemiological questions related to screening for 
prediabetes and diabetes. Identifying asymptomatic individuals at risk for diabetes and its 
related adverse outcomes is critical to reduce the disease burden and identify 
opportunities for prevention. To address key gaps in the literature, we characterized 
trajectories of kidney function by diabetes status over time, evaluated the comparative 
prognostic performance of five different definitions of prediabetes—all of which are in 
current clinical use—and interrogated whether a novel biomarker, 1,5-anhydroglucitol, 
might have a role for diabetes screening and risk stratification. 
Summary of Findings and Implications 
Chapter 1 analyses characterized trajectories of kidney function by diabetes status 
with up to four measurements of serum creatinine per person and over 25 years of follow-
up. We observed that persons with diabetes have a decline in kidney function that was 
much more steep (approximately twice the rate of decline) than those without diabetes. 
We also observed that persons with undiagnosed diabetes decline more steeply than those 
without diabetes, after an initial period of less steep average decline, which may suggest a 
period of hyperfiltration. Additionally, we identified subgroups of persons with diabetes 
with genetic, demographic, and modifiable risk factors that may indicate risk of steeper 
decline.  
These results provide information on expected decline by diabetes status, 
emphasize the risk of kidney function decline in persons with diabetes, and should inform 
the design and conduct of clinical trials that use eGFR as a surrogate endpoint. This 
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research also highlights the importance of diabetes screening to identify persons at risk 
for kidney disease, the need for rigorous monitoring of kidney parameters and glycemic 
control in persons with diagnosed diabetes to prevent kidney function decline.  
Chapter 21 directly compared the five different definitions of prediabetes which 
have been recommended by different international diabetes organizations. All five of 
these definitions are in current clinical use, causing confusion regarding which group of 
persons truly has prediabetes and which definition might be optimal for screening in the 
general population. Indeed, we observed that the prevalence of prediabetes—in a single 
population—ranged from 9% to 38%, depending on the definition used. The American 
Diabetes Association (ADA) fasting glucose-based definition resulted in the largest 
prevalence estimate, while the International Expert Committee HbA1c-definition 
identified the smallest group of people. The characteristics of persons with prediabetes by 
the different definitions also varied, with HbA1c-based definitions identifying those with 
worse cardiometabolic risk profiles. 
Following participants for up to 22 years for incident diabetes, chronic kidney 
disease, atherosclerotic cardiovascular disease, peripheral arterial disease, and all-cause 
mortality, we compared the test characteristics and prognostic value of the various 
definitions. We saw that prediabetes was a high-risk condition for future outcomes 
regardless of definition. Comparatively, we observed that HbA1c-based prediabetes 
definitions and the World Health Organization (WHO) fasting glucose-based definition 
were more specific for identification of future outcomes than the ADA fasting glucose-
based definition. Glucose-based definitions (ADA fasting glucose, ADA and WHO 2-
hour glucose), with the exception of WHO fasting glucose, had higher sensitivity. 
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HbA1c-based definitions had higher incidence rates and larger hazard ratios and c-
statistics for chronic kidney disease, atherosclerotic cardiovascular disease, peripheral 
arterial disease, and all-cause mortality.  
The results of this analyses supports a call for action to obtain international 
consensus on definitions of prediabetes. The drastically varying proportions of people 
identified by the different definitions demonstrate the importance of consistency for 
public health efforts and coordination of prevention programs. Formal recommendations 
to help guide the choice of prediabetes definition under different scenarios are needed to 
help inform resource allocation and program planning.  
Chapter 3 was a diagnostic screening study, comparing 1,5-anhydroglucitol (1,5-
AG) to 2-hour glucose for identification of undiagnosed diabetes. We observed 
substantial discordance between low 1,5-AG and categories of hyperglycemia defined by 
2-hour glucose and fasting glucose. Categories of 1,5-AG resulted in low sensitivity but 
high specificity for identification of undiagnosed diabetes defined by 2-hour glucose 
regardless of the 1,5-AG cut point used. Comparing continuous values of the two markers 
in receiver operating characteristic (ROC) analyses resulted in similar conclusions. 
Through this study, we also identified a group of individuals with “low isolated 
1,5-AG”, or those with low 1,5-AG but no hyperglycemia defined by the glucose 
measures. The characteristics associated with this provocative group were age, black 
race, decreased kidney function, and increased kidney damage. While we concluded that 
1,5-AG is unlikely to be a useful screening test in the community, further understanding 
those with low isolated 1,5-AG may further inform its utility.  
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In Chapter 4, we compared the associations of 1,5-AG and 2-hour glucose for risk 
of incident diabetes, cardiovascular disease, chronic kidney disease, and all-cause 
mortality. We observed that 1,5-AG was not as strongly associated with risk of future 
outcomes as 2-hour glucose, and that risk was not continuous across the distribution. We 
also saw that those with “low isolated 1,5-AG” were at high risk of future diabetes. This 
suggests that there could have been misclassification by both 2-hour glucose and fasting 
glucose. 
It also highlights that although the lowest values of 1,5-AG may be largely 
influenced by hyperglycemia, there are likely a number of factors that influence the 
remaining values in the distribution including diet2,3, kidney function4, liver disease5, and 
genetic variants that influence glucose metabolism6. Controlled studies are needed to 
further understand this heterogeneous group missed by traditional screening tests that are 
at increased risk for diabetes. 
The Methodological Supplement described a calibration study that was conducted 
to statistically correct our Visit 4 1,5-AG plasma measurements (conducted in 2015-2016 
at the Atherosclerosis Clinical Research Laboratory at the Baylor College of Medicine) to 
align them with prior Visit 2 and Visit 5 serum 1,5-AG measurements (conducted in 
2011-2013 at the Advanced Research and Diagnostic Laboratory at the University of 
Minnesota). We also derived a correction to account for substantial drift over time that 
was observed during 2015-2016 in the Visit 4 1,5-AG measurements. This work helps 
minimize potential bias in epidemiologic analyses using these data and improves the 
comparability of 1,5-AG measurements conducted across two laboratories.  
Future Directions 
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Answering open questions regarding hyperfiltration 
Our results suggest that hyperfiltration may occur early in the course of diabetes. 
Given that persons with new onset diabetes may be particularly targeted for prevention of 
chronic kidney disease progression, further understanding this complex relationship 
would have great clinical utility. Better understanding of whether hyperfiltration occurs, 
the period of time for which it occurs, characteristics of the persons in which it occurs, 
and whether it is indicative of higher risk of adverse outcomes is important. 
Data on serial measurements of creatinine over 4 years among Pima Indians 
without diabetes, impaired glucose tolerance, newly diagnosed diabetes, and established 
diabetes7, which in part, prompted this line of investigation, should be replicated and 
extended in a community-based population, if possible. However, the natural history of 
diabetes and kidney function will be more difficult to assess using modern data given that 
some newer diabetes medications have significant interplay with the kidney. If existing 
datasets have more measurements of serum creatinine in shorter-time frames with 
information on diabetes duration, this question should be pursued. 
Better definitions of prediabetes? 
Reaching consensus on a definition of prediabetes is critical for public health 
coordination and planning, but it is also important to recognize that all of our current 
definitions have limitations. Some experts have criticized the entire category of 
“prediabetes” especially as incidence rates of progression from prediabetes to diabetes 
are low8. Although data are sparse and conversion also depends on the definition in use, 
studies estimate that half to two-thirds of persons with prediabetes will not have diabetes 
in 10 years8,9. That some persons with prediabetes never go on to develop diabetes also 
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complicates resource allocation and planning. Experts have advocated for a 
multidimensional approach and the development of risk-based definitions of prediabetes 
that incorporate glycemic variables plus additional factors10,11. Developing a new method 
to identify those with prediabetes who are at high-risk for developing diabetes would be 
useful in both clinical practice and public health planning. 
Future utility of 1,5-AG  
 1,5-AG is approved by the U.S. Food and Drug Administration for short-term 
monitoring of glycemic control among persons with diabetes, is currently being marketed 
for use in the U.S. by GlycoMark®, and is reimbursed by Medicare, Medicaid, and most 
private insurers. However, the evidence for its clinical utility is still developing and there 
are a number of open questions. Epidemiological studies, similar to the ones we 
conducted, provide useful information on how tests like 1,5-AG perform in the general 
population. 
We saw in the setting outside of diagnosed diabetes that its potential to substitute 
for existing more burdensome markers, like 2-hour glucose, is limited. However, there is 
evidence that 1,5-AG may provide information above and beyond traditional markers of 
glycemia to identify those at high risk for adverse outcomes at least among persons with 
diabetes12,13. Whether that additional information leads to better clinical outcomes is less 
clear. Exploring whether panels of non-fasting biomarkers measured at one time, which 
would limit participant burden and provide more information, could be helpful. Further, 
understanding whether the additional information gained is associated with improved 
clinical outcomes is critical. 
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1,5-AG could also have other uses. For example, 1,5-AG could provide means to 
better risk stratify particular subgroups, for example, older adults with diabetes. Diabetes 
in older adults is a very heterogeneous condition with open questions about who should 
receive treatment. Given its specificity, 1,5-AG could provide information to better 
identify high-risk individuals. 
We should continue to search for alternative biomarkers given limitations of 
current measures and to develop more epidemiologic data that assess performance in 
general populations. Future studies are needed to build the evidence base and continue to 
understand the clinical utility of measures like 1,5-AG. 
Summary 
This dissertation extended the existing epidemiological evidence base of 
screening for prediabetes and diabetes. Future research in this line of investigation is 
needed to refine who is at highest risk of prediabetes, diabetes, and their associated 
complications and who may most benefit from preventative measures. Informing 
allocation of clinical and public health resources will remain critical as this pressing 




Appendix A: Methodological supplement 
Summary 
Existing measurements of 1,5-anhydroglucitol (1,5-AG) are available at visit 2 
and visit from serum samples measured at the University of Minnesota in 2011-2013. 
Subsequent measurements of 1,5-AG were conducted in stored visit 4 plasma samples at 
Baylor College of Medicine from 2015-2016. To ensure comparability to previous 
measurements conducted at the University of Minnesota (visit 2 and visit 5 serum 
samples in 2011-2013), we performed a calibration study using visit 5 samples from 
University of Minnesota and Baylor College of Medicine. We applied the serum-plasma 
Deming regression equation and conducted additional correction by time for 1,5-
anhydroglucitol. 
Amended visit 4 1,5-anhydroglucitol values were stored in a cleaned data set for use: 
(File Name: /Volumes/ARIC$/Special Projects/V4 Glycemic Markers/STATA 
data/v4_glycemicmarkers_v2.dta). 
Background 
1,5-AG (GlycoMark) was measured in plasma on the Beckman/Olympus AU480 
autoanalyzer at Baylor College of Medicine (Baylor, Ballantyne/Hoogeveen) as part of 
Ancillary #2009.16 (PI: Selvin). These tests were coordinated with Ancillary Studies 
#2013.20 and #2013.21 (PI: Ballantyne) and were conducted in the same visit 4 plasma 
samples and run on the same autoanalyzers, using incremental volume only. This visit 4 
testing took place from July 2015-August 2016. 
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1,5-AG was previously measured at visits 2 and 5 with the same assays, but in serum 
samples and using the Roche Modular P800 instrument at the University of Minnesota 
(UMN, Steffes/Eckfeldt). 
To ensure the comparability of the Baylor measurements to those previously assessed at 
UMN, we conducted a 2-step calibration study: 
(a) Serum-to-serum preliminary comparison: 50 randomly selected visit 5 IDs (25 
with and 25 without diagnosed diabetes) to conduct serum-to-serum comparison 
using visit 5 serum samples stored at Baylor. This study compared lab-to-lab 
differences of visit 5 serum measurements. This study compared previously 
measured serum measurements conducted at the University of Minnesota (Roche 
Modular P800) to the same biomarkers measured in stored visit 5 serum samples 
at Baylor College of Medicine using the Beckman Olympus 480 auto analyzer 
(UMN serum measurements as reference). This serum-to-serum preliminary 
comparison study informed the serum-to-plasma calibration study. 
(b) Serum-to-plasma laboratory calibration study: 200 randomly selected visit 5 IDs 
to conduct a formal calibration study in visit 5 plasma samples stored at Baylor to 
ensure comparability to previous visit 5 serum measurements conducted at UMN 
(serum UMN measurements as reference). This serum-to-plasma calibration study 
enabled generation of re-calibration equations between the measurements at 
Baylor in plasma compared to UMN in serum. We then applied those equations to 
the visit 4 measurements when there was a difference > 10%. 
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Table A-1. Overview of study sample and corresponding visit, sample type, lab, and auto-
analyzer 
Measurements N Sample type Lab Auto-analyzer 
Visit 5 Preliminary Comparison 
Study Samples 
(Reference) 




Visit 5 Preliminary Comparison 
Study Samples  50 Serum 
Baylor College 
of Medicine Olympus 480 
Visit 5 Calibration Study 
Samples 200 Plasma 
Baylor College 
of Medicine Olympus 480 
Visit 5 Calibration Study 





Visit 4 Measurements in All 
Participants 
To which calibration equations 
will be applied, as needed 
~10,400 Plasma Baylor College 
of Medicine Olympus 480 
 
Methods 
To enable comparison of new visit 4 measurements with previous measurements, 
we formally compared measurements conducted in different laboratories and in different 
sample types/methodologies and documented systematic differences and corrected any 
observed “laboratory drift”. We implemented a standard process used previously 110, as 
described below: 
(1) Iteratively identified outliers +/- 3SD from difference of measurements for both 
the preliminary comparison and calibration studies 
(2) Assessed agreement between the two measurements by Pearson’s correlations, 
scatterplots, Bland-Altman plots again for both the preliminary comparison and 
calibration studies 
(3) Conducted Deming regression using serum (UMN) measurements as the 
dependent variable and plasma (Baylor) measurements as the independent 
variable to generate recalibration equations (calibration study) 
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(4) Corrected measurements with differences > 10% to align visit 4 measurements to 
UMN (calibration study) 
Serum-to-Serum Preliminary Comparison Study 
Corresponding .Do File(s) 
/Volumes/ARIC$/Special Projects/V4 Glycemic Markers/Serum-Serum/Code/Serum-Serum 
Programs_v4.do 
/Volumes/ARIC$/Special Projects/ V4 Glycemic Markers/Serum-Serum/Code/Serum-Serum_v4.do 
 
Table A-2. Outliers identified as +/- 3*SD of the difference and the number of iterations 
required for their identification 
Glycemia Marker Iteration Number of Outliers Identified 
1,5-AG (ug/mL) 0 0 
 
Table A-3. Summary statistics and mean differences comparing Baylor (serum) to UMN 




Lab N Mean SD Median Min Max p-value* 
1,5-AG (ug/mL) 
UMN 50 14.93 6.05 15.4 1.8 26.3 - 
Baylor 50 16.17 6.56 16.3 2.2 29.1 - 
Difference UMN-Baylor 50 -1.25 0.77 -1.1 -3.5 -0.20 <.001 
* Test for difference between means 
 
Table A-4. Pearson’s correlation coefficients (Baylor (serum) to UMN (serum)) without 
inclusion of outliers. Outliers defined as +/- 3*SD of the difference (2 iterations maximum). 
Glycemic Marker Number of outliers 
Correlation coefficient, 
outliers excluded 





Figure A-1. Scatterplot and Bland-Altman Plot. Scatterplots of 1,5-AG without outliers, 
UMN (serum) vs. Baylor (serum). Outliers defined as +/- 3*SD of the mean difference (2 
iterations). Bland-Altman plot of 1,5-AG without outliers, UMN (serum) vs. Baylor (serum). 
Outliers (defined as +/- 3*SD of the mean difference, 2 iterations). Y-axis tick marks are 
determined by SDs. 
 
 
Lab-to-lab differences (all > 5%) existed when comparing measurements conducted in 
the same sample type (serum) at Baylor compared to UMN. 
 
Serum-to-Plasma Calibration Study 
Corresponding .Do File(s) 
/Volumes/ARIC$/Special Projects/V4 Glycemic Markers/Serum-Plasma/Code/Serum-Plasma 
Programs_v4.do 
/Volumes/ARIC$/Special Projects/ V4 Glycemic Markers/Serum-Plasma/Code/Serum-Plasma_v4.do 
 
Table A-5. Outliers identified as +/- 3*SD of the difference and the number of iterations 
required for their identification. Analyses that include outliers provided in the Supplement. 
 
Table A-6. Summary statistics and mean differences comparing plasma (Baylor) to serum 




Lab N Mean SD Median Min Max p-value* 
1,5-AG (ug/mL) 
Serum (UMN) 199 15.0 6.73 15.3 1.2 30.2 - 
Plasma (Baylor) 198 15.3 6.93 15.7 0.90 29.3 - 
Difference Serum-Plasma 198 -0.34 0.53 -0.30 -1.7 1.1 <0.001 
* Test for difference between means 
Glycemia Marker Iteration Number of Outliers Identified 
1,5-AG (ug/mL) 1 1 
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Table A-7. Pearson’s correlation coefficients (plasma [Baylor] to serum [UMN]) without 
inclusion of outliers. Outliers defined as +/- 3*SD of the difference (2 iterations maximum). 
Glycemic Marker Number of outliers 
Correlation coefficient, 
outliers excluded 
1,5-AG (ug/mL) 1 0.998 
 
Figure A-2. Scatterplot and Bland-Altman Plot. Scatterplot of 1,5-AG without outliers, 
Serum (UMN) vs. Plasma (Baylor). Outliers defined as +/- 3*SD of the mean difference (2 
iterations). Bland-Altman plot of 1,5-AG without outliers, serum (UMN) vs. plasma 
(Baylor). Outliers (defined as +/- 3*SD of the mean difference, 2 iterations). Y-axis tick 
marks are determined by SDs. 
  
 
Deming Regression and Serum-Plasma Calibration 
Table A-8. Deming regression results (intercept and slope) calculated with serum (UMN) 
measurements as dependent variable and plasma (Baylor) measurements as independent 
variable after exclusion of outliers 











1 198 0.209 0.071 0.004 0.964 0.005 <0.001 0.964*(1,5-AG)+0.209 
 
Table A-9. Summary statistics comparing calibrated plasma (Baylor) measurements to 
serum (UMN) measurements, excluding outliers. Outliers defined as +/- 3*SD of the 
difference (2 iterations maximum). 
 
 
Lab N Mean SD Median Min Max p-value* 
1,5-AG (ug/mL) 
Serum (UMN) 199 15.0 6.73 15.3 1.2 30.2 - 
Plasma (Baylor), 
Calibrated 198 14.9 6.68 15.3 1.08 28.5 
- 
Difference Serum-Plasma 198 0.003 0.46 -0.08 -1.18 1.94 0.935 
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Calibration of 1,5-AG 
Corresponding .Do File(s) 
/Volumes/ARIC$/Special Projects/V4 Glycemic Markers/1,5-AG Calibration/Code/1,5-ag_v1.do 
/Volumes/ARIC$/Special Projects/V4 Glycemic Markers/1,5-AG Calibration/Code/1,5-
ag_programs_v1.do 
 
Prior to applying any statistical correction, we plotted the measurements over time 
to assess whether there were differences (Figure A-4). We then applied the serum-
plasma correction factor from Table A-8, and then calibrated the values correct for 
differences by time using lowess (locally weighted) regression. This helped to minimize 
differences between visit 2, 4, and 5 measurements (Figure A-5 a and b). 
The calibrated 1,5-AG values are provided in a dataset on the ARIC drive: 










5/4/15 & 5/6/15 
Serum-plasma, n=200 
3/15/16 & 3/17/16 
Visit Mean 
+/- 2 CV of blind duplicates 
Lowess Smoother 
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Figure A-5 (a-b). Scatterplot of Visits 2, 4, and 5 1,5-anhydroglucitol values by age  
(a) Before correction 
 
 






Table A-10. Summary of 1,5-AG before and after calibration. 
 
 








10383† 18.7 7.26 19.2 0.1 47.9 - 
Difference Before-After 10383 0.505 2.01 -0.06 -3.67 10.2 <0.001 
* Test for difference between means 
† 18 observations were imputed as 0.1, as calibration resulted in values <0  
 
Table A-11. Correlations of 1,5-AG before and after calibration with visit 4 traditional 


















Pearson’s r -0.423 -0.248 -0.545 -0.576 -0.205 -0.220 
n 9888 8126 1024 209 8864 7917 
After serum-plasma 
and lowess correction 
Pearson’s r -0.437 -0.258 -0.554 -0.589 -0.216 -0.230 
n 9888 8126 1024 209 8864 7917 
 
Note: trajectory analyses of 1,5-AG should still be approached with caution given values 
measured at visit 4 are higher, on average, than values measured at visit 2. 
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Figure B-2. Distribution of unadjusted and adjusted annual eGFR slopes from Visit 2 to Visit 5, by diabetes status 
Unadjusted        Adjusted 
  
 Percentile and corresponding change in eGFR per year (mL/min/1.73m2) 
 Unadjusted Adjusted* 
 10th 25th 50th 75th 90th 10th 25th 50th 75th 90th 
No diabetes -2.0 -1.6 -1.4 -1.2 -0.9 -1.9 -1.6 -1.4 -1.2 -1.0 
Undiagnosed diabetes -2.8 -2.2 -2.1 -1.9 -1.5 -2.5 -2.0 -1.9 -1.7 -1.4 
Diagnosed diabetes -3.7 -2.8 -2.8 -2.4 -2.0 -3.4 -2.5 -2.5 -2.2 -1.8 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their means: age 
(ref=54.67 years), sex (ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, Minneapolis-White, 
Washington County-White), systolic blood pressure (ref=121.22), hypertension medication use (ref=no; yes), body mass index (ref=27.68), 
HDL (ref=51.60), prevalent coronary heart disease (ref=no; yes), smoking status (ref=never; former, current), annual family income (ref: 
<$25,000; ≥$25,000), and educational status (ref: high school; less than high school, vocational school, college, graduate/professional school) 
Abbreviations: eGFR estimated glomerular filtration rate 
 
Legend: No diabetes  Undiagnosed diabetes  Diagnosed diabetes 
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Table B-1. Adjusted mean annual decline in eGFR by diabetes status without assignment of 15 ml/min/1.73m2 at time of onset of end stage 
renal disease 
Diabetes status 
Adjusted* mean annual decline in 
eGFR (ml/min/1.73m2) 




No diabetes -1.4 (-1.5, -1.4) 0 (REF)  
Undiagnosed diabetes -1.6 (-1.8, -1.5) -0.2 (-0.3, -0.1) 0.005 
Diagnosed diabetes -2.0 (-2.2, -1.9) -0.6 (-0.7, -0.5) <0.001 
* Adjusted for the following characteristics at baseline and their interactions with time, continuous variables centered at their 
means: age (ref=54.67 years), sex (ref=male), race-center (ref=Forsyth County-White; Forsyth County-Black, Jackson-Black, 
Minneapolis-White, Washington County-White), systolic blood pressure (ref=121.22), hypertension medication use (ref=no; 
yes), body mass index (ref=27.68), HDL (ref=51.60), prevalent coronary heart disease (ref=no; yes), smoking status (ref=never; 
former, current), annual family income (ref: <$25,000; ≥$25,000), and educational status (ref: high school; less than high school, 
vocational school, college, graduate/professional school) 
Abbreviations: eGFR estimated glomerular filtration rate 
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Appendix C: Supplementary Materials for Chapter 2 




Table C-1. Baseline characteristics of ARIC participants without a history of cardiovascular disease, peripheral arterial disease, or 
diagnosed diabetes by clinical categories by different biomarkers of hyperglycemia* 






 WHO fasting glucose clinical categories IEC HbA1c clinical categories 
Visit 2 (1990-92) 
N = 10,844 
<6.1 mmol/L 
n = 9,114 
6.1-6.9 mmol/L 
n = 1,213 
≥7.0 mmol/L 
n = 517 
<42 mmol/mol 
n = 9,412 
42-46 
mmol/mol 
n = 970 
≥48 
mmol/mol 
n = 462 
Age (years) 57.0 (5.6) 58.1 (5.7) 57.7 (5.6) 56.9 (5.6) 58.4 (5.6) 58.1 (5.6) 
Female, % 58.6 45.8 54.4 56.9 55.4 61.5 
Black, % 19.2 29.8 37.3 17.1 47.8 49.8 
Less than high school education, % 17.7 22.7 28.1 16.9 30.8 32.3 
Body Mass Index (kg/m2) 27.1 (5.0) 29.9 (5.3) 31.6 (6.1) 27.2 (4.9) 30.0 (5.8) 32.3 (6.3) 
Obese (≥30 kg/m2), % 22.8 41.8 54.4 23.1 43.3 59.5 
Waist-to-hip ratio 0.91 (0.1) 0.95 (0.1) 0.97 (0.1) 0.91 (0.1) 0.95 (0.1) 0.97 (0.1) 
Fasting glucose (mmol/L) 5.32 (0.4) 6.44 (0.2) 8.62 (2.5) 5.42 (0.5) 6.08 (0.8) 8.29 (2.91) 
HbA1c (mmol/mol) 35.4 (4.3) 39.7 (5.3) 52.7 (17) 35.0 (3.5) 43.5 (1.5) 57.6 (16) 
Hypercholesterolemia, % 76.1 84.4 87.6 76.4 84.5 87.9 
Hypertension, % 27.7 45.8 54.6 28.1 47.9 53.9 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
97.1 (13) 97.1 (14) 99.7 (15) 
96.9 (13) 98.5 (16) 101 (16) 
Current smoker, % 21.5 22.1 19.7 20.7 28.0 23.6 
Current drinker, % 60.6 56.5 54.2 62.0 47.9 41.8 
Family history of diabetes, % 21.3 27.4 33.7 21.7 26.0 34.0 
* Mean (SD) unless otherwise indicated 
Abbreviations: HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization  
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Table C-1., continued 
 WHO fasting glucose clinical categories 
Visit 4 (1996-98) 
N = 7,194 
<6.1 mmol/L 
n = 6,241 
6.1-6.9 mmol/L 
n = 621 
≥7.0 mmol/L 
n = 332 
Age (years) 62.7 (5.5) 63.1 (5.5) 63.1 (5.4) 
Female, % 59.7 45.1 51.8 
Black, % 15.8 24.2 25.6 
Less than high school education, % 14.4 20.9 23.2 
Body Mass Index (kg/m2) 27.9 (5.1) 31.1 (5.3) 32.1 (6.0) 
Obese (≥30 kg/m2), % 28.2 54.1 60.2 
Waist-to-hip ratio 0.94 (0.1) 0.98 (0.1) 0.98 (0.1) 
Fasting glucose (mmol/L) 5.26 (0.4) 6.45 (0.2) 8.72 (2.5) 
2-hour glucose (mmol/L) 6.99 (2.1) 9.45 (2.7) 14.8 (4.3) 
Hypercholesterolemia, % 75.5 85.4 87.7 
Hypertension, % 38.4 53.5 60.5 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
88.2 (12) 88.4 (13) 89.6 (12) 
Current smoker, % 14.2 13.2 11.8 
Current drinker, % 55.4 53.6 49.1 
Family history of diabetes, % 21.2 28.0 33.1 
* Mean (SD) unless otherwise indicated 
Abbreviations: HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health 
Organization  
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Table C-2 (a-c). Cross-tabulation of participants by different clinical categories of prediabetes 
a.) by ADA fasting glucose 
  ADA fasting glucose 






Visit 2 (1990-92)     
WHO fasting glucose 
<6.1 mmol/L 6,215 2,899 0 9,114 
6.1-6.9 mmol/L 0 1,213 0 1,213 
≥7.0 mmol/L‡ 0 0 517 517 
ADA HbA1c 
<39 mmol/mol 5,496 2,802 57 8,355 
39-46 mmol/mol 701 1,161 165 2,027 
≥48 mmol/mol‡ 18 149 295 462 
IEC HbA1c 
<42 mmol/mol 5,935 3,385 92 9,412 
42-46 mmol/mol 262 578 130 970 
≥48 mmol/mol‡ 18 149 295 462 
Visit 4 (1996-98)      
   ADA fasting glucose   
 







WHO fasting glucose 
<6.1 mmol/L 4,720 1,521 0 6,241 
6.1-6.9 mmol/L 0 621 0 621 
> 7.0 mmol/L‡ 0 0 332 332 
ADA/WHO 2-hour 
glucose 
<7.8 mmol/L 3,416 1,017 9 4,442 
7.8-11.0 mmol/L 1,152 814 43 2,009 
≥11.0 mmol/L‡ 152 311 280 743 
‡ Undiagnosed diabetes 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization  
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b.) by WHO fasting glucose 
  WHO fasting glucose 






Visit 2 (1990-92)     
ADA HbA1c 
<39 mmol/mol 7,693 605 57 8,355 
39-46 mmol/mol 1,359 503 165 2,027 
≥48 mmol/mol‡ 62 105 295 462 
IEC HbA1c 
< 42 mmol/mol 8,501 819 92 9,412 
42-46 mmol/mol 551 289 130 970 
≥48 mmol/mol‡ 62 105 295 462 
Visit 4 (1996-98)      











<7.8 mmol/L 4,259 174 9 4,442 
7.8-11.0 mmol/L 1,691 275 43 2,009 
≥11.0 mmol/L‡ 291 172 280 743 
‡ Undiagnosed diabetes 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization 
 
 
c.) by ADA HbA1c 
  ADA HbA1c 






Visit 2 (1990-92)     
IEC HbA1c 
<42 mmol/mol 8,355 1,057 0 9,412 
42-46 mmol/mol 0 970 0 970 
≥48 mmol/mol‡ 0 0 462 462 
‡ Undiagnosed diabetes 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee 
  
 127 
Table C-3. Number of events and incidence rates per 1,000 person-years (95% confidence interval) for incident outcomes by different 
clinical categories of prediabetes and undiagnosed diabetes  


















































































































































































































































‡ Undiagnosed diabetes; Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; IEC, International Expert 
Committee; IR, incidence rate; WHO, World Health Organization 
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Table C-3., continued 




























































































































































































‡ Undiagnosed diabetes; Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; IEC, International 
Expert Committee; IR, incidence rate; WHO, World Health Organization 
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Table C-4. Fully adjusted hazard ratios and Harrell’s C-statistic (95% confidence intervals) for incident outcomes by different clinical 
categories of prediabetes and undiagnosed diabetes 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.26 (2.08, 2.45)* 1.04 (0.95, 1.13) 1.07 (0.96, 1.20) 1.15 (0.87, 1.50) 1.05 (0.97, 1.13) 
≥7.0 mmol/L‡ 12.4 (11.0, 14.0)* 1.41 (1.19, 1.66)* 1.56 (1.28, 1.90)* 2.48 (1.64, 3.77)* 1.35 (1.16, 1.57)* 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 2.85 (2.60, 3.12)* 1.11 (0.98, 1.24) 1.02 (0.88, 1.18) 1.12 (0.78, 1.59) 1.12 (1.01, 1.24)* 
≥7.0 mmol/L‡ 9.77 (8.71, 11.0)* 1.40 (1.20, 1.65)* 1.50 (1.25, 1.81)* 2.35 (1.59, 3.47)* 1.35 (1.17, 1.56)* 














<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 2.71 (2.45, 2.95)* 1.27 (1.15, 1.40)* 1.40 (1.24, 1.58)* 1.39 (1.02, 1.87)* 1.31 (1.21, 1.43)* 
≥48 mmol/mol‡ 13.6 (12.0, 15.4)* 1.69 (1.43, 2.01)* 1.78 (1.45, 2.17)* 3.86 (2.62, 5.69)* 1.56 (1.34, 1.82)* 














<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 3.14 (2.83, 3.47)* 1.31 (1.15, 1.49)* 1.53 (1.32, 1.78)* 1.45 (0.99, 2.11) 1.35 (1.21, 1.51)* 
≥48 mmol/mol‡ 11.8 (10.5, 13.4)* 1.64 (1.39, 1.94)* 1.72 (1.41, 2.09)* 3.69 (2.53, 5.39)* 1.50 (1.30, 1.75)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, 
HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering 
medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes; * p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert 
Committee; WHO, World Health Organization  
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Table C-4., continued 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.78 (2.51, 3.09)* 0.91 (0.81, 1.03) 1.10 (0.94, 1.29) 0.99 (0.65, 1.51) 1.13 (1.01, 1.26)* 
≥7.0 mmol/L‡ 15.6 (13.3, 18.2)* 1.10 (0.87, 1.39) 1.39 (1.03, 1.86)* 1.76 (0.87, 3.57) 1.68 (1.36, 2.08)* 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 3.50 (3.10, 3.96)* 1.05 (0.88, 1.26) 0.97 (0.76, 1.23) 0.58 (0.27, 1.26) 1.29 (1.09, 1.51)* 
≥7.0 mmol/L‡ 11.6 (10.0, 13.4)* 1.16 (0.92, 1.46) 1.32 (0.99, 1.75) 1.66 (0.84, 3.27) 1.66 (1.35, 2.04)* 
















<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 2.07 (1.85, 2.31)* 1.07 (0.95, 1.21) 0.98 (0.82, 1.16) 0.83 (0.53, 1.31) 1.18 (1.05, 1.33)* 
≥11.0 mmol/L‡ 7.61 (6.72, 8.61)* 1.17 (0.99, 1.39) 1.19 (0.95, 1.48) 0.87 (0.46, 1.65) 1.33 (1.14, 1.56)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, 
HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering 
medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert 
Committee; WHO, World Health Organization  
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Table C-5. Difference in Harrell’s C-statistic (95% confidence interval) to assess discrimination of models with clinical categories‡ for risk 
future clinical outcomes 




















































































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, 
total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-
lowering medication use (yes, no), family history of diabetes (yes, no) 
* p < 0.05 




Table C-5., continued 



















































































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, 
total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-
lowering medication use (yes, no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-5., continued 





















































































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, 
total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-
lowering medication use (yes, no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-6. Net reclassification index✝  (95% confidence intervals) for 10-year risk of incident outcomes by different clinical categories‡ of 
prediabetes and undiagnosed diabetes compared to ADA fasting glucose 
Visit 2 (1990-92) 















ADA fasting glucose 
definition 
Ref Ref Ref 























































































ADA fasting glucose 
definition 
Ref Ref Ref 





















































































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, 
total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-
lowering medication use (yes, no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin A1c; WHO, World Health Organization 
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Table C-6., continued 
Visit 2 (1990-92) 










ADA fasting glucose 
definition 
Ref Ref 




























































ADA fasting glucose 
definition 
Ref Ref 


























































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, 
Washington County, MD; black, Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college 
or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status 
(current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family history 
of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin A1c; 
WHO, World Health Organization 
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Table C-6., continued 
Visit 4 (1996-98) 















ADA fasting glucose 
definition 
Ref Ref Ref 




























































ADA fasting glucose 
definition 
Ref Ref Ref 


























































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, 
total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-
lowering medication use (yes, no), family history of diabetes (yes, no) 
* p < 0.05 




Table C-6., continued 
Visit 4 (1996-98) 




































































































































‡ Clinical categories refer to normoglycemia, prediabetes, and undiagnosed diabetes 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; 
white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, NC)  
Fully adjusted included Demographic adjusted + education level (less than high school, high school or equivalent, 
college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, 
smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, 
no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin 
A1c; WHO, World Health Organization 
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Table C-7. Demographic adjusted hazard ratio and Harrell’s C-statistic (95% confidence intervals) for incident outcomes by different 
clinical categories of prediabetes, excluding undiagnosed diabetes 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.92 (2.70, 3.16)* 1.17 (1.08, 1.27)* 1.23 (1.11, 1.37)* 1.30 (1.00, 1.69)* 1.12 (1.04, 1.20)* 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 3.85 (3.52, 4.21)* 1.28 (1.14, 1.43)* 1.21 (1.05, 1.41)* 1.32 (0.93, 1.87) 1.24 (1.12, 1.37)* 














<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 3.40 (3.13, 3.70)* 1.41 (1.28, 1.56)* 1.70 (1.51, 1.92)* 1.75 (1.30, 2.35)* 1.49 (1.37, 1.62)* 














<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 4.11 (3.71, 4.55)* 1.48 (1.31, 1.69)* 1.91 (1.65, 2.21)* 1.83 (1.26, 2.66)* 1.55 (1.39, 1.73)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-7., continued 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 3.47 (3.13, 3.84)* 1.07 (0.96, 1.20) 1.24 (1.06, 1.45)* 1.08 (0.72, 1.62) 1.14 (1.02, 1.27)* 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 4.55 (4.03, 5.13)* 1.23 (1.04, 1.46)* 1.10 (0.86, 1.39) 0.62 (0.29, 1.35) 1.29 (1.10, 1.51)* 















<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 2.58 (2.31, 2.88)* 1.16 (1.03, 1.31)* 1.09 (0.92, 1.28) 0.82 (0.53, 1.27) 1.18 (1.05, 1.32)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-8. Fully adjusted hazard ratio and Harrell’s C-statistic (95% confidence intervals) for incident outcomes by different clinical 
categories of prediabetes, excluding undiagnosed diabetes 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.26 (2.08, 2.45)* 1.04 (0.96, 1.13) 1.08 (0.97, 1.21) 1.14 (0.87, 1.50) 1.04 (0.96, 1.12) 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 2.85 (2.60, 3.12)* 1.11 (0.99, 1.25) 1.02 (0.88, 1.19) 1.11 (0.78, 1.59) 1.12 (1.01, 1.24)* 














<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 2.71 (2.48, 2.95)* 1.26 (1.14, 1.39)* 1.41 (1.25, 1.60)* 1.35 (1.00, 1.83) 1.31 (1.20, 1.43)* 














<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 3.12 (2.81, 3.46)* 1.29 (1.13, 1.47)* 1.55 (1.33, 1.80)* 1.41 (0.96, 2.06) 1.34 (1.20, 1.50)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, 
triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, 
no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization  
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Table C-8., continued 















<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 2.70 (2.43, 3.00)* 0.92 (0.82, 1.04) 1.10 (0.94, 1.30) 1.00 (0.65, 1.52) 1.12 (1.00, 1.26) 















<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 3.41 (3.01, 3.85)* 1.07 (0.89, 1.27) 0.97 (0.76, 1.24) 0.59 (0.27, 1.28) 1.28 (1.09, 1.51)* 















<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 2.06 (1.84, 2.31)* 1.09 (0.96, 1.23) 1.00 (0.84, 1.18) 0.82 (0.52, 1.30) 1.20 (1.07, 1.35)* 











Adjusted for age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; 
white, Forsyth County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, 
triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, 
no), family history of diabetes (yes, no) 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-9. Demographic adjusted hazard ratios (95% CI) and p-values for interaction for incident outcomes by different clinical 
categories of prediabetes and undiagnosed diabetes, by race (visit 2: black N=2,299, white N=8,545; visit 4: black N=1,221, white N=5,973) 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 
































































p-value 0.007 0.14 0.61 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-9., continued 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 






























































p-value < 0.0001 0.018 0.36 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-9., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause mortality 
















































p-value 0.72 0.026 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 





Table C-9., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause morality 














































p-value 0.41 0.0001 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-9., continued 
Visit 4 (1996-98) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 

































































































p-value 0.018 0.67 0.32 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-9., continued 
Visit 4 (1996-98) 
Peripheral arterial disease All-cause mortality 









































































p-value 0.59 0.46 
Adjusted for age, sex (male, female) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-10. Fully adjusted hazard ratios (95% CI) and p-values for interaction for incident outcomes by different clinical categories of 
prediabetes and undiagnosed diabetes, by race (visit 2: black N=2,299, white N=8,545; visit 4: black N=1,221, white N=5,973) 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 
































































p-value 0.35 0.19 0.59 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total 
cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering 
medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-10., continued 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 






























































p-value <0.0001 0.069 0.40 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total 
cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering 
medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-10., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause mortality 
















































p-value 0.77 0.045 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or 
above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status 
(current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family 
history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 





Table C-10., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause morality 














































p-value 0.57 0.0007 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or 
above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status 
(current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family 
history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-10., continued 
Visit 4 (1996-98) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 

































































































p-value 0.030 0.65 0.41 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, 
HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication 
use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-10., continued 
Visit 4 (1996-98) 
Peripheral arterial disease All-cause mortality 









































































p-value 0.66 0.56 
Adjusted for age, sex (male, female), education level (less than high school, high school or equivalent, college or 
above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status 
(current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family 
history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-11. Demographic adjusted hazard ratios (95% CI) and p-values for interaction for incident outcomes by different clinical 
categories of prediabetes and undiagnosed diabetes, by sex (visit 2: male N=4,668, female N=6,176; visit 4: male N=3,015, female N=4,179) 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 
































































p-value 0.13 0.49 0.19 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, 
NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-11., continued 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 






























































p-value 0.77 0.95 0.27 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, 
NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-11., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause mortality 
















































p-value 0.0092 0.0028 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 





Table C-11., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause morality 














































p-value 0.017 0.14 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-11., continued 
Visit 4 (1996-98) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 

































































































p-value 0.16 0.53 0.15 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, 
NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-11., continued 
Visit 4 (1996-98) 
Peripheral arterial disease All-cause mortality 









































































p-value 0.82 0.018 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-12. Fully adjusted hazard ratios (95% CI) and p-values for interaction for incident outcomes by different clinical categories of 
prediabetes and undiagnosed diabetes, by sex (visit 2: male N=4,668, female N=6,176; visit 4: male N=3,015, female N=4,179) 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease Atherosclerotic cardiovascular disease 
































































p-value 0.57 0.55 0.77 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth 
County, NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, 
triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use 
(yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert 
Committee; WHO, World Health Organization 
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Table C-12., continued 
Visit 2 (1990-92) 
Incident diabetes Chronic kidney disease Atherosclerotic cardiovascular disease 






























































p-value 0.0003 0.67 0.70 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, 
NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, 
hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family 
history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-12., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause mortality 
















































p-value 0.063 0.010 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC), education level (less than high school, high school or equivalent, 
college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, 
smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use 
(yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 





Table C-12., continued 
Visit 2 (1990-92) 
Peripheral arterial disease All-cause morality 


















































p-value 0.032 0.18 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC), education level (less than high school, high school or equivalent, 
college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, 
smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use 
(yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-12., continued 
Visit 4 (1996-98) 
Incident diabetes Chronic kidney disease 
Atherosclerotic cardiovascular 
disease 

































































































p-value 0.28 0.40 0.15 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, Forsyth County, NC; white, Forsyth County, 
NC), education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, 
hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, no), family 
history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-12., continued 
Visit 4 (1996-98) 
Peripheral arterial disease All-cause mortality 









































































p-value 0.67 0.0071 
Adjusted for age, race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC), education level (less than high school, high school or equivalent, 
college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, 
smoking status (current, former, never), drinking status (current, former, never), lipid-lowering medication use (yes, 
no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard 
ratio; IEC, International Expert Committee; WHO, World Health Organization
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ANCILLARY ANALYSES – Third National Health and Nutrition Examination Survey 
(NHANES III) 
We conducted ancillary analyses in the Third National Health and Nutrition 
Examination Survey (NHANES III) for comparison to our results in the Atherosclerosis 
Risk in Communities (ARIC) Study. NHANES III (1988-1994) is a complex sample 
survey of the general non-institutionalized civilian population of the United States. 
Measurements of fasting glucose, hemoglobin A1c (HbA1c), and 2-hour glucose are 
available in NHANES III and can be linked with the National Death Index to provide 
prospective follow-up for mortality (1).  
For these ancillary analyses, we limited our population to the 3,894 participants 
who were aged 40 or older, attended the morning fasting session of the NHANES III 
examination, who did not have diagnosed diabetes, and were not missing information on 
fasting glucose or HbA1c. For analyses of 2-hour glucose, our analyses were limited to 
the subsample of these persons (eligible participants aged 40-74 years) who had valid 
oral glucose tolerance tests (OGTT) (n=2,970). In prospective analyses, we excluded 
persons missing follow-up information (n=6 for all-cause mortality and n=23 for 
cardiovascular mortality). We conducted all analyses of NHANES III accounting for the 
complex survey design and weighted to represent the general U.S. non-institutionalized 
population of adults aged 40 or older.  
We defined prediabetes using three definitions recognized by the American 
Diabetes Association (ADA): fasting glucose 5.6-6.9 mmol/L; HbA1c 39-46 mmol/mol; 
and 2-hour glucose 7.8-11.0 mmol/L, along with the additional definition recognized by 
the World Health Organization (WHO): fasting glucose 6.1-6.9 mmol/L; and 
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International Expert Committee (IEC): HbA1c 42-46 mmol/mol. We linked our sample 
with the National Death Index to obtain all-cause and cardiovascular mortality outcomes. 
Cardiovascular mortality was defined as deaths due to diseases of the heart (International 
Classification of Disease-10 Codes: I00-I09, I11, I13, I20-I51). 
We compared baseline characteristics across the different clinical categories 
(normoglycemia, prediabetes, and undiagnosed diabetes). We calculated prevalence 
estimates for prediabetes overall and in the population of black and white persons aged 
47-70 (to align with the ARIC Study visit 2 age range). We calculated sensitivity and 
specificity (and other relevant metrics) for each definition of prediabetes using 10-year 
Kaplan-Meier estimates comparing those with prediabetes to those with normoglycemia 
against those with and without the events of interest. Cox proportional hazards models 
were used to estimate adjusted hazard ratios of incident events associated with clinical 
categories, with normoglycemia as the reference group. Demographic adjusted models 
included age, sex, and race. Fully adjusted models included all variables in demographic 
adjusted models plus education level, body mass index, waist-to-hip ratio, total 
cholesterol, HDL-cholesterol, triglycerides, eGFR, hypertension, smoking status, alcohol 
use, and family history of diabetes. We used Harrell’s C-statistic to compare 
discrimination of models with the different clinical categories with respect to future risk 
of all-cause and cardiovascular mortality. We provide here the results for all-cause and 
fatal coronary heart disease in ARIC for direct comparison to the results from NHANES 
III. 
Characteristics of U.S. adults aged 40 or older without diagnosed diabetes are 
shown in Table C-13. Prediabetes prevalence estimates across definitions were similar, 
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although slightly lower as compared to ARIC (Table C-14.A). We observed similar 
patterns in prevalence to those observed in ARIC with ADA fasting glucose-defined 
prediabetes having the highest prevalence, followed by ADA/WHO 2-hour glucose. The 
ADA and IEC HbA1c- based definitions and WHO fasting glucose definition had the 
lowest prevalence. When NHANES III analyses were restricted to the same age and race 
groups as in the ARIC Study, prevalence estimates were more similar to ARIC (Table C-
14.B).  
During a median of approximately 18 years of follow-up, there were 1,860 total 
deaths and 467 cardiovascular deaths. Analyses of sensitivity and specificity comparing 
those with prediabetes by each definition to those with normoglycemia yielded similar 
results to ARIC. We found that WHO fasting glucose and the HbA1c-based definitions 
were more specific, but ADA fasting glucose and the ADA/WHO 2-hour glucose-based 
definitions were more sensitive (Table C-15). 
With the exception of ADA/WHO 2-hour glucose defined prediabetes, all other 
definitions were significantly associated with all-cause mortality (Table C-16). 
Associations with cardiovascular mortality were less robust (Table C-16), likely due to 
limited precision as a result of the small number of events in this general population 
(Table C-17). Consistent with associations observed in the ARIC Study (Table C-18), 
hazard ratios for HbA1c-based definitions for all-cause mortality in NHANES III were 
higher than those for fasting glucose or 2-hour glucose-based definitions of prediabetes 
(Table C-16). For cardiovascular mortality in NHANES III, patterns were similar but 
HbA1c-based definitions were not consistently stronger, although it is difficult to draw 
firm conclusions due to the more limited power for this outcome. C-statistics were 
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generally similar across all definitions except 2-hour glucose, which were lower, however 
the limited number of events is, again, a concern. 
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Table C-13. Baseline characteristics of U.S Adults aged 40+ without diagnosed diabetes by different definitions of prediabetes*, NHANES 
III (1988-1994) 
 Normoglycemia Prediabetes Undiagnosed diabetes 
 ADA Fasting glucose clinical categories 
N = 3,894 
<5.6 mmol/L 
n = 2,252 
5.6-6.9 mmol/L 
n = 1,402 
≥7.0 mmol/L 
n = 240 
Age (years) 55.4 (54.5-56.2) 59.1 (57.4-60.7) 61.8 (59.6-63.9) 
Female, % 60.3 (57.2-63.4) 42.2 (38.3-46.0) 45.5 (35.4-55.5) 
Black, % 8.71 (7.25-10.2) 8.64 (6.88-10.4) 11.1 (7.23-15.0) 
Less than high school education, % 26.0 (23.1-28.9) 33.6 (29.4-37.8) 40.9 (31.3-50.5) 
Body Mass Index (kg/m2) 26.2 (25.9-26.5) 28.1 (27.7-28.6) 30.8 (29.8-31.9) 
Obese (≥30 kg/m2), % 19.1 (16.9-21.2) 31.2 (27.0-35.4) 56.8 (49.4-64.2) 
Waist-to-hip ratio 0.91 (0.91-0.92) 0.96 (0.96-0.97) 1.00 (0.98-1.01) 
Fasting glucose (mmol/L) 5.13 (5.10-5.15) 6.03 (6.00-6.06) 9.27 (8.84-9.70) 
HbA1c (mmol/mol) 34.0 (33.7-34.3) 35.6 (35.3-35.9) 48.7 (45.4-51.9) 
Hypercholesterolemia, % 77.4 (74.0-80.7) 83.0 (79.9-86.1) 95.4 (92.1-98.7) 
Hypertension, % 27.7 (24.4-31.0) 38.4 (35.3-41.5) 58.0 (48.5-67.5) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 89.4 (88.0-90.8) 84.8 (82.4-87.1) 82.8 (78.9-86.8) 
Current smoker, % 24.3 (21.7-26.9) 22.5 (19.0-26.0) 22.5 (15.8-29.3) 
Current drinker, % 46.9 (42.6-51.3) 47.0 (42.7-51.4) 32.5 (22.1-42.9) 
Family history of diabetes, % 41.6 (37.8-45.4) 41.9 (38.2-45.6) 49.8 (39.9-59.8) 




Table C-13., continued 
 Normoglycemia Prediabetes Undiagnosed diabetes 
 WHO Fasting glucose clinical categories 
N = 3,894 
<6.1 mmol/L 
n = 3,112 
6.1-6.9 mmol/L 
n = 542 
≥7.0 mmol/mol 
n = 240 
Age (years) 56.0 (55.0-57.0) 61.0 (59.2-62.9) 61.8 (59.6-63.9) 
Female, % 55.6 (53.3-57.9) 43.5 (38.2-48.8) 45.5 (35.4-55.5) 
Black, % 8.63 (7.35-9.92) 9.08 (6.43-11.7) 11.1 (7.23-15.0) 
Less than high school education, % 27.6 (24.6-30.5) 35.9 (29.2-42.5) 40.9 (31.3-50.5) 
Body Mass Index (kg/m2) 26.6 (26.3-26.9) 28.9 (28.1-29.6) 30.8 (29.8-31.9) 
Obese (≥30 kg/m2), % 21.5 (19.4-23.6) 35.4 (29.4-41.4) 56.8 (49.4-64.2) 
Waist-to-hip ratio 0.92 (0.92-0.93) 0.98 (0.97-0.98) 1.00 (0.98-1.01) 
Fasting glucose (mmol/L) 5.29 (5.27-5.32) 6.42 (6.38-6.46) 9.27 (8.84-9.70) 
HbA1c (mmol/mol) 34.3 (34.1-34.5) 36.3 (35.8-36.8) 48.7 (45.4-51.9) 
Hypercholesterolemia, % 78.7 (76.1-81.4) 83.1 (79.0-87.1) 95.4 (92.1-98.7) 
Hypertension, % 29.7 (26.8-32.6) 43.1 (34.7-51.6) 58.0 (48.5-67.5) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 88.5 (87.2-89.9) 82.7 (79.4-86.0) 82.8 (78.9-86.8) 
Current smoker, % 24.4 (22.0-26.8) 18.1 (13.5-22.8) 22.5 (15.8-29.3) 
Current drinker, % 47.4 (43.3-51.4) 44.1 (36.3-51.8) 32.5 (22.1-42.9) 
Family history of diabetes, % 41.3 (38.2-44.4) 44.7 (38.5-51.0) 49.8 (39.9-59.8) 
Abbreviations: WHO, World Health Organization; HbA1c, hemoglobin A1c 
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Table C-13., continued 
 Normoglycemia Prediabetes Undiagnosed diabetes 
 ADA HbA1c clinical categories 
N = 3,894 
<39 mmol/mol 
n = 3,221 
39-46 mmol/mol 
n = 574 
≥48 mmol/mol 
n = 99 
Age (years) 56.4 (55.4-57.3) 62.6 (60.8-64.3) 61.1 (57.6-64.6) 
Female, % 54.2 (52.2-56.3) 51.4 (44.2-58.6) 49.1 (35.7-62.4) 
Black, % 7.33 (6.20-8.46) 21.0 (17.5-24.5) 18.1 (9.80-26.3) 
Less than high school education, % 27.6 (24.7-30.5) 44.0 (38.7-49.3) 46.0 (31.8-60.3) 
Body Mass Index (kg/m2) 26.8 (26.6-27.1) 28.5 (27.8-29.2) 31.6 (29.3-33.8) 
Obese (≥30 kg/m2), % 23.1 (20.9-25.3) 34.5 (27.9-41.1) 60.6 (46.1-75.1) 
Waist-to-hip ratio 0.93 (0.92-0.94) 0.96 (0.95-0.98) 0.98 (0.95-1.01) 
Fasting glucose (mmol/L) 5.43 (5.40-5.46) 6.22 (6.06-6.38) 11.8 (10.7-12.9) 
2-hour glucose (mmol/L) 6.29 (6.16-6.42) 8.60 (8.01-9.18) 19.5 (18.0-21.0) 
Hypercholesterolemia, % 78.8 (76.2-81.3) 89.3 (86.6-92.0) 94.9 (89.3-100.5) 
Hypertension, % 30.8 (28.1-33.5) 46.5 (40.0-53.0) 59.1 (44.1-74.1) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 88.3 (87.0-89.5) 80.7 (77.2-84.3) 83.5 (74.8-92.2) 
Current smoker, % 22.5 (20.3-24.6) 33.6 (27.1-40.0) 24.7 (13.4-36.1) 
Current drinker, % 47.7 (43.8-51.6) 31.1 (25.0-37.2) 42.7 (25.4-60.0) 
Family history of diabetes, % 41.8 (38.9-44.7) 43.1 (36.8-49.4) 46.2 (31.4-61.0) 




Table C-13., continued 
 Normoglycemia Prediabetes Undiagnosed diabetes 
 IEC HbA1c clinical categories 
N = 3,894 
<42 mmol/mol 
n = 3,646 
42-46 mmol/L 
n = 149 
≥48 mmol/L 
n = 99 
Age (years) 56.8 (55.9-57.7) 65.2 (62.8-67.7) 61.1 (57.6-64.6) 
Female, % 54.2 (52.2-56.1) 44.3 (34.8-53.8) 49.1 (35.7-62.4) 
Black, % 8.36 (7.14-9.58) 24.6 (17.7-31.5) 18.1 (9.80-26.3) 
Less than high school education, % 28.8 (26.0-31.7) 49.3 (39.1-59.5) 46.0 (31.8-60.3) 
Body Mass Index (kg/m2) 26.9 (26.7-27.2) 28.9 (27.7-30.1) 31.6 (29.3-33.8) 
Obese (≥30 kg/m2), % 23.9 (21.8-26.0) 40.5 (28.4-52.7) 60.6 (46.1-75.1) 
Waist-to-hip ratio 0.93 (0.93-0.94) 0.98 (0.96-0.99) 0.98 (0.95-1.01) 
Fasting glucose (mmol/L) 5.48 (5.44-5.51) 6.89 (6.56-7.21) 11.8 (10.7-12.9) 
2-hour glucose (mmol/L) 6.41 (6.28-6.54) 11.2 (9.8-12.6) 19.5 (18.0-21.0) 
Hypercholesterolemia, % 79.6 (77.3-81.9) 89.4 (83.8-95.0) 94.9 (89.3-100.5) 
Hypertension, % 31.9 (29.5-34.4) 51.8 (39.2-64.4) 59.1 (44.1-74.1) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 87.7 (86.4-89.0) 78.6 (72.3-84.9) 83.5 (74.8-92.2) 
Current smoker, % 23.5 (21.3-25.6) 29.6 (18.0-41.1) 24.7 (13.4-36.1) 
Current drinker, % 46.4 (42.5-50.2) 29.2 (19.9-38.5) 42.7 (25.4-60.0) 
Family history of diabetes, % 41.8 (39.0-44.6) 47.3 (35.0-59.5) 46.2 (31.4-61.0) 
Abbreviations: IEC, International Expert Committee; HbA1c, hemoglobin A1c 
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Table C-13., continued 
 Normoglycemia Prediabetes Undiagnosed diabetes 
 ADA/WHO 2-hour glucose clinical categories 
N = 2,970 
<7.8 mmol/L 
n = 2,137 
7.8-11.0 mmol/L 
n = 578 
≥11.0 mmol/L 
n = 255 
Age (years) 52.9 (52.1-53.7) 57.1 (55.9-58.4) 60.5 (58.6-62.4) 
Female, % 51.8 (49.2-54.5) 53.6 (47.9-59.3) 46.5 (36.7-56.3) 
Black, % 8.91 (7.53-10.3) 8.11 (5.98-10.3) 8.53 (4.77-12.3) 
Less than high school education, % 23.1 (19.7-26.6) 33.6 (28.6-38.7) 36.1 (25.6-46.6) 
Body Mass Index (kg/m2) 26.8 (26.4-27.1) 28.5 (27.7-29.2) 30.3 (29.2-31.5) 
Obese (≥30 kg/m2), % 21.6 (18.9-24.4) 35.8 (30.3-41.4) 56.9 (49.0-64.7) 
Waist-to-hip ratio 0.92 (0.92-0.93) 0.96 (0.95-0.97) 0.99 (0.98-1.00) 
Fasting glucose (mmol/L) 5.35 (5.32-5.38) 5.80 (5.71-5.90) 8.26 (7.73-8.79) 
2-hour glucose (mmol/L) 34.2 (33.9-34.4) 35.6 (35.2-36.1) 45.4 (42.2-48.7) 
Hypercholesterolemia, % 77.7 (74.8-80.6) 86.4 (82.2-90.6) 91.6 (86.9-96.3) 
Hypertension, % 27.3 (23.9-30.7) 42.0 (35.9-48.1) 53.5 (43.7-63.4) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 91.6 (90.3-92.9) 87.6 (85.3-89.9) 83.2 (79.3-87.2) 
Current smoker, % 27.2 (24.8-29.6) 17.6 (13.3-21.9) 23.5 (16.5-30.5) 
Current drinker, % 51.5 (47.3-55.8) 39.3 (33.5-45.0) 44.6 (34.5-54.8) 
Family history of diabetes, % 43.4 (39.9-46.9) 44.9 (37.7-52.0) 52.3 (42.6-62.0) 




Table C-14. Prevalence (95% confidence interval) of prediabetes by definition in U.S Adults aged 40+ without diagnosed diabetes overall 
and by race and age, NHANES III 
(a) Overall (U.S. Adults 40+) 
 N Prevalence (95%CI) 
ADA Fasting glucose, 5.6-6.9 mmol/L 3,894 32.2 (29.9-34.6) 
WHO Fasting glucose, 6.1-6.9 mmol/L 3,894 11.6 (10.4-12.9) 
ADA HbA1c, 39-46 mmol/mol 3,894 10.2 (9.0-11.5) 
IEC HbA1c, 42-46 mmol/mol 3,894 2.3 (1.8-3.1) 
ADA/WHO 2-hour glucose, 7.8-11.0 mmol/L 2,970 17.1 (15.1-19.2) 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, 
International Expert Committee; OGTT, oral glucose tolerance test; WHO, World Health 
Organization 
 
(b) Black and white adults aged 47-70 (for consistency with ARIC Study design) 
 N Prevalence (95%CI) 
ADA Fasting glucose, 5.6-6.9 mmol/L 1,476 32.6 (29.8-35.6) 
WHO Fasting glucose, 6.1-6.9 mmol/L 1,476 12.0 (10.6-13.4) 
ADA HbA1c, 39-46 mmol/mol 1,476 10.2 (8.5-12.1) 
IEC HbA1c, 42-46 mmol/mol 1,476 2.5 (1.7-3.6) 
ADA/WHO 2-hour glucose, 7.8-11.0 mmol/L 1,390 18.7 (16.4-21.2) 
Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, 




Table C-15. 10-year sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, and negative 
likelihood ratio and corresponding 95% confidence intervals of incident clinical outcomes according to different definitions of prediabetes 
(vs. normoglycemia) at baseline 
 
Outcome 












All-cause mortality (n/N) 830/3,653 830/3,653 878/3,793 878/3,793 322/2,715 
Sensitivity 0.45 (0.42, 0.49) 0.18 (0.16, 0.21) 0.20 (0.18, 0.23) 0.07 (0.05, 0.08) 0.25 (0.20, 0.30) 
Specificity 0.64 (0.62, 0.66) 0.86 (0.85, 0.87) 0.86 (0.85, 0.88) 0.97 (0.96, 0.98) 0.79 (0.78, 0.81) 
PPV 0.27 (0.25, 0.29) 0.28 (0.24, 0.32) 0.31 (0.27, 0.35) 0.39 (0.31, 0.48) 0.14 (0.11, 0.17) 
NPV 0.80 (0.78, 0.82) 0.77 (0.77, 0.80) 0.78 (0.77, 0.80) 0.78 (0.76, 0.79) 0.89 (0.87, 0.90) 
+LR 1.25 (1.14, 1.37) 1.33 (1.12, 1.57) 1.50 (1.27, 1.76) 2.14 (1.55, 2.95) 1.19 (0.97, 1.47) 
-LR 0.86 (0.80, 0.92) 0.95 (0.92, 0.98) 0.92 (0.89, 0.96) 0.96 (0.95, 0.98) 0.95 (0.89, 1.01) 
Cardiovascular mortality (n/N) 235/3,638 235/3,638 251/3,776 251/3,776 82/2,710 
Sensitivity 0.45 (0.39, 0.52) 0.17 (0.13, 0.23) 0.18 (0.14, 0.24) 0.07 (0.04, 0.11) 0.27 (0.18, 0.38) 
Specificity 0.62 (0.60, 0.64) 0.85 (0.84, 0.87) 0.85 (0.84, 0.86) 0.96 (0.96, 0.97) 0.79 (0.77, 0.80) 
PPV 0.08 (0.06, 0.09) 0.08 (0.05, 0.10) 0.08 (0.06, 0.11) 0.12 (0.07, 0.18) 0.04 (0.02, 0.06) 
NPV 0.94 (0.93, 0.95) 0.94 (0.93, 0.95) 0.94 (0.93, 0.94) 0.94 (0.93, 0.94) 0.97(0.96, 0.98) 
+LR 1.19 (1.03, 1.38) 1.19 (0.89, 1.58) 1.24 (0.94, 1.62) 1.84 (1.13, 2.99) 1.27 (0.88, 1.83) 
-LR 0.88 (0.79, 1.00) 0.97 (0.91, 1.03) 0.96 (0.90, 1.02) 0.97 (0.94, 1.00) 0.93 (0.81, 1.06) 
Abbreviations: ADA, American Diabetes Association; IEC, International Expert Committee; HbA1c, hemoglobin A1c; PPV, positive predictive value; NPV, 




Table C-16. Adjusted hazard ratio and Harrell’s C-statistic (95% confidence intervals) for incident outcomes by different clinical 
categories of prediabetes and undiagnosed diabetes  
 
All-cause mortality Cardiovascular mortality 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 
HR (95% CI) 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 




N 3,888 2,593 3,871 2,587 
<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 1.17 (1.01, 1.36)* 1.17 (0.99, 1.39) 1.37 (1.03, 1.83)* 1.31 (0.91, 1.88) 
≥7.0 mmol/L‡ 1.31 (0.97, 1.76) 1.30 (0.93, 1.82) 1.51 (1.01, 2.27)* 1.37 (0.82, 2.28) 




N 3,888 2,593 3,871 2,587 
<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 1.20 (1.04, 1.39)* 1.13 (0.96, 1.33) 1.06 (0.78, 1.46) 0.98 (0.68, 1.42) 
≥7.0 mmol/L‡ 1.26 (0.95, 1.67) 1.23 (0.91, 1.68) 1.32 (0.91, 1.90) 1.17 (0.75, 1.83) 
C-statistic (95% CI) 0.794 (0.784, 0.803)  0.804 (0.793, 0.816) 0.830 (0.813, 0.847) 0.847 (0.828, 0.865) 
ADA HbA1c 
definition 
N 3,888 2,593 3,871 2,587 
<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 1.42 (1.21, 1.66)* 1.17 (1.02, 1.35)* 1.27 (0.86, 1.88) 0.92 (0.59, 1.44) 
≥48 mmol/mol‡ 1.06 (0.64, 1.75) 1.30 (0.76, 2.21) 0.68 (0.23, 2.04) 0.64 (0.29, 1.41) 
C-statistic (95% CI) 0.794 (0.784, 0.803) 0.804 (0.793, 0.816) 0.830 (0.813, 0.847) 0.847 (0.828, 0.866) 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC); Fully adjusted included demographic adjusted + education level (less than high school, high school or 
equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, 
never), drinking status (current, former, never), family history of diabetes (yes, no)  
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-16., continued 
 
All-cause mortality Cardiovascular mortality 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 
HR (95% CI) 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 
HR (95% CI) 
IEC HbA1c 
definition 
N 3,888 2,593 3,871 2,587 
<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 1.49 (1.20, 1.84)* 1.34 (1.06, 1.70)* 1.63 (1.00, 2.64)* 1.53 (0.92, 2.55) 
≥48 mmol/mol‡ 1.02 (0.61, 1.70) 1.28 (0.75, 2.17) 0.67 (0.22, 2.02) 0.68 (0.31, 1.51) 
C-statistic (95% CI) 0.794 (0.784, 0.803) 0.804 (0.793, 0.816) 0.831 (0.814, 0.848) 0.847 (0.829, 0.866) 




N 2,968 1,981 2,961 1,978 
<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 1.02 (0.85, 1.22) 1.10 (0.90, 1.35) 1.13 (0.78, 1.64) 1.10 (0.69, 1.76) 
≥11.0 mmol/L‡ 1.46 (1.10, 1.92)* 1.43 (0.99, 2.05) 1.17 (0.70, 1.97) 0.96 (0.54, 1.71) 
C-statistic (95% CI) 0.749 (0.735, 0.763) 0.770 (0.754, 0.787) 0.796 (0.770, 0.822) 0.829 (0.800, 0.858) 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC); Fully adjusted included demographic adjusted + education level (less than high school, high school or 
equivalent, college or above), BMI, waist-to-hip ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, 
never), drinking status (current, former, never), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert Committee; 
WHO, World Health Organization 
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Table C-17. Number of all-cause and cardiovascular mortality events by different clinical categories of prediabetes and undiagnosed 
diabetes 
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Abbreviations: ADA, American Diabetes Association; HbA1c, hemoglobin A1c; IEC, International Expert Committee; WHO, World Health Organization 
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Table C-18. Adjusted hazard ratio and Harrell’s C-statistic (95% confidence intervals) for incident outcomes in ARIC by different 
clinical categories of prediabetes and undiagnosed diabetes 
Visit 2 (1990-92) 
All-cause mortality Fatal Coronary Heart disease 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 
HR (95% CI) 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 





<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 1.12 (1.04, 1.21)* 1.05 (0.97, 1.13) 1.23 (0.95, 1.60) 1.02 (0.78, 1.33) 
≥7.0 mmol/L‡ 1.55 (1.35, 1.79)* 1.35 (1.16, 1.57)* 2.95 (2.01, 4.34)* 2.08 (1.38, 3.14)* 





<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 1.25 (1.13, 1.38)* 1.12 (1.01, 1.24)* 1.37 (0.98, 1.91) 1.10 (0.78, 1.55) 
≥7.0 mmol/L‡ 1.52 (1.32, 1.75)* 1.35 (1.17, 1.56)* 2.81 (1.94, 4.05)* 2.10 (1.42, 3.10)* 




<39 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
39-46 mmol/mol 1.49 (1.37, 1.62)* 1.31 (1.21, 1.43)* 2.31 (1.76, 3.02)* 1.77 (1.34, 2.33)* 
≥48 mmol/mol‡ 1.81 (1.57, 2.10)* 1.56 (1.34, 1.82)* 2.89 (1.87, 4.45)* 1.97 (1.25, 3.10)* 




<42 mmol/mol 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
42-46 mmol/mol 1.56 (1.40, 1.73)* 1.35 (1.21, 1.51)* 2.49 (1.81, 3.42)* 1.83 (1.33, 2.53)* 
≥48 mmol/mol‡ 1.73 (1.50, 1.99)* 1.50 (1.30, 1.75)* 2.58 (1.68, 3.95)* 1.80 (1.16, 2.81)* 
C-statistic (95% CI) 0.687 (0.678, 0.696) 0.722 (0.713, 0.730) 0.738 (0.708, 0.767) 0.794 (0.767, 0.820) 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip 
ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), 
lipid-lowering medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert 
Committee; WHO, World Health Organization 
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Table C-18., continued 
Visit 4 (1996-98) 
All-cause mortality Fatal Coronary Heart disease 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 
HR (95% CI) 
Demographic adjusted 
HR (95% CI) 
Fully adjusted 





<5.6 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
5.6-6.9 mmol/L 1.15 (1.03, 1.28)* 1.13 (1.01, 1.26)* 1.44 (0.97, 2.13) 1.21 (0.81, 1.83) 
≥7.0 mmol/L‡ 1.68 (1.37, 2.05)* 1.68 (1.36, 2.08)* 2.92 (1.59, 5.35)* 2.25 (1.18, 4.30)* 





<6.1 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
6.1-6.9 mmol/L 1.29 (1.10, 1.51)* 1.29 (1.09, 1.51)* 1.76 (1.05, 2.93)* 1.53 (0.91, 2.59) 
≥7.0 mmol/L‡ 1.65 (1.35, 2.01)* 1.66 (1.35, 2.04)* 2.73 (1.52, 4.91)* 2.22 (1.19, 4.13)* 






<7.8 mmol/L 1 (Ref) 1 (Ref) 1 (Ref) 1 (Ref) 
7.8-11.0 mmol/L 1.17 (1.05, 1.31)* 1.18 (1.05, 1.33)* 1.25 (0.82, 1.91) 1.13 (0.73, 1.75) 
≥11.0 mmol/L‡ 1.33 (1.15, 1.55)* 1.33 (1.14, 1.56)* 1.78 (1.07, 2.96)* 1.43 (0.83, 2.46) 
C-statistic (95% CI) 0.685 (0.672, 0.698) 0.714 (0.701, 0.726) 0.745 (0.701, 0.789) 0.783 (0.743, 0.824) 
Demographic adjusted included age, sex (male, female), race-center (white, Minneapolis, MN; black, Jackson, MS; white, Washington County, MD; black, 
Forsyth County, NC; white, Forsyth County, NC) 
Fully adjusted included demographic adjusted + education level (less than high school, high school or equivalent, college or above), BMI, waist-to-hip 
ratio, total cholesterol, HDL, triglycerides, hypertension (yes, no), eGFR, smoking status (current, former, never), drinking status (current, former, never), 
lipid-lowering medication use (yes, no), family history of diabetes (yes, no) 
‡ Undiagnosed diabetes 
* p < 0.05 
Abbreviations: ADA, American Diabetes Association; CI, confidence interval; HbA1c, hemoglobin A1c; HR, hazard ratio; IEC, International Expert 





Appendix D: Supplementary Materials for Chapter 3 
Figure D-1. 7,813 ARIC study participants without diagnosed diabetes included in this analysis 
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Table D-1. Categories of hyperglycemia based on clinical cut-points for diabetes 
 Category ARIC study visit (dates) 
Primary analyses 
2-hour glucose ≥200 mg/dL 
Visit 4 (1996-98) Fasting glucose ≥126 mg/dL 
2-hour glucose ≥200 mg/dL and fasting glucose ≥126 mg/dL 
Secondary analyses  
HbA1c ≥6.5% 
Visit 2 (1990-92) 
HbA1c ≥6.5% and fasting glucose ≥126 mg/dL 
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Figure D-2. Scatterplots of 1,5-AG with lowess curves and Spearman’s (p) and Pearson’s (r) correlations of 2-hour glucose and fasting 




Table D-2. Performance of 1,5-AG <10 µg/mL compared to identify elevated 2-hour glucose and/or fasting glucose excluding those with 
G3b, G4, and G5 chronic kidney disease, n=7,738 









1,5-AG compared to 2-hour glucose ≥ 200 mg/dL (n=807) 
Area under the ROC: 0.66 (0.64, 0.68) 
< 10 µg/mL  19.3% 96.1% 4.98 0.84 36.7% 91.1% 
(n = 425) (16.7, 22.2) (95.6, 96.6) (4.15, 5.98) (0.81, 0.87) (32.1, 41.5) (90.4, 91.7)  
1,5-AG compared to fasting glucose ≥ 126 mg/dL (n=394) 
Area under the ROC: 0.72 (0.69, 0.75) 
< 10 µg/mL  31.2% 95.9% 7.59 0.72 28.9% 96.3% 
(n = 425) (26.7, 36.0) (95.4, 96.3) (6.32, 9.12) (0.67, 0.77) (24.7, 33.5) (95.8, 96.7) 
1,5-AG compared to 2-hour glucose ≥ 200 mg/dL and fasting glucose ≥ 126 mg/dL (n=311) 
Area under the ROC: 0.78 (0.745, 0.81) 
< 10 µg/mL  38.3% 95.9% 9.29 0.64 28.0% 97.4% 




Table D-3. Performance of 1,5-AG <10 µg/mL compared to identify elevated 2-hour glucose and/or fasting glucose excluding those with 
elevated liver enzymes (ALT >38.1 U/L or AST > 44.4 U/L), n=7,588 









1,5-AG compared to 2-hour glucose ≥ 200 mg/dL (n=775) 
Area under the ROC: 0.66 (0.64, 0.68) 
< 10 µg/mL  18.6% 96.1% 4.71 0.85 34.9% 91.2% 
(n = 413) (15.9, 21.5) (95.6, 96.5) (3.90, 5.68) (0.82, 0.88) (30.3, 39.7) (90.5, 91.9)  
1,5-AG compared to fasting glucose ≥ 126 mg/dL (n=372) 
Area under the ROC: 0.72 (0.69, 0.75) 
< 10 µg/mL  30.4% 95.8% 7.31 0.73 27.4% 96.4% 
(n = 413) (25.7, 35.3) (95.4, 96.3) (6.04, 8.83) (0.68, 0.78) (23.1, 31.9) (95.9, 96.8) 
1,5-AG compared to 2-hour glucose ≥ 200 mg/dL and fasting glucose ≥ 126 mg/dL (n=293) 
Area under the ROC: 0.78 (0.74, 0.81) 
< 10 µg/mL  37.2% 95.8% 8.93 0.66 26.4% 97.4% 
(n = 413) (31.7, 43.0) (95.3, 96.3) (7.42, 10.7) (0.60, 0.72) (22.2, 30.9) (97.0, 97.8) 
Abbreviations: 1,5-AG, 1,5-anhydroglucitol; ALT, alanine aminotransferase; AST, aspartate aminotransferase 
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Table D-4. Performance of 1,5-AG <10 µg/mL compared to identify elevated HbA1c and/or elevated fasting glucose, measured from 
ARIC Visit 2 samples (1990-92), n=11,582 









1,5-AG compared to HbA1c ≥ 6.5% (n=470) 
Area under the ROC: 0.74 (0.71, 0.77) 
< 10 µg/mL  27.3% 95.0% 5.41 0.77 27.6% 94.9% 
(n = 754) (24.2, 30.6) (94.5, 95.4) (4.69, 6.23) (0.73, 0.80) (24.4, 30.9) (94.5, 95.3) 
1,5-AG compared to fasting glucose ≥ 126 mg/dL (n=762) 
Area under the ROC: 0.67 (0.64, 0.69) 
< 10 µg/mL  37.9% 94.8% 7.31 0.66 23.6% 97.3% 
(n = 754) (33.5, 42.4) (94.4, 95.2) (6.35, 8.41) (0.61, 0.70) (20.6, 26.8) (97.0, 97.6) 
1,5-AG compared to HbA1c ≥ 6.5% and fasting glucose ≥ 126 mg/dL (n=344) 
Area under the ROC: 0.80 (0.77, 0.83) 
< 10 µg/mL  47.7% 94.7% 9.08 0.55 21.8% 98.3% 





Figure D-3. Scatterplots of 1,5-AG with lowess curves and Spearman’s (p) and Pearson’s (r) correlations of dairy intake and bread and/or 
rice intake among ARIC participants without diagnosed diabetes, n=7,813 
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Appendix E: Supplementary Materials for Chapter 4 
Figure E-1. ARIC participants who attended Visit 4 (1996-98) without prevalent diabetes, chronic kidney disease, or cardiovascular 
disease included in our analysis, n=6,644 
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Table E-1. Adjusted hazard ratios and 95% CI of categories of 1,5-AG, 2-hour glucose, and fasting glucose for risk of incident diagnosed 
diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality, n=6,644 
Biomarker Categories 
Diagnosed diabetes Chronic kidney disease 
Model 1 Model 2 Model 1 Model 2 
1,5-AG ≥10 µg/mL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
1,5-AG <10 µg/mL 2.71 (2.31, 3.16) 2.74 (2.34, 3.20) 1.11 (0.89, 1.39) 1.05 (0.84, 1.31) 
2-hour glucose <200 mg/dL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
2-hour glucose ≥200 mg/dL 6.98 (6.25, 7.78) 5.30 (4.73, 5.94) 1.31 (1.11, 1.54) 1.06 (0.90, 1.35) 
Fasting glucose <126 mg/dL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
Fasting glucose ≥126 mg/dL 13.2 (11.5, 15.0) 8.14 (7.07, 9.38) 1.40 (1.12, 1.74) 1.04 (0.83, 1.31) 
 
Cardiovascular disease All-cause mortality 
Model 1 Model 2 Model 1 Model 2 
1,5-AG ≥10 µg/mL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
1,5-AG <10 µg/mL 1.18 (0.89, 1.57) 1.15 (0.87, 1.53) 1.02 (0.84, 1.25) 1.01 (0.82, 1.23) 
2-hour glucose <200 mg/dL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
2-hour glucose ≥200 mg/dL 1.46 (1.20, 1.78) 1.21 (0.99, 1.49) 1.27 (1.11, 1.45) 1.23 (1.07, 1.42) 
Fasting glucose <126 mg/dL 1 (REF) 1 (REF) 1 (REF) 1 (REF) 
Fasting glucose ≥126 mg/dL 1.67 (1.29, 2.16) 1.28 (0.98, 1.67) 1.56 (1.30, 1.87) 1.49 (1.24, 1.80) 
Bold indicates p<0.05 
Model 1: age, sex, race-center 
Model 2: Model 1 + body mass index, systolic blood pressure, hypertension medication use (no, yes), total cholesterol, HDL, triglycerides, 
education (less than high school, high school/vocational school, college or higher), smoking status (current, former, never), drinking 
status (current, former, never), history of parental diabetes (no, yes), eGFRcr, and log albumin-to-creatinine ratio  
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Table E-2. Differences in Harrell’s C-statistics from adjusted associations of 1,5-AG, 2-hour glucose, and fasting glucose with incident 
diagnosed diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality modeled with restricted cubic splines, n=6,644 
 Differences in Harrell’s C-statistic (95% CI) 
 Diagnosed diabetes Chronic kidney disease 
 Model 1 Model 2 Model 1 Model 2 
2-hour glucose – 1,5-AG 0.14 (0.13, 0.16) 0.06 (0.05, 0.07) 0.01 (0.00, 0.01) 0.00 (0.00, 0.00) 
Fasting glucose – 1,5-AG 0.15 (0.13, 0.17) 0.06 (0.05, 0.07) 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
 Cardiovascular disease All-cause mortality 
 Model 1 Model 2 Model 1 Model 2 
2-hour glucose – 1,5-AG 0.01 (0.00, 0.01) 0.00 (0.00, 0.00) 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Fasting glucose – 1,5-AG 0.01 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.01) 0.00 (0.00, 0.00) 
Bold indicates p<0.05 
Model 1: age, sex, race-center 
Model 2: Model 1 + body mass index, systolic blood pressure, hypertension medication use (no, yes), total cholesterol, HDL, 
triglycerides, education (less than high school, high school/vocational school, college or higher), smoking status (current, former, 




Table E-3. Adjusted hazard ratios and 95% CI of categories of hyperglycemia and 1,5-AG concordance for risk of incident diagnosed 
diabetes, chronic kidney disease, cardiovascular disease, and all-cause mortality, n=6,644 
 
Categories of Hyperglycemia 
and 1,5-AG concordance 
 Diagnosed Diabetes CKD 
n Events 
HR (95% CI) 
Events 
HR (95% CI) 
Model 1 Model 2 Model 1 Model 2 
True Negative (TN) 5681 1166 1 (REF) 1 (REF) 1112 1 (REF) 1 (REF) 
False Positive (FP) 220 59 1.41 (1.09, 1.83) 1.52 (1.17, 1.97) 39 0.83 (0.60, 1.15) 0.83 (0.61, 1.15) 
False Negative (FN) 610 409 6.31 (5.62, 7.09) 4.90 (4.35, 5.52) 141 1.16 (0.97, 1.38) 0.92 (0.77, 1.10) 
True Positive (TP) 133 116 16.5 (13.6, 20.1) 11.9 (9.70, 14.6) 42 1.68 (1.24, 2.29) 1.30 (0.95, 1.79) 
 
 CVD All-cause mortality 
n Events 
HR (95% CI) 
Events 
HR (95% CI) 
Model 1 Model 2 Model 1 Model 2 
True Negative (TN) 5681 653 1 (REF) 1 (REF) 1466 1 (REF) 1 (REF) 
False Positive (FP) 220 27 1.04 (0.71, 1.53) 1.13 (0.77, 1.66) 55 0.88 (0.68, 1.16) 0.85 (0.65, 1.12) 
False Negative (FN) 610 103 1.43 (1.16, 1.77) 1.19 (0.96, 1.48) 219 1.25 (1.09, 1.45) 1.21 (1.05, 1.40) 
True Positive (TP) 133 25 1.55 (1.04, 2.32) 1.24 (0.83, 1.87) 48 1.34 (1.01, 1.79) 1.37 (1.02, 1.84) 
Bold indicates p<0.05 
Model 1: age, sex, race-center 
Model 2: Model 1 + body mass index, systolic blood pressure, hypertension medication use (no, yes), total cholesterol, HDL, triglycerides, education (less than 
high school, high school/vocational school, college or higher), smoking status (current, former, never), drinking status (current, former, never), history of 




References for Introduction 
1.  NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 
1980: a pooled analysis of 751 population-based studies with 4·4 million 
participants. Lancet. 2016;387:1513-1530. 
2.  Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J. Identifying Trends in 
Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A 
Cross-sectional Study. Ann Intern Med. 2017. doi:10.7326/M17-1272. 
3.  Centers for Disease Control and Prevention. National Diabetes Statistics Report, 
2017: Estimates of Diabetes and Its Burden in the United States. Atlanta; 2017. 
doi:10.1177/1527154408322560. 
4.  Efendić S. Pathogenesis of NIDDM. Diabetes Res Clin Pract. 1988;4(SUPPL. 
1):8-10. doi:10.1016/0168-8227(88)90005-8. 
5.  American Diabetes Association. Standards of Medical Care in Diabetes - 2017. 
Diabetes Care. 2017;40(Supplement 1):S1-S135. doi:10.2337/dc14-S014. 
6.  Nathan DM. Long-term Complications of Diabetes Mellitus. N Engl J Med. 
1993;328(23):1676-1685. doi:10.1056/NEJM199308123290707. 
7.  Poretsky L, ed. Principles of Diabetes Mellitus. Third. New York: Springer 
International Publishing; 2017. doi:10.1007/978-0-387-09841-8. 
8.  United States Renal Data System. 2017 USRDS Annual Data Report: 
Epidemiology of Kidney Disease in the United States. Bethesda, MD; 2017. 
9.  Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 
2010;376(9735):124-136. doi:10.1016/S0140-6736(09)62124-3. 
10.  Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in Prevalence and Control of 
Diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 
2014;160(8):517-526. 
11.  Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of 
diabetes in people with various categories of dysglycemia: A systematic overview 
and meta-analysis of prospective studies. Diabetes Res Clin Pract. 
2007;78(3):305-312. doi:10.1016/j.diabres.2007.05.004. 
12.  Ford ES, Zhao G, Li C. Pre-Diabetes and the Risk for Cardiovascular Disease. A 
Systematic Review of the Evidence. J Am Coll Cardiol. 2010;55(13):1310-1317. 
doi:10.1016/j.jacc.2009.10.060. 
13.  Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes : A 
high-risk state for developing diabetes. Lancet. 2012;379(9833):2279-2290. 
doi:10.1016/S0140-6736(12)60283-9.Prediabetes. 
14.  Riegelman RK. Studying a Study & Testing a Test: How to Read the Medical 
 194 
Evidence. Fifth. Lippincott Williams & Wilkins; 2005. 
15.  The ADVANCE Collaborative Group. Intensive blood glucose control and 
vascular outcomes in patients with type 2 diabetes. New Engl J Med. 
2008;358:2560-2572. doi:10.1056/NEJMoa0802987. 
16.  Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular 
complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-
139. 
17.  Clark WM, The Action to Control Cardiovascular Risk in Diabetes Study Group. 
Effects of Intensive Glucose Lowering in Type 2 Diabetes. N Engl J Med. 
2008;358(24):2545-2559. doi:10.1056/NEJMoa1208410. 
18.  UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control 
with sulphonylureas or insulin compared with conventional treatment and risk of 
complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-
853. 
19.  The Diabetes Control and Complications Trial Research Group. The effect of 
intensive treatment of diabetes on the development and progression of long-term 
complications in insulin-depedent diabetes mellitus. N Engl J Med. 
1993;329(14):977-986. 
20.  Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-Year Follow-up of 
Intensive Glucose Control in Type 2 Diabetes. N Engl J Med. 2008;359(1577-89). 
21.  The Diabetes Control and Complications Trial/Epidemiology of Diabetes 
Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive 
Diabetes Treatment and Cadiovascular Disease in Patients with Type 1 Diabetes. N 
Engl J Med. 2005;353(25):2643-2653. 
22.  Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 
2 Diabetes With Lifestyle Intervention or Metformin. N Engl J Med. 
2002;346(6):393-403. doi:10.1056/NEJMoa012512. 
23.  Lindström J, Louheranta A, Mannelin M, et al. The Finnish Diabetes Prevention 
Study (DPS): Lifestyle intervention and 3-year results on diet and physical 
activity. Diabetes Care. 2003;26(12):3230-3236. doi:10.2337/diacare.26.12.3230. 
24.  Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM 
in people with impaired glucose tolerance: The Da Qing IGT and diabetes study. 
Diabetes Care. 1997;20(4):537-544. 
25.  Davidson MB, Schriger DL, Peters AL, Lorber B. Relationship between fasting 
plasma glucose and glycosylated hemoglobin: potential for false-positive 
diagnoses of type 2 diabetes using new diagnostic criteria. JAMA. 
1999;281(13):1203-1210. 
26.  American Diabetes Association. Standards of Medical Care -- 2018. Diabetes 
Care. 2018;41(January):Supplement 1. doi:https://doi.org/10.2337/dc18-Sint01. 
27.  Imperatore G, Mercado CI, Li R, Gregg EW. Prevalence of Major Behavioral Risk 
Factors for Type 2 Diabetes. 2018:1-8. doi:10.2337/dc17-1775/-/DC1.The. 
 195 
28.  Siu AL. Screening for Abnormal Blood Glucose and Type 2 Diabetes Mellitus: 
U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 
2015. doi:10.7326/M15-2345. 
29.  Canadian Task Force on Preventative Health Care. Recommendations on screening 
for type 2 diabetes in adults. Can Med Assoc J. 2012;184(15):1687-1696. 
doi:10.1503/cmaj.120732. 
30.  National Institute for Health and Clinical Excellence. Preventing Type 2 Diabetes: 
Risk Identification and Interventions for Individuals at High Risk; 2012.  
31.  Simmons RK, Echouffo-Tcheugui JB, Sharp SJ, et al. Screening for type 2 
diabetes and population mortality over 10 years (ADDITION-Cambridge): A 
cluster-randomised controlled trial. Lancet. 2012;380(9855):1741-1748. 
doi:10.1016/S0140-6736(12)61422-6. 
32.  Simmons RK, Rahman M, Jakes RW, et al. Effect of population screening for type 
2 diabetes on mortality: Long-term follow-up of the Ely cohort. Diabetologia. 
2011;54(2):312-319. doi:10.1007/s00125-010-1949-8. 
33.  Kirchhof M, Popat N, Malowany J. Diagnostic Review A Historical Perspective of 
the Diagnosis of Diabetes. Uwomj 78(1)2008. 2009;78(1):7-11. 
34.  Guthrie DW. Diabetes Urine Testing : An Historical Perspective. 1973:521-525. 
doi:10.1177/014572178801400615. 
35.  Myers GB, Mckean RM. The Oral Glucose Tolerance Test: A Review of the 
Literature. Am J Clin Pathol. 1935;5(4):299-312. 
36.  Conn JW. Interpretation of the glucose tolerance test. The necessity of a stand ard 
preparatory diet. Am J Med Sci. 1940;199:555-564. 
37.  World Health Organization. Diabetes Mellitus: Report of a WHO Expert 
Committee. Geneva; 1965. 
38.  National Diabetes Data Group. Classification and Diagnosis of Diabetes Mellitus 
and Other Categories of Glucose Intolerance. Diabetes. 1979;28(12):1039-1057. 
doi:10.2337/diab.28.12.1039. 
39.  Keen H, Chlouverakis C, Fuller J, Jarrett RJ. The concomitants of raised blood 
sugar: Studies in newly-detected hyperglycaemics. Int J Epidemiol. 2014;43(1):11-
15. doi:10.1093/ije/dyt257. 
40.  Jarrett RJ, Mccartney P, Keen H. The Bedford Study: Ten Year Mortality Rates in 
Newly Diagnosed Diabetics, Borderline Diabetics and Normoglycaemic Controls 
and Risk Indices for Coronary Heart Disease in Borderline Diabetics. 
Diabetologia. 1982;22:79-84. 
41.  The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 
Report of the Expert Committee on the Diagnosis and Classification of Diabetes 
Mellitus. Diabetes Care. 1997;20(7):1183-1197. doi:10.2337/diacare.25.2007.S5. 
42.  World Health Organization. Definition, Diagnosis and Classification of Diabetes 
Mellitus and Its Complications. Geneva; 1999. 
43.  Genuth S, Alberti K, Bennett P. Follow-up Report on the Diagnosis of Diabetes 
 196 
Mellitus. Diabetes Care. 2003;26(11):3160-3167. doi:10.2337/diacare.26.11.3160. 
44.  The International Expert Committee. International Expert Committee report on the 
role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 
2009;32(7):1327-1334. doi:10.2337/dc09-9033. 
45.  Azizi MH, Bahadori M, Azizi F. Breakthrough discovery of HbA1c by professor 
Samuel Rahbar in 1968. Arch Iran Med. 2013;16(12):743-745. 
46.  American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. 
Diabetes Care. 2010;33:S62-S69. doi:10.2337/dc10-S062. 
47.  Yudkin JS. “Prediabetes”: Are There Problems With This Label? Yes, the Label 
Creates Further Problems! Diabetes Care. 2016;39(8):1468-1471. 
doi:10.2337/dc15-2113. 
48.  Yudkin J, Montori V. The epidemic of pre-diabetes : the medicine and the politics. 
Bmj. 2014;4485(July):1-6. doi:10.1136/bmj.g4485. 
49.  Buse JB, Freeman JLR, Edelman S V, Jovanovic L, McGill JB. Serum 1,5-
anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol 
Ther. 2003;5(3):355-363. doi:10.1089/152091503765691839. 
50.  Yamanouchi T, Tachibana Y, Akanuma H, et al. Origin and disposal of 1,5-
anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992;263:268-
273. 
51.  GlycomarkTM. GlycoMark: For the Quantitative Measurement of 1,5-
Anhydroglucitol (1,5-AG) in Serum or Plasma. New York; 2013. 
52.  Yamanouchi T, Minoda S, Yabuuchi M, et al. Plasma 1,5-anhydro-D-glucitol as 
new clinical marker of glycemic control in NIDDM patients. Diabetes. 
1989;38(6):723-729. doi:10.2337/diab.38.6.723. 
53.  Konishi Y, Hashima K, Kishida K. Increases in 1,5-anhydroglucitol levels in 
germinating amaranth seeds and in ripening banana. Biosci Biotechnol Biochem. 
2000;64(11):2462-2465. doi:10.1271/bbb.64.2462. 
54.  Juraschek SP, McAdams-Demarco M, Gelber AC, et al. Effects of Lowering 
Glycemic Index of Dietary Carbohydrate on Plasma Uric Acid Levels: The 
OmniCarb Randomized Clinical Trial. Arthritis Rheumatol. 2016;68(5):1281-
1289. doi:10.1002/art.39527. 
55.  Robertson DA, Alberti KGMM, Dowse GK, Zimmet P, Tuohiletho J, Gareeboo H. 
Is serum anhydroglucitol an alternative to the oral glucose tolerance test for 
diabetes screening? Diabet Med. 1993;10:56-60. 
56.  Kim WJ, Park C-Y. 1,5-Anhydroglucitol in diabetes mellitus. Endocrine. 
2013;43(1):33-40. doi:10.1007/s12020-012-9760-6. 
57.  Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic 
control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9-19. 
doi:10.1586/14737159.8.1.9. 
58.  Koga M, Murai J, Saito H, et al. 1 , 5-Anhydroglucitol levels are low irrespective 
of plasma glucose levels in patients with chronic liver disease. 2011;(January 
 197 
1995):121-125. 
59.  Selvin E, Rynders GP, Steffes MW. Comparison of Two Assays for Serum 1,5-
Anhydroglucitol. Clin Chim Acta. 2011;412(9-10):793-795. 
doi:10.1016/j.cca.2011.01.007. 
60.  McGill JB, Cole TG, Nowatzke W, et al. Circulating 1,5-anhydroglucitol levels in 
adult patients with diabetes reflect longitudinal changes of glycemia: A U.S. trial 
of the GlycoMark assay. Diabetes Care. 2004;27(8):1859-1865. 
doi:10.2337/diacare.27.8.1859. 
61.  Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial 
hyperglycemia as measured by continuous glucose monitoring system in 
moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214-
1219. doi:10.2337/dc06-1910. 
62.  Selvin E, Rawlings A, Lutsey P, et al. Association of 1,5-Anhydroglucitol With 
Cardiovascular Disease and Mortality. Diabetes. 2016;65(1):201-208. 
doi:10.2337/db15-0607. 
63.  Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 
1,5-anhydroglucitol with diabetes and microvascular conditions. Clin Chem. 
2014;60(11):1409-1418. doi:10.1373/clinchem.2014.229427. 
64.  Malkan UY, Gunes G, Corakci A. Rational diagnoses of diabetes: the comparison 
of 1,5-anhydroglucitol with other glycemic markers. Springerplus. 2015;4:587. 
doi:10.1186/s40064-015-1389-5. 
65.  Yamanouchi T, Akanuma Y, Toyota T, et al. Comparison of 1,5-Anhydroglucitol, 
HbA1c, and Fructosamine for Detection of Diabetes Mellitus. Diabetes. 
1991;40:52-57. 
66.  Goto M, Yamamoto-Honda R, Shimbo T, et al. Correlation between baseline 
serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during 
oral glucose tolerance tests. Endocr J. 2011;58(1):13-17. 
doi:10.1507/endocrj.K10E-224. 
67.  Parrinello CM, Lutsey PL, Couper D, et al. Total Short-Term Variability in 
Biomarkers of Hyperglycemia in Older Adults. Clin Chem. 2015;1548:1540-1541. 
doi:10.1373/clinchem.2015.246231. 
68.  The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Sudy: 
Design and Objectives. Am J Epidemiol. 1989;129(4):687-702. 
69.  Warren B, Pankow JS, Matsushita K, et al. Comparative prognostic performance 
of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis 




References for Chapter 1 
1.  Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and Trends in 
Diabetes Among Adults in the United States, 1988-2012. Jama. 
2015;314(10):1021-1029. 
2.  NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 
1980: a pooled analysis of 751 population-based studies with 4·4 million 
participants. Lancet. 2016;387:1513-1530. 
3.  United States Renal Data System. 2017 USRDS Annual Data Report: 
Epidemiology of Kidney Disease in the United States. Bethesda, MD; 2017. 
4.  Levey AS, Inker LA, Matsushita K, et al. GFR decline as an end point for clinical 
trials in CKD: A scientific workshop sponsored by the national kidney foundation 
and the US food and drug administration. Am J Kidney Dis. 2014;64(6):821-835. 
doi:10.1053/j.ajkd.2014.07.030. 
5.  Poretsky L, ed. Principles of Diabetes Mellitus. Third. New York: Springer 
International Publishing; 2017. doi:10.1007/978-0-387-09841-8. 
6.  The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Sudy: 
Design and Objectives. Am J Epidemiol. 1989;129(4):687-702. 
7.  Parrinello CM, Grams ME, Couper D, et al. Recalibration of blood analytes over 
25 years in the Atherosclerosis Risk in Communities Study: Impact of 
recalibration on chronic kidney disease prevalence and incidence. Clin Chem. 
2015;61(7):938-947. 
8.  Levey AS, Stevens L a, Schmid CH, et al. A New Equation to Estimate 
Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604-613. 
9.  Rebholz CM, Coresh J, Ballew SH, et al. Kidney Failure and ESRD in the 
Atherosclerosis Risk in Communities (ARIC) Study: Comparing Ascertainment of 
Treated and Untreated Kidney Failure in a Cohort Study. Am J Kidney Dis. 
2015;66(2):231-239. doi:10.3109/10253890.2015.1094689. 
10.  ARIC Study Investigators. Operations Manual No 2: Cohort Component 
Procedures, Version 2.0. Chapel Hill; 1988. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Cohort_Procedur
es.1_2.pdf. 
11.  ARIC Study Investigators. Operations Manual No 11: Sitting Blood Pressure, 
Version 1.0.; 1987. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Sitting_Blood_P
ressure_and_Postural_Changes_in_Blood_Pressure_and_Heart_Rate.1_11.pdf. 
12.  Parsa A, Kao WHL, Xie D, et al. APOL1 Risk Variants, Race, and Progression of 
Chronic Kidney Disease. N Engl J Med. 2013;369(23):2183-2196. 
doi:10.1056/NEJMoa1310345. 
13.  Grams ME, Rebholz CM, Chen Y, et al. Race, APOL1 Risk, and eGFR Decline in 
the General Population. J Am Soc Nephrol. 2016:2842-2850. 
doi:10.1681/ASN.2015070763. 
 199 
14.  Selvin E, Coresh J, Zhu H, Folsom A, Steffes MW. Measurement of HbA1c from 
stored whole blood samples in the Atherosclerosis Risk in Communities study. J 
Diabetes. 2010;2:118-124. 
15.  Low S, Lim SC, Yeoh LY, et al. Effect of long-term glycemic variability on 
estimated glomerular filtration rate decline among patients with type 2 diabetes 
mellitus: Insights from the Diabetic Nephropathy Cohort in Singapore. J Diabetes. 
2017:1-12. 
16.  Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of 
hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the 
ACCORD randomised trial. Lancet. 2010;376(9739):419-430. doi:10.1016/S0140-
6736(10)60576-4. 
17.  The ADVANCE Collaborative Group. Intensive blood glucose control and 
vascular outcomes in patients with type 2 diabetes. New Engl J Med. 
2008;358:2560-2572. doi:10.1056/NEJMoa0802987. 
18.  Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular 
complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-
139. 
19.  Hemmelgarn BR, Zhang J, Manns BJ, et al. Progression of kidney dysfunction in 
the community-dwelling elderly. Kidney Int. 2006;69(12):2155-2161. 
doi:10.1038/sj.ki.5000270. 
20.  Imai E, Horio M, Yamagata K, et al. Slower Decline of Glomerular Filtration Rate 
in the Japanese General Population: A Longitudinal 10-Year Follow-Up Study. 
Hypertens Res. 2008;31(3):433-441. doi:10.1291/hypres.31.433. 
21.  Linderman RD, Tobin J, Nathan W. Shock. Longitudinal Studies on the Rate of 
Decline in Renal Function with Age. J Am Geriatr Soc. 1985;33(4):278-285. 
22.  National Kidney Fundation. Frequently Asked Questions About Gfr Estimates. 
New York; 2014. https://www.kidney.org/sites/default/files/docs/12-10-
4004_abe_faqs_aboutgfrrev1b_singleb.pdf. 
23.  Nelson RG, Bennett PH, Beck GJ, et al. Development and Progression of Renal 
Disease in Pima Indians With Non-insulin Depedent Diabetes Mellitus. N Engl J 
Med. 1996;335(22):1636-1642. 
24.  Silveiro SP, Friedman R, De Azevedo MJ, Canani LH, Gross JL. Five-year 
prospective study of glomerular filtration rate and albumin excretion rate in 
normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes 
Care. 1996;19(2):171-174. doi:10.2337/diacare.19.2.171. 
25.  Ruggenenti P, Porrini EL, Gaspari F, et al. Glomerular hyperfiltration and renal 
disease progression in type 2 diabetes. Diabetes Care. 2012;35(10):2061-2068. 
doi:10.2337/dc11-2189. 
26.  Ficociello LH, Perkins BA, Roshan B, et al. Renal hyperfiltration and the 
development of microalbuminuria in type 1 diabetes. Diabetes Care. 
2009;32(5):889-893. doi:10.2337/dc08-1560. 
27.  Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is 
 200 
hyperfiltration associated with the future risk of developing diabetic nephropathy? 
A meta-analysis. Diabetologia. 2009;52(4):691-697. doi:10.1007/s00125-009-
1268-0. 
28.  Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in 
measures of glycemia and implications for the classification of diabetes. Arch 
Intern Med. 2007;167(14):1545-1551. doi:10.1001/archinte.167.14.1545. 
29.  American Diabetes Association. Standards of Medical Care in Diabetes - 2017. 




References for Chapter 2 
1. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in Prevalence and Control of 
Diabetes in the United States, 1988-1994 and 1999-2010. Ann Intern Med. 
2014;160(8):517–26. 
2. World Health Organization. Use of glycated haemoglobin (HbA1c) in the 
diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. 2011. 
3. Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. 2012. 
4. Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, Danchin N, et al. ESC 
guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in 
collaboration with the EASD. European Heart Journal. 2013. 
5. The International Expert Committee. International Expert Committee report on the 
role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 
2009;32(7):1327–34. 
6. American Diabetes Association. Standards of Medical Care in Diabetes-2016. 
Diabetes Care. 2016;39:S1–112. 
7. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 
2 Diabetes With Lifestyle Intervention or Metformin. N Engl J Med. 
2002;346(6):393–403. 
8. Levey AS, de Jong PE, Coresh J, Nahas M El, Astor BC, Matsushita K, et al. The 
definition, classification, and prognosis of chronic kidney disease: a KDIGO 
Controversies Conference report. Kidney Int. 2011;80:17–28. 
9. The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Sudy: 
Design and Objectives. Am J Epidemiol. 1989;129(4):687–702. 
10. Parrinello CM, Grams ME, Couper D, Ballantyne CM, Hoogeveen RC, Eckfeldt 
JH, et al. Recalibration of blood analytes over 25 years in the Atherosclerosis Risk 
in Communities Study: Impact of recalibration on chronic kidney disease 
prevalence and incidence. Clin Chem. 2015;61(7):938–47. 
11. Selvin E, Coresh J, Zhu H, Folsom A, Steffes MW. Measurement of HbA1c from 
stored whole blood samples in the Atherosclerosis Risk in Communities study. J 
Diabetes. 2010;2(2):118–24. 
12. Anonymous. Operations Manual No 7: Blood collection and processing. 1997. 
13. Selvin E, Steffes MW, Zhu H, Matsushita K, Wagenknecht L, Pankow J, et al. 
Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N 
Engl J Med. 2010;362(9):800–11. 
14. Schneider ALC, Pankow JS, Heiss G, Selvin E. Validity and reliability of self-
reported diabetes in the atherosclerosis risk in communities study. Am J 
Epidemiol. 2012;176(8):738–43. 
15. Grams ME, Rebholz CM, McMahon B, Whelton S, Ballew SH, Selvin E, et al. 
Identification of incident CKD stage 3 in research studies. Am J Kidney Dis. 
2014;64(2):214–21. 
 202 
16. Levey AS, Stevens L a, Schmid CH, Zhang YL, Iii AFC, Feldman HI, et al. A 
New Equation to Estimate Glomerular Filtration Rate. Ann Intern Med. 
2009;150(9):604–13. 
17. Anonymous. Operations Manual No 2: Cohort component procedures, version 1.0. 
1987. 
18. Anonymous. Operations Manual No 11: Sitting blood pressure, version 1.0. 1987. 
19. Anonymous. Operations Manual No 10: Clinical chemistry determinations, version 
1.0. 1987. 
20. Newson R. Confidence intervals for rank statistics: Somers’ D and extensions. 
Stata J. 2006;6(3):309–34. 
21. Eastwood S V., Tillin T, Sattar N, Forouhi NG, Hughes AD, Chaturvedi N. 
Associations Between Prediabetes, by Three Different Diagnostic Criteria, and 
Incident CVD Differ in South Asians and Europeans. Diabetes Care. 
2015;38:2325–32. 
22. Pankow JS, Kwan DK, Duncan BB, Schmidt MI, Couper DJ, Golden S, et al. 
Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: 
The atherosclerosis risk in communities study. Diabetes Care. 2007;30(2):325–31. 
23. The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and 
prediction of cardiovascular disease. JAMA. 2014;311(12):1225–33. 
24. The DECODE Study Group on behalf of the European Diabetes Epidemiology 
Group. Glucose Tolerance and Cardiovascular Mortality. Arch Intern Med. 
2001;161:397–405. 
25. Huang Y, Cai X, Chen P, Mai W, Tang H, Huang Y, et al. Associations of 
prediabetes with all-cause and cardiovascular mortality: A meta-analysis. Ann 
Med. 2014;46(8):684–92. 
26. Ford ES, Zhao G, Li C. Pre-Diabetes and the Risk for Cardiovascular Disease. A 
Systematic Review of the Evidence. J Am Coll Cardiol. 2010;55(13):1310–7. 
27. Samuels TA, Cohen D, Brancati FL, Coresh J, Kao WHL. Delayed Diagnosis of 




References for Chapter 3 
1.  Centers for Disease Control and Prevention. National Diabetes Statistics Report, 
2017: Estimates of Diabetes and Its Burden in the United States. Atlanta; 2017. 
doi:10.1177/1527154408322560. 
2.  American Diabetes Association. Standards of Medical Care in Diabetes - 2017. 
Diabetes Care. 2017;40(Supplement 1):S1-S135. doi:10.2337/dc14-S014. 
3.  National Diabetes Data Group. Classification and Diagnosis of Diabetes Mellitus 
and Other Categories of Glucose Intolerance. Diabetes. 1979;28(12):1039-1057. 
doi:10.2337/diab.28.12.1039. 
4.  De Vegt F, Dekker JM, Ruhé HG, et al. Hyperglycaemia is associated with all-
cause and cardiovascular mortality in the Hoorn population: The Hoorn study. 
Diabetologia. 1999;42(8):926-931. doi:10.1007/s001250051249. 
5.  The DECODE Study Group on behalf of the European Diabetes Epidemiology 
Group. Glucose Tolerance and Cardiovascular Mortality. Arch Intern Med. 
2001;161:397-405. 
6.  Ito C, Maeda R, Ishida S, Harada H, Inoue N. Importance of OGTT for diagnosing 
diabetes mellitus based on prevalence and incidence of retinopathy. 2000;49:181-
186. 
7.  Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and 
cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362(9):800-811. 
8.  Selvin E, Crainiceanu CM, Brancati FL, Coresh J. Short-term variability in 
measures of glycemia and implications for the classification of diabetes. Arch 
Intern Med. 2007;167(14):1545-1551. doi:10.1001/archinte.167.14.1545. 
9.  Stolk, Orchard, Grobbee. Why use the oral glucose tolerance test? Diabetes Care. 
1995;18(July):1045-1049. http://care.diabetesjournals.org/content/18/7/1045.short. 
10.  Malkan UY, Gunes G, Corakci A. Rational diagnoses of diabetes: the comparison 
of 1,5-anhydroglucitol with other glycemic markers. Springerplus. 2015;4:587. 
doi:10.1186/s40064-015-1389-5. 
11.  Yamanouchi T, Akanuma Y, Toyota T, et al. Comparison of 1,5-Anhydroglucitol, 
HbA1c, and Fructosamine for Detection of Diabetes Mellitus. Diabetes. 
1991;40:52-57. 
12.  Goto M, Yamamoto-Honda R, Shimbo T, et al. Correlation between baseline 
serum 1,5-anhydroglucitol levels and 2-hour post-challenge glucose levels during 
oral glucose tolerance tests. Endocr J. 2011;58(1):13-17. 
doi:10.1507/endocrj.K10E-224. 
13.  Buse JB, Freeman JLR, Edelman S V, Jovanovic L, McGill JB. Serum 1,5-
anhydroglucitol (GlycoMark ): a short-term glycemic marker. Diabetes Technol 
Ther. 2003;5(3):355-363. doi:10.1089/152091503765691839. 
14.  Dungan KM, Buse JB, Largay J, et al. 1,5-Anhydroglucitol and postprandial 
hyperglycemia as measured by continuous glucose monitoring system in 
moderately controlled patients with diabetes. Diabetes Care. 2006;29(6):1214-
 204 
1219. doi:10.2337/dc06-1910. 
15.  The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Sudy: 
Design and Objectives. Am J Epidemiol. 1989;129(4):687-702. 
16.  The ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol: 
Manual 2 Cohort Component Procedures, Visit 4. Chapel Hill, NC; 1997. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Cohort_Procedur
es.4_2.pdf. 
17.  Selvin E, Coresh J, Zhu H, Folsom A, Steffes MW. Measurement of HbA1c from 
stored whole blood samples in the Atherosclerosis Risk in Communities study. J 
Diabetes. 2010;2:118-124. 
18.  Selvin E, Wang D, Lee AK, Bergenstal RM, Coresh J. Identifying Trends in 
Undiagnosed Diabetes in U.S. Adults by Using a Confirmatory Definition: A 
Cross-sectional Study. Ann Intern Med. 2017. doi:10.7326/M17-1272. 
19.  The ARIC Investigators. ARIC Data Book, Cohort, Exam 3, Dietary Intake Form. 
Chapel Hill, NC 
https://www2.cscc.unc.edu/aric/sites/default/files/public/datasets/DTIC04.pdf. 
20.  Levey AS, Stevens L a, Schmid CH, et al. A New Equation to Estimate 
Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604-613. 
21.  Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated 
with the incidence of atrial fibrillation: The atherosclerosis risk in communities 
(ARIC) Study. Circulation. 2011;123(25):2946-2953. 
doi:10.1161/CIRCULATIONAHA.111.020982. 
22.  National Kidney Foundation CKD Work Group. KDIGO 2012 Clinical Practice 
Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney 
Int Suppl. 2013;3(1). doi:10.1038/kisup.2012.76. 
23.  Kim WJ, Rhee EJ, Park CY, et al. Serum 1,5-anhydroglucitol concentrations are a 
reliable index of glycemic control in type 2 diabetes with mild or moderate renal 
dysfunction. Diabetes Care. 2012;35(2):281-286. doi:10.2337/dc11-1462. 
24.  Hasslacher C, Kulozik F. Effect of renal function on serum concentration of 1,5-
anhydroglucitol in type 2 diabetic patients in chronic kidney disease stages I–III: A 
comparative study with HbA1c and glycated albumin. J Diabetes. 2016;8(5):712-
719. doi:10.1111/1753-0407.12354. 
25.  Koga M, Murai J, Saito H, et al. 1,5-Anhydroglucitol levels are low irrespective of 
plasma glucose levels in patients with chronic liver disease. Ann Clin Biochem. 
2011;48(2):121-125. doi:10.1258/acb.2010.010053. 
26.  Larsson J, Godfrey AJR. Area-Proprotional Euler and Venn Diagrams with Circles 
or Ellipses: Package “eulerr.” 2017. 
27.  Robertson DA, Alberti KGMM, Dowse GK, Zimmet P, Tuohiletho J, Gareeboo H. 
Is serum anhydroglucitol an alternative to the oral glucose tolerance test for 
diabetes screening? Diabet Med. 1993;10:56-60. 
28.  Juraschek SP, McAdams-Demarco M, Gelber AC, et al. Effects of Lowering 
 205 
Glycemic Index of Dietary Carbohydrate on Plasma Uric Acid Levels: The 
OmniCarb Randomized Clinical Trial. Arthritis Rheumatol. 2016;68(5):1281-
1289. doi:10.1002/art.39527. 
29.  Koga M, Murai J, Saito H, Mukai M, Kasayama S. Habitual intake of dairy 
products influences serum 1,5-anhydroglucitol levels independently of plasma 
glucose. Diabetes Res Clin Pract. 2010;90(1):122-125. 
doi:10.1016/j.diabres.2010.06.023. 
30.  Yamanouchi T, Tachibana Y, Akanuma H, et al. Origin and disposal of 1,5-
anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992;263:268-
273. 
31.  Konishi Y, Hashima K, Kishida K. Increases in 1,5-anhydroglucitol levels in 
germinating amaranth seeds and in ripening banana. Biosci Biotechnol Biochem. 
2000;64(11):2462-2465. doi:10.1271/bbb.64.2462. 
32.  Li M, Maruthur NM, Loomis SJ, et al. Genome-wide association study of 1,5-
anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci 
Rep. 2017;7(1):2812. doi:10.1038/s41598-017-02287-x. 




References for Chapter 4 
1.  Centers for Disease Control and Prevention. National Diabetes Statistics Report, 
2017: Estimates of Diabetes and Its Burden in the United States. Atlanta; 2017. 
doi:10.1177/1527154408322560. 
2.  Nathan DM. Long-term Complications of Diabetes Mellitus. N Engl J Med. 
1993;328(23):1676-1685. doi:10.1056/NEJM199308123290707. 
3.  American Diabetes Association. Standards of Medical Care -- 2018. Diabetes 
Care. 2018;41(January):Supplement 1. doi:https://doi.org/10.2337/dc18-Sint01. 
4.  Malkan UY, Gunes G, Corakci A. Rational diagnoses of diabetes: the comparison 
of 1,5-anhydroglucitol with other glycemic markers. Springerplus. 2015;4:587. 
doi:10.1186/s40064-015-1389-5. 
5.  Yamanouchi T, Akanuma Y, Toyota T, et al. Comparison of 1,5-Anhydroglucitol, 
HbA1c, and Fructosamine for Detection of Diabetes Mellitus. Diabetes. 
1991;40:52-57. 
6.  Dungan KM. 1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic 
control and glycemic excursions. Expert Rev Mol Diagn. 2008;8(1):9-19. 
doi:10.1586/14737159.8.1.9. 
7.  The DECODE Study Group on behalf of the European Diabetes Epidemiology 
Group. Glucose Tolerance and Cardiovascular Mortality. Arch Intern Med. 
2001;161:397-405. 
8.  Smith NL, Barzilay JI, Shaffer D, et al. Fasting and 2-Hour Postchallenge Serum 
Glucose Measures and Risk of Incident Cardiovascular Events in the Elderly. Arch 
Intern Med. 2002;162(2):209-216. doi:10.1001/archinte.162.2.209. 
9.  Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 
1,5-anhydroglucitol with diabetes and microvascular conditions. Clin Chem. 
2014;60(11):1409-1418. doi:10.1373/clinchem.2014.229427. 
10.  Selvin E, Rawlings A, Lutsey P, et al. Association of 1,5-Anhydroglucitol With 
Cardiovascular Disease and Mortality. Diabetes. 2016;65(1):201-208. 
doi:10.2337/db15-0607. 
11.  Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T. 
Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: An 
11-year population-based Cohort study in Japan, the Suita study. Atherosclerosis. 
2011;216(2):477-483. doi:10.1016/j.atherosclerosis.2011.02.033. 
12.  The ARIC Investigators. The Atherosclerosis Risk In Communities (ARIC) Sudy: 
Design and Objectives. Am J Epidemiol. 1989;129(4):687-702. 
13.  The ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol: 
Manual 2 Cohort Component Procedures, Visit 4. Chapel Hill, NC; 1997. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Cohort_Procedur
es.4_2.pdf. 
14.  Warren B, Lee AK, Ballantyne CM, et al. Performance of 1,5-anhydroglucitol 
compared to the oral glucose tolerance test for identification of diabetes in the 
 207 
community. Circulation. 2017;135:AMP018. 
15.  Schneider ALC, Pankow JS, Heiss G, Selvin E. Validity and reliability of self-
reported diabetes in the atherosclerosis risk in communities study. Am J Epidemiol. 
2012;176(8):738-743. doi:10.1093/aje/kws156. 
16.  Levey AS, Stevens L a, Schmid CH, et al. A New Equation to Estimate 
Glomerular Filtration Rate. Ann Intern Med. 2009;150(9):604-613. 
17.  Grams ME, Rebholz CM, McMahon B, et al. Identification of incident CKD stage 
3 in research studies. Am J Kidney Dis. 2014;64(2):214-221. 
18.  The ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol, 
Manual 2, Cohort Component Procedures, Visit 4. Chapel Hill; 1997. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Cohort_Procedur
es.4_2.pdf. 
19.  The ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol, 
Manual 7, Blood Collection and Processing Visit 4. Chapel Hill; 1997. 
https://www2.cscc.unc.edu/aric/sites/default/files/public/manuals/Blood_Collectio
n_and_Processing.4_7.pdf. 
20.  The ARIC Investigators. Atherosclerosis Risk in Communities Study Protocol, 
Manual 11, Sitting Blood Pressure, Visit 4. Chapel Hill; 1997. 
21.  Alonso A, Lopez FL, Matsushita K, et al. Chronic kidney disease is associated 
with the incidence of atrial fibrillation: The atherosclerosis risk in communities 
(ARIC) Study. Circulation. 2011;123(25):2946-2953. 
doi:10.1161/CIRCULATIONAHA.111.020982. 
22.  Juraschek SP, Miller ER, Appel LJ, Christenson RH, Sacks FM, Selvin E. Effects 
of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: 
Results from the OmniCarb trial. Diabet Med. 2017;34(10):1407-1413. 
23.  Koga M, Murai J, Saito H, Mukai M, Kasayama S. Habitual intake of dairy 
products influences serum 1,5-anhydroglucitol levels independently of plasma 
glucose. Diabetes Res Clin Pract. 2010;90(1):122-125. 
doi:10.1016/j.diabres.2010.06.023. 
24.  Yamanouchi T, Tachibana Y, Akanuma H, et al. Origin and disposal of 1,5-
anhydroglucitol, a major polyol in the human body. Am J Physiol. 1992;263:268-
273. 
25.  Kim WJ, Rhee EJ, Park CY, et al. Serum 1,5-anhydroglucitol concentrations are a 
reliable index of glycemic control in type 2 diabetes with mild or moderate renal 
dysfunction. Diabetes Care. 2012;35(2):281-286. doi:10.2337/dc11-1462. 
26.  Koga M, Murai J, Saito H, et al. 1,5-Anhydroglucitol levels are low irrespective of 
plasma glucose levels in patients with chronic liver disease. Ann Clin Biochem. 
2011;48(2):121-125. doi:10.1258/acb.2010.010053. 
27.  Li M, Maruthur NM, Loomis SJ, et al. Genome-wide association study of 1,5-
anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci 
Rep. 2017;7(1):2812. doi:10.1038/s41598-017-02287-x. 
 208 
28.  The International Expert Committee. International Expert Committee report on the 




References for Conclusion 
1.  Warren B, Pankow JS, Matsushita K, et al. Comparative prognostic performance 
of definitions of prediabetes: a prospective cohort analysis of the Atherosclerosis 
Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 
2016;8587(16):1-9. doi:10.1016/S2213-8587(16)30321-7. 
2.  Juraschek SP, Miller ER, Appel LJ, Christenson RH, Sacks FM, Selvin E. Effects 
of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: 
Results from the OmniCarb trial. Diabet Med. 2017;34(10):1407-1413. 
3.  Koga M, Murai J, Saito H, Mukai M, Kasayama S. Habitual intake of dairy 
products influences serum 1,5-anhydroglucitol levels independently of plasma 
glucose. Diabetes Res Clin Pract. 2010;90(1):122-125. 
doi:10.1016/j.diabres.2010.06.023. 
4.  Kim WJ, Rhee EJ, Park CY, et al. Serum 1,5-anhydroglucitol concentrations are a 
reliable index of glycemic control in type 2 diabetes with mild or moderate renal 
dysfunction. Diabetes Care. 2012;35(2):281-286. doi:10.2337/dc11-1462. 
5.  Koga M, Murai J, Saito H, et al. 1 , 5-Anhydroglucitol levels are low irrespective 
of plasma glucose levels in patients with chronic liver disease. 2011;(January 
1995):121-125. 
6.  Li M, Maruthur NM, Loomis SJ, et al. Genome-wide association study of 1,5-
anhydroglucitol identifies novel genetic loci linked to glucose metabolism. Sci 
Rep. 2017;7(1):2812. doi:10.1038/s41598-017-02287-x. 
7.  Nelson RG, Bennett PH, Beck GJ, et al. Development and Progression of Renal 
Disease in Pima Indians With Non-insulin Depedent Diabetes Mellitus. N Engl J 
Med. 1996;335(22):1636-1642. 
8.  Yudkin J, Montori V. The epidemic of pre-diabetes : the medicine and the politics. 
Bmj. 2014;4485(July):1-6. doi:10.1136/bmj.g4485. 
9.  Gerstein HC, Santaguida P, Raina P, et al. Annual incidence and relative risk of 
diabetes in people with various categories of dysglycemia: A systematic overview 
and meta-analysis of prospective studies. Diabetes Res Clin Pract. 
2007;78(3):305-312. doi:10.1016/j.diabres.2007.05.004. 
10.  Vas PRJ, Alberti KG, Edmonds ME. Prediabetes: moving away from a 
glucocentric definition. Lancet Diabetes Endocrinol. 2017;8587(17):10-11. 
doi:10.1016/S2213-8587(17)30234-6. 
11.  Tabak AG, Herder C, Rathmann W, Brunner EJ, Kivimaki M. Prediabetes : A 
high-risk state for developing diabetes. Lancet. 2012;379(9833):2279-2290. 
doi:10.1016/S0140-6736(12)60283-9.Prediabetes. 
12.  Selvin E, Rawlings AM, Grams M, Klein R, Steffes M, Coresh J. Association of 
1,5-anhydroglucitol with diabetes and microvascular conditions. Clin Chem. 
2014;60(11):1409-1418. doi:10.1373/clinchem.2014.229427. 
13.  Selvin E, Rawlings A, Lutsey P, et al. Association of 1,5-Anhydroglucitol With 
Cardiovascular Disease and Mortality. Diabetes. 2016;65(1):201-208. 
 210 
Curriculum Vitae 




Place of Birth     
Downingtown, PA     
    
Home Address   
2117 10th Street NW  
Apartment 102     
Washington, DC 20001      
(484) 678-8330      
    
Work Address 
Johns Hopkins Bloomberg School of Public Health 
Department of Epidemiology  
Welch Center for Prevention, Epidemiology, and Clinical Research 
2024 E Monument Street, Suite 2-600 





2014-Present  Doctor of Philosophy (PhD), Johns Hopkins University Bloomberg 
School of Public Health      
Department of Epidemiology  
NIH/NHLBI Pre-doctoral Trainee in Cardiovascular Disease 
Epidemiology 
Dissertation: “Screening and Diagnosis of Prediabetes and Diabetes: 
Epidemiologic Research to Inform Prevention” 
Advisor: Elizabeth Selvin, PhD, MPH 
Current GPA: 3.94/4.00 
 
2014-Present Certificate in Global Health, Johns Hopkins University Bloomberg 
School of Public Health 
  Department of International Health 
Current GPA: 4.00/4.00 
 
2012  Certified Base Programmer for SAS®9, SAS® 
 
2006-2010 Bachelor’s of Arts (BA), University of Pennsylvania 
magna cum laude 
Major: Health and Societies, Public Health 
Minor: Organizations and Environmental Management, a joint business 





2015-Present Johns Hopkins University Bloomberg School of Public Health    
Research Assistant to Dr. Elizabeth Selvin, Professor, Department of 
Epidemiology 
 
2010-2014 Booz Allen Hamilton    
Associate (Prior Roles: Senior Consultant, Consultant) 
Managers: Dr. Anita Cattrell and Ms. Jeni Fan 
 
2009-2010 Children’s Hospital of Philadelphia    
Research Coordinator for Dr. Nicolas Stettler, Pediatric Nutrition 
 
2008-2010 University of Pennsylvania, School of Medicine   
Research Coordinator for Dr. Peter Kanetsky, Associate Professor, Center 
for Clinical Epidemiology and Biostatistics 
 
2008-2010 University of Pennsylvania, Penn Global Health Initiative   




2015  Johns Hopkins University Bloomberg School of Public Health  
  Lead Teaching Assistant, Epidemiological Methods I 
 
2016   Johns Hopkins University Bloomberg School of Public Health  




Jung, M, Warren B, Grams M, Kwong D, Sharfi T, Coresh J, Rebholz C, Selvin E. 
Beyond HbA1c: Performance of Nontraditional Hyperglycemia Biomarkers by Chronic 
Kidney Disease Status in Older Adults with Diabetes: Results from the Atherosclerosis 
Risk in Communities Study. Journal of Diabetes. 2017. In Press. 
 
Lee, AK, Warren B, Lee CJ, Huang ES, Sharrett AR, Coresh J, Selvin E. The 
Association of Severe Hypoglycemia with Incident Cardiovascular Events and Mortality 
in Adults with Type 2 Diabetes. Diabetes Care. 2018. 41(1): 104-111. 
 
Selvin, E, Warren, B, Zhe, X, Sacks, D, and Saenger, A. Reference intervals for 
fructosamine, glycated albumin, and 1,5-anhydroglucitol. Clinical Chemistry. In Press. 
 
Warren B, Pankow JS, Matsushita K, Punjabi N, Daya NR, Grams M, Woodward M, 
Selvin E. Comparative Prognostic Performance of Definitions of Prediabetes: a 
Prospective Cohort Analysis of the Atherosclerosis Risk in Communities (ARIC) Study. 
Lancet Diabetes Endocrinol. 2017. 5(1): 34-42. 
 
 212 
Warren B, Rawlings AM, Lee AK, Grams M, Coresh J, Selvin E. Increases in 
Biomarkers of Hyperglycemia with Age in the Atherosclerosis Risk in Communities 
(ARIC) Study. Diab Care. 2017. 40(8): e96-e97. 
 
Non Peer-Reviewed Publications 
 
Selvin E, Warren B, Matsushita K, Punjabi NM. Prediabetes definitions and clinical 




Warren, B, Rebholz, C, Lee, AK, Coresh, J, Selvin, E, and Grams, M. Diabetes and 
Trajectories of Estimated Glomerular Filtration Rate (eGFR) in the Atherosclerosis Risk 
in Communities (ARIC) Study. Diabetes Care. 2017; (Supplement):A428. 
 
Warren, B, Ballantyne, C, Hoogeveen, R, Pankow, JS, Köttgen, A, and Selvin, E. 
Performance of 1,5-anhydroglucitol compared to the oral glucose tolerance test and 
fasting glucose for identification of diabetes in the community. Circulation. 2017; 
135(Supplement 1): AMP018. 
 
Warren, B, Ballantyne, C, Hoogeveen, R, Pankow, JS, Köttgen, A, and Selvin, E. 
Comparison of the prognostic value of 1,5-anhydroglucitol and the oral glucose tolerance 
test in the Atherosclerosis Risk in Communities Study. Circulation. 2017; 
135(Supplement 1): AMP034. 
 
Warren, B, Rawlings, A, Lee, AK, Parrinello, C, Coresh, J, and Selvin, E. Age-related 
changes in hyperglycemia: Comparison of different biomarkers. Diabetes Care. 2016; 
(Supplement):A360. 
 
Warren, B, Rawlings, A, Sharrett, AR, Coresh, J, Köttgen, A, and Selvin, E. 1,5-
anhydroglucitol to Identify Older Adults with Diabetes at Risk of Hospitalization and 
All-cause Mortality. In Press. 
 
Warren, B, Pankow, JS, Matsushita, K, Woodward, M, and Selvin, E. Comparative 
Prognostic Performance of Different Definitions of Prediabetes in ARIC. Circulation. 




Moderated Poster: “1,5-anhydroglucitol to Identify Older Adults with Diabetes at Risk 
of Hospitalization and All-cause Mortality,” American Heart Association Scientific 
Sessions; New Orleans, LA, March 2018. 
 
Moderated Poster: “Diabetes and Trajectories of Estimated Glomerular Filtration Rate 
(eGFR) in the Atherosclerosis Risk in Communities (ARIC) Study,” American Diabetes 
Association; San Diego, CA, June 2017. 
 
 213 
Oral Presentation: “Comparative prognostic performance of definitions of prediabetes: 
a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study”, 
American Heart Association Scientific Sessions (Hot Off the Press); Portland, OR, March 
2017. 
 
Moderated Poster: “Performance of 1,5-anhydroglucitol compared to the oral glucose 
tolerance test and fasting glucose for identification of diabetes in the community,” 
American Heart Association Scientific Sessions; Portland, OR, March 2017. 
 
Poster: “Comparison of the prognostic value of 1,5-anhydroglucitol and the oral glucose 
tolerance test in the Atherosclerosis Risk in Communities Study,” American Heart 
Association Scientific Sessions; Portland, OR, March 2017. 
 
Moderated Poster: “Age-related changes in hyperglycemia: Comparison of different 
biomarkers,” American Diabetes Association; New Orleans, LA, June 2016. 
 
Oral Presentation: “Comparative Prognostic Performance of Different Definitions of 
Prediabetes in ARIC,” T32 NHLBI Trainee Session, American Heart Association 
Scientific Sessions; Phoenix, AZ, March 2016. 
 
Moderated Poster: “Comparative Prognostic Performance of Different Definitions of 
Prediabetes in ARIC,” American Heart Association Scientific Sessions; Phoenix, AZ, 
March 2016. 
 
Awards and Fellowships 
 
 NIH/NHLBI Pre-doctoral Training Grant in Cardiovascular Disease, 2014-Present 
 American Heart Association, EPI Early Career Travel Grant, 2018 
 Johns Hopkins University Bloomberg School of Public Health, Department of 
Epidemiology, Student Travel Support Fund, 2017 
 Dean’s List, University of Pennsylvania, 2007-2010 
 Intercollegiate Women’s Lacrosse Association Academic Award, 2009 




 Reviewer: Atherosclerosis Risk in Communities Study (Internal Manuscript Review 
Process), 2016, 2017 
 Co-reviewer: New England Journal of Medicine, 2017; Lancet Diabetes and 
Endocrinology, 2017; Diabetic Medicine, 2017; Clinical Chemistry, 2016; Journal of 
American College of Cardiology, and Nutrition, Metabolism, and Cardiovascular 
Diseases, 2016 
 Member, American Heart Association, 2014-Present 
